

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAKAB1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	3	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	4	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	5	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	6	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	7	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	8	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	9	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	10	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	11	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	12	JUN 25	CA/CAPplus and USPAT databases updated with IPC reclassification data
NEWS	13	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	14	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS	15	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS	16	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS	17	JUL 28	CA/CAPplus patent coverage enhanced
NEWS	18	JUL 28	EPFULL enhanced with additional legal status information from the epline Register
NEWS	19	JUL 28	IFICDB, IFIPAT, and IFIUIDB reloaded with enhancements
NEWS	20	JUL 28	STN Viewer performance improved
NEWS	21	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS	22	AUG 13	CA/CAPplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS	23	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS	24	AUG 15	CAPplus currency for Korean patents enhanced
NEWS	25	AUG 25	CA/CAPplus, CASREACT, and IFI and USPAT databases enhanced for more flexible patent number searching
NEWS	26	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,

AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS      STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN      Welcome Banner and News Items  
NEWS IPC8        For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 09:38:02 ON 16 SEP 2008

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:38:07 ON 16 SEP 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 SEP 2008 HIGHEST RN 1049628-87-6

DICTIONARY FILE UPDATES: 15 SEP 2008 HIGHEST RN 1049628-87-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10524977\_updated.str



```

chain nodes :
12 13 15
ring nodes :
1 2 3 4 5 6 7 8 9 10 11
chain bonds :
2-7 3-15 5-12 12-13
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11
exact/norm bonds :
2-3 3-4 3-15 4-5 5-12
exact bonds :
1-2 1-5 2-7 12-13
normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11
isolated ring systems :
containing 1 : 6 :

```

G1:H,Cb,Cy,Ak

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:CLASS 13:CLASS 15:CLASS

L1 STRUCTURE UPLOADED

=> d L1

L1 HAS NO ANSWERS

L1 STR



G1 H,Cb,Cy,Ak

Structure attributes must be viewed using STN Express query preparation.

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.46

0.67

FILE 'CAPLUS' ENTERED AT 09:38:30 ON 16 SEP 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Sep 2008 VOL 149 ISS 12

FILE LAST UPDATED: 15 Sep 2008 (20080915/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s L1 SSS full

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 09:38:34 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 15682 TO ITERATE

100.0% PROCESSED 15682 ITERATIONS

671 ANSWERS

SEARCH TIME: 00.00.02

L2 671 SEA SSS FUL L1

L3 70 L2

=> d ibib abs hitstr 1-

YOU HAVE REQUESTED DATA FROM 70 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:824619 CAPLUS Full-text

DOCUMENT NUMBER: 149:122546

TITLE: In vitro methods for the induction and maintenance of plant cell lines as single suspension cells with intact cell walls, and transformation thereof

INVENTOR(S): Jayakumar, Pon Samuel; Beringer, Jeffrey R.; Schmitzer, Paul; Burroughs, Frank; Garisson, Robbi; Ainley, William Michael; Samboju, Narasimha Chary

PATENT ASSIGNEE(S): Dow Agrosciences LLC, USA

SOURCE: PCT Int. Appl., 63pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2008083233	A2	20080710	WO 2007-US88970	20071227
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2006-878028P P 20061229

OTHER SOURCE(S): MARPAT 149:122546

AB The subject invention provides simple and consistent methods to break suspension cell aggregates to single cells with intact primary cell walls. The subject invention relates in part to cell separation of suspension cell aggregates cultured in medium containing pectin- degrading enzymes or tubulin de-polymerizing compds. including colchicine. The subject invention also relates to novel uses of compds. for such purposes. Another aspect of the subject invention relates to transformation of the subject, isolated cells. Such processes simplify and integrate single-cell-based transformation and selection processes into transgenic and transplastomic event-generation work processes. The subject invention also removes tech. constraints and produces marker-free and uniformly expressing transgenic lines in a high throughput fashion to support various needs of animal health, biopharma, and trait and crop protection platforms. The ability to isolate and grow single cells has numerous possible applications. For example, methods outlined herein have utility in the improvement of processes related to the productivity of plant cell cultures for animal health applications. Embodiments of the subject invention can help in screening of transgenic cell line elite clones, such as in mini suspension cell culture initiation in minimizing batch to batch variation, to develop a Standard Operating Protocol (SOP) for single-cell-based transformation systems to minimize or eliminate non-transgenic cells in aggregates.

IT 1036731-14-2, DAS-PMTI 1


RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(culturing plant cells in medium containing; in vitro methods for induction

and maintenance of plant cell lines as single suspension cells with  
intact cell walls, and transformation thereof)

RN 1036731-14-2 CAPLUS

CN Acetic acid, 2-[(4-chloro-1,5-diphenyl-1H-pyrazol-3-yl)oxy]-, ethyl ester  
(CA INDEX NAME)



L3 ANSWER 2 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:644186 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 148:585896

TITLE: Preparation of pyrazolyloxyalkylamines as  
 $\sigma$ -receptor antagonists.

INVENTOR(S): Laggner, Christian; Cuberes-Altisent, Maria Rosa;  
Holenz, Joerg; Berrocal-Romero, Juana Maria;  
Contijoch-Llobet, Maria Montserrat

PATENT ASSIGNEE(S): Austria

SOURCE: U.S. Pat. Appl. Publ., 32pp., Cont.-in-part of U.S.  
Ser. No. 978,250.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080125416	A1	20080529	US 2007-574361	20070809
EP 1634872	A1	20060315	EP 2004-77421	20040827
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
ES 2251316	A1	20060416	ES 2004-2441	20041014
ES 2251316	B1	20070316		
US 20060106068	A1	20060518	US 2004-978250	20041029
WO 2006021462	A1	20060302	WO 2005-EP9375	20050829
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: EP 2004-77421 A 20040827  
ES 2004-2441 A 20041014  
US 2004-978250 A2 20041029

OTHER SOURCE(S):  
GI

MARPAT 148:585896



AB Title compds. [I; R1 = H, cyano, NO<sub>2</sub>, halo, (substituted) alkyl, cycloalkyl, alkenyl, aralkyl, heterocyclyl, heterocyclylalkyl, etc.; R2 = H, cyano, halo, halo, (substituted) alkyl, cycloalkyl, alkenyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, etc.; R3, R4 = H, cyano, NO<sub>2</sub>, halo, (substituted) alkyl, cycloalkyl, alkenyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, etc.; R5, R6 = H, cyano, NO<sub>2</sub>, halo, (substituted) alkyl, cycloalkyl alkenyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, etc.; R5R6N = (substituted) heterocyclyl; n = 1-8], were prepared Thus, 4-[2-[1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yl]oxy]ethyl]morpholine [3-step preparation from 3,4-dichlorophenylhydrazine, Et acetoacetate, and N-(2-chloroethyl)morpholine hydrochloride given] showed 102.1%  $\sigma_1$  receptor binding at 10<sup>-7</sup> M.


IT 878141-43-6P 878141-44-7P 878141-45-8P  
878141-46-9P 878141-47-0P 878141-48-1P  
878142-10-0P 878142-11-1P 878142-12-2P  
878142-13-3P 1028204-89-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolyloxyalkylamines as  $\sigma$ -receptor antagonists)

RN 878141-43-6 CAPLUS


CN Morpholine, 4-[2-[[1-(3,4-dichlorophenyl)-5-phenyl-1H-pyrazol-3-yl]oxy]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 878141-44-7 CAPLUS


CN 1H-Pyrazole, 1-(3,4-dichlorophenyl)-5-phenyl-3-[2-(1-pyrrolidinyl)ethoxy]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 878141-45-8 CAPLUS

CN 1H-Pyrazole, 1-(3,4-dichlorophenyl)-5-phenyl-3-[3-(1-pyrrolidinyl)propoxy]-  
(CA INDEX NAME)



RN 878141-46-9 CAPLUS


CN Piperidine, 1-[2-[[1-(3,4-dichlorophenyl)-5-phenyl-1H-pyrazol-3-yl]oxy]ethyl]-  
(CA INDEX NAME)



RN 878141-47-0 CAPLUS

CN 1H-Pyrazole, 1-(3,4-dichlorophenyl)-3-[2-(1H-imidazol-1-yl)ethoxy]-5-phenyl-, hydrochloride (1:1) (CA INDEX NAME)






● HCl

RN 878141-48-1 CAPLUS


CN Isoquinoline, 2-[2-[[1-(3,4-dichlorophenyl)-5-phenyl-1H-pyrazol-3-yl]oxy]ethyl]-1,2,3,4-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 878142-10-0 CAPLUS

CN Morpholine, 4-[2-[[1-(3,4-dichlorophenyl)-5-phenyl-1H-pyrazol-3-yl]oxy]ethyl]- (CA INDEX NAME)




RN 878142-11-1 CAPLUS


CN 1H-Pyrazole, 1-(3,4-dichlorophenyl)-5-phenyl-3-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)




RN 878142-12-2 CAPLUS  
 CN 1H-Pyrazole, 1-(3,4-dichlorophenyl)-3-[2-(1H-imidazol-1-yl)ethoxy]-5-phenyl- (CA INDEX NAME)



RN 878142-13-3 CAPLUS  
 CN Isoquinoline, 2-[2-[[1-(3,4-dichlorophenyl)-5-phenyl-1H-pyrazol-3-yl]oxy]ethyl]-1,2,3,4-tetrahydro- (CA INDEX NAME)




RN 1028204-89-8 CAPLUS  
 CN Morpholine, 4-[4-[[1-(3,4-dichlorophenyl)-5-phenyl-1H-pyrazol-3-yl]oxy]butyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L3 ANSWER 3 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2008:572186 CAPLUS Full-text  
 DOCUMENT NUMBER: 149:119490  
 TITLE: Effect of CV159-Ca<sup>2+</sup>/Calmodulin Blockade on Redox Status Hepatic Ischemia-Reperfusion Injury in Mice Evaluated by a Newly Developed In Vivo EPR Imaging

	Technique
AUTHOR(S):	Kobayashi, Hiromichi P.; Watanabe, Taiji; Oowada, Shigeru; Hirayama, Aki; Nagase, Sohji; Kamibayashi, Masato; Otsubo, Takehito
CORPORATE SOURCE:	Department of Gastroenterological and General Surgery, St. Marianna School of Medicine, Kawasaki, Kanagawa, Japan
SOURCE:	Journal of Surgical Research (2008), 147(1), 41-49 CODEN: JSGRA2; ISSN: 0022-4804
PUBLISHER:	Elsevier
DOCUMENT TYPE:	Journal
LANGUAGE:	English
AB	1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid Me 6-(5-phenyl-3-pyrazolyloxy)hexyl ester (CV159) exhibits selective blocking of Ca2+/calmodulin and inhibits Ca2+ overloading in living organisms. The effects of this antagonist in mice with hepatic ischemia-reperfusion injury were investigated using ESR imaging (EPRI) and ex vivo EPR (x-band EPR) techniques. The EPRI determined that the 3-carbamoyl-2,2,5,5-tetramethylpyrrolidine-1-oxyl half-life in CV159-treated mice was significantly shorter than that in untreated mice and was almost equal to that in the sham group. Both the cytosolic and the mitochondrial superoxide scavenging activities in CV-treated mice were significantly higher than that in untreated mice. Faint staining of the anti-superoxide dismutase antibody and strong staining of anti-inducible nitric oxide synthase antibody were observed in the liver of control group. In contrast to these findings, immunostaining of these antibodies in the liver of CV159-treated mice were reversed compared to control group. Western blotting showed that CV159 contributed to the high superoxide dismutase expression and low expression of inducible nitric oxide synthase. The alanine aminotransferase level in CV159-treated mice significantly decreased in comparison to that observed in the untreated mice. We conclude that CV159 retains its organ-reducing activity against radicals in hepatic reperfusion injury, which is mediated by the inhibition of Ca2+ overloading.
IT	86384-98-7, CV159
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (CV159-calcium-calmodulin blockade retained organ-reducing activity against reactive oxygen species in mouse hepatic ischemia-reperfusion injury as evaluated by ESR imaging)
RN	86384-98-7 CAPLUS
CN	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 6-[(5-phenyl-1H-pyrazol-3-yl)oxy]hexyl ester (9CI) (CA INDEX NAME)




DOCUMENT NUMBER: 148:577196  
 TITLE: The Role of the New Ca<sup>2+</sup> Antagonist, CV159, in Hepatic I/R Injury - The Evaluation of Hepatic Organ Reducing Activity Using In Vivo and Ex Vivo EPR  
 AUTHOR(S): Watanabe, Taiji; Oowada, Shigeru; Kobayashi, Hiromichi P.; Kamibayashi, Masato; Ishiuchi, Atsuko; Jinnouchi, Yuji; Koizumi, Satoshi; Asano, Takayuki; Shimamura, Tsukasa; Asakura, Takeshi; Nakano, Hiroshi; Kubota, Sunao; Otsubo, Takehito  
 CORPORATE SOURCE: Department of Gastroenterological Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan  
 SOURCE: Journal of Surgical Research (2008), 145(1), 49-56  
 CODEN: JSGRA2; ISSN: 0022-4804  
 PUBLISHER: Elsevier  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB We investigated the organ-reducing ability of 1,2-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine-dicarboxylic acid methyl 6-(5-phenyl-3-pyrazolyloxy) hexyl ester (CV159) that exhibits selective blocking of Ca<sup>2+</sup>/calmodulin and inhibition of Ca<sup>2+</sup> overloading in living organisms (Sprague Dawley rats) using an in vivo and an ex vivo electron paramagnetic imaging technique. Decay rates in CV159-treated rats were significantly higher than those in untreated rats and were almost equal to those in the sham group. Both cytosol and mitochondrial superoxide scavenging activity in CV159-treated rats were significantly higher than those in untreated rats, and cytosol superoxide scavenging activity only was slightly higher than that in the sham group. Faint staining for anti-superoxide dismutase antibody was markedly observed in necrotic lesions in the liver of control group. Alanine aminotransferase level in CV-treated rats were significantly decreased as compared with the levels in untreated rats. Electron microscopy showed a decreased number of damaged mitochondria, whereas mitochondrial damage was significantly reduced in CV-treated animals. We conclude that CV159 retains the organ-reducing activity against radicals in hepatic I/R injury that is mediated by the inhibition of Ca<sup>2+</sup> overloading.

IT 86384-98-7, CV159  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (Ca<sup>2+</sup> antagonist CV159 induced organ reducing activity against radicals and prevented accumulation of reactive oxygen species in rat with hepatic ischemia reperfusion injury that was mediated by Ca<sup>2+</sup> overloading)

RN 86384-98-7 CAPLUS



CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 6-[(5-phenyl-1H-pyrazol-3-yl)oxy]hexyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2007:1258734 CAPLUS Full-text  
DOCUMENT NUMBER: 147:541866  
TITLE: Preparation of trisubstituted 1H-pyrazoles as  
inhibitors of transforming growth factor  $\beta$   
INVENTOR(S): Li, Song; Li, Xingzhou; Dai, Xianping; Zheng, Zhibing;  
Wang, Lili; Xiao, Junhai; Liu, Hongying  
PATENT ASSIGNEE(S): Institute of Pharmacology and Toxicology, Academy of  
Military Medical Sciences, The Chinese People's  
Liberation Army, Peop. Rep. China  
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 113pp.  
CODEN: CNXXEV  
DOCUMENT TYPE: Patent  
LANGUAGE: Chinese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
CN 101062916	A	20071031	CN 2006-10078014	20060429
PRIORITY APPLN. INFO.:			CN 2006-10078014	20060429
OTHER SOURCE(S):		CASREACT 147:541866		
GI				



AB The title trisubstituted 1H-pyrazole compds. I [wherein R1 and R2 = independently (un)substituted or (un)fused aryl or heterocyclyl; R3 = (un)substituted aryl, heterocyclyl, halo, alkyl, etc.], or isomers, pharmaceutically acceptable salts, or hydrates there of were prepared as inhibitors of transforming growth factor  $\beta$  (TGF- $\beta$ ). For example, II was prepared in a multi-step synthesis. II showed 45.28% inhibitory activity against TGF- $\beta$ . The compds. are useful for treatment of chronic nephritis, arthritis, diabetic nephrosis, arteriosclerosis, pulmonary fibrosis, liver fibrosis, etc. (no data).


IT 957653-68-8P 957653-69-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of trisubstituted 1H-pyrazoles as TGF- $\beta$  inhibitors)


RN 957653-68-8 CAPLUS

CN 1H-Pyrazole, 3-ethoxy-1-(2-fluorophenyl)-5-(4-fluorophenyl)- (CA INDEX NAME)



RN 957653-69-9 CAPLUS

CN 1H-Pyrazole, 3-ethoxy-1-(2-fluorophenyl)-5-phenyl- (CA INDEX NAME)



L3 ANSWER 6 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1026910 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 147:486374

TITLE: Efficient regiocontrolled synthesis and antimicrobial activity of pyrazoles

AUTHOR(S): Braibante, Mara E. F.; Braibante, Hugo T. S.; de Carvalho Tavares, Luciana; Rohte, Simone F.; Costa, Carla C.; Morel, Ademir F.; Stuker, Caroline Z.; Burrow, Robert A.

CORPORATE SOURCE: Departamento de Quimica, Universidade Federal de Santa Maria, Santa Maria, 97105-900, Brazil

SOURCE: Synthesis (2007), (16), 2485-2490

CODEN: SYNTBF; ISSN: 0039-7881

PUBLISHER: Georg Thieme Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 147:486374


AB A series of 1,5-diphenyl-1H-pyrazol-3-amines, 3-ethoxy-5-phenyl-1H-pyrazole, 5-ethoxy-1,3-diphenyl-1H-pyrazole and 3-ethoxy-1,5-diphenyl-1H-pyrazole were efficiently prepared from the regiocontrolled cyclization of  $\alpha$ -oxoketene O,N-acetals and/or  $\beta$ -oxo thioesters with hydrazine derivs. using montmorillonite K-10 as solid support with ultrasound. The antimicrobial activity of the heterocyclic compds. was evaluated by direct bioautog. test.

IT 16105-56-9F


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of pyrazoles by the regiocontrolled cyclization of  $\alpha$ -oxoketene O,N-acetals and/or  $\beta$ -oxo thioesters with hydrazine derivs. using montmorillonite K-10 as solid support with ultrasound)

RN 16105-56-9 CAPLUS  
CN 1H-Pyrazole, 3-ethoxy-5-phenyl- (CA INDEX NAME)



IT 300543-33-3P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of pyrazoles by the regiocontrolled cyclization of  
 $\alpha$ -oxoketene O,N-acetals and/or  $\beta$ -oxo thioxoesters with  
hydrazine derivs. using montmorillonite K-10 as solid support with  
ultrasound)  
RN 300543-33-3 CAPLUS  
CN 1H-Pyrazole, 3-ethoxy-1,5-diphenyl- (CA INDEX NAME)



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2007:593479 CAPLUS Full-text  
DOCUMENT NUMBER: 147:31122  
TITLE: Pyrazole and triazole derivatives as glucokinase  
activators and their preparation, pharmaceutical  
compositions and use in the treatment of diseases  
INVENTOR(S): Cao, Sheldon X.; Feng, Jun; Gwaltney, Stephen L.;  
Hosfield, David J.; Imaeda, Yasuhiro; Takakura,  
Nobuyuki; Tang, Mingnam  
PATENT ASSIGNEE(S): Takeda San Diego, Inc., USA  
SOURCE: PCT Int. Appl., 267pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2007061923	A2	20070531	WO 2006-US44822	20061117
WO 2007061923	A3	20071101		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,  
KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK,  
MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,



RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,  
 TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

US 20070197532 A1 20070823 US 2006-561307 20061117  
 EP 1948614 A2 20080730 EP 2006-827873 20061117

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,  
 BA, HR, MK, RS

PRIORITY APPLN. INFO.: US 2005-738350P P 20051118  
 WO 2006-US44822 W 20061117

OTHER SOURCE(S): MARPAT 147:31122  
 GI



AB Compds., pharmaceutical compns., kits and methods are provided for use with glucokinase that comprise a compound selected from the group consisting of formula I or II wherein the variables are as defined herein. Compds. of formula I and II wherein A is (un)substituted C3-12 (hetero)cycloalkyl, (un)substituted C9-10 (hetero)bicycloalkyl, (un)substituted (hetero)aryl, (un)substituted (hetero)bicycloaryl; Z is CR<sub>3</sub> and H; L is absent or a linker providing 1 - 6 atoms separation between R<sub>2</sub> and the ring; R<sub>2</sub> and R<sub>3</sub> are independently H, halo, NO<sub>2</sub>, CN, thio, oxy, OH, alkoxy, (hetero)aryloxy, etc.; are claimed. Example compound III was prepared by a general procedure (procedure given). All the invention compds. were evaluated for their glucokinase activation. From the assay, it was determined that compound III exhibited pK<sub>act</sub> value of ≥ 5.7 against GK.


IT 939051-67-9P 939052-15-0P 939052-23-0P  
 939052-34-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate and intermediate; preparation of pyrazole and triazole derivs. as glucokinase activators)

RN 939051-67-9 CAPLUS




CN Acetic acid, 2-[[5-(2-methoxyphenyl)-1H-pyrazol-3-yl]oxy]- (CA INDEX NAME)



RN 939052-15-0 CAPLUS


CN 1H-Pyrazole, 3-methoxy-5-[2-(2-methoxy-1-methylethoxy)-5-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 939052-23-0 CAPLUS

CN Acetic acid, 2-[[5-[2-[(1S)-2-methoxy-1-methylethoxy]-5-[4-(methylsulfonyl)phenoxy]phenyl]-1H-pyrazol-3-yl]oxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 939052-34-3 CAPLUS


CN Acetic acid, 2-[[5-[3-[(1S)-2-methoxy-1-methylethoxy]-5-[4-(methylsulfonyl)phenoxy]phenyl]-1H-pyrazol-3-yl]oxy]- (CA INDEX NAME)


Absolute stereochemistry.




(drug candidate; preparation of pyrazole and triazole derivs. as  
glucokinase  
activators)

CN 1H-Pyrazole, 3-[(2-fluorophenyl)methoxy]-5-(2-methoxyphenyl)- (CA INDEX NAME)







RN 939051-27-1 CAPLUS  
 CN 1H-Pyrazole, 3-[(2-fluorophenyl)methoxy]-5-(2-methylphenyl)- (CA INDEX NAME)



RN 939051-30-6 CAPLUS  
 CN 1H-Pyrazole, 5-(2,4-dimethoxyphenyl)-3-[(2-fluorophenyl)methoxy]- (CA INDEX NAME)




RN 939051-44-2 CAPLUS  
 CN 1H-Pyrazole, 5-(2,3-dimethoxyphenyl)-3-[(2-fluorophenyl)methoxy]- (CA INDEX NAME)



RN 939051-50-0 CAPLUS


CN 1H-Pyrazole, 3-[(2-fluorophenyl)methoxy]-5-[2-(1-methylethoxy)-5-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 939051-65-7 CAPLUS


CN 2-Piperazinone, 6-[[[5-(2-methoxyphenyl)-1H-pyrazol-3-yl]oxy]methyl]-, (6R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 939051-69-1 CAPLUS

CN Ethanone, 2-[[[5-(2-methoxyphenyl)-1H-pyrazol-3-yl]oxy]-1-(4-morpholinyl)- (CA INDEX NAME)




RN 939052-19-4 CAPLUS

CN Pyridine, 2-[[3-(3-methoxy-1H-pyrazol-5-yl)-5-[4-(methylsulfonyl)phenoxy]phenoxy]methyl]-3-methyl- (CA INDEX NAME)




RN 939052-20-7 CAPLUS

CN 1H-Pyrazole, 3-methoxy-5-[3-[(2-methylphenyl)methoxy]-5-[4-(methylsulfonyl)phenoxy]phenyl]- (CA INDEX NAME)



RN 939052-21-8 CAPLUS


CN Thiazole, 5-[2-[[5-[2-(2-methoxy-1-methylethoxy)-5-(phenylmethoxy)phenyl]-1H-pyrazol-3-yl]oxy]ethyl]-4-methyl- (CA INDEX NAME)



RN 939052-22-9 CAPLUS


CN Thiazole, 5-[2-[[5-[5-[(2-fluorophenyl)methoxy]-2-[(1S)-2-methoxy-1-methylethoxy]phenyl]-1H-pyrazol-3-yl]oxy]ethyl]-4-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 939052-28-5 CAPLUS

CN 1H-Pyrazole, 3-methoxy-5-[2-(2-methoxy-1-methylethoxy)-5-[2-(3-thienyl)ethoxy]phenyl]- (CA INDEX NAME)




RN 939052-29-6 CAPLUS

CN 1H-Pyrazole, 3-methoxy-5-[2-(2-methoxy-1-methylethoxy)-5-[[4-(methylsulfonyl)phenyl]methoxy]phenyl]- (CA INDEX NAME)



RN 939052-30-9 CAPLUS


CN Pyridine, 4-[[4-(2-methoxy-1-methylethoxy)-3-(3-methoxy-1H-pyrazol-5-yl)phenoxy]methyl]- (CA INDEX NAME)



RN 939052-31-0 CAPLUS

CN 1H-Pyrazole, 3-methoxy-5-[3-[(1S)-2-methoxy-1-methylethoxy]-5-[4-(methylsulfonyl)phenoxy]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 939052-32-1 CAPLUS

CN 1H-Pyrazole, 3-methoxy-5-[3-[(1S)-2-methoxy-1-methylethoxy]-5-[[4-(methylsulfonyl)phenyl]methoxy]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 939052-33-2 CAPLUS

CN 1H-Pyrazole, 3-methoxy-5-[3-[(1S)-2-methoxy-1-methylethoxy]-5-[2-(3-thienyl)ethoxy]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 939052-35-4 CAPLUS

CN Ethanone, 1-(4-acetyl-1-piperazinyl)-2-[[5-[3-[(1S)-2-methoxy-1-methylethoxy]-5-[4-(methylsulfonyl)phenoxy]phenyl]-1H-pyrazol-3-yl]oxy]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 939052-36-5 CAPLUS

CN Ethanone, 2-[[5-[3-[(1S)-2-methoxy-1-methylethoxy]-5-[4-(methylsulfonyl)phenoxy]phenyl]-1H-pyrazol-3-yl]oxy]-1-(4-morpholinyl)-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 939052-37-6 CAPLUS



CN Acetamide, N-ethyl-2-[[5-[3-[(1S)-2-methoxy-1-methylethoxy]-5-[4-(methylsulfonyl)phenoxy]phenyl]-1H-pyrazol-3-yl]oxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 939053-61-9 CAPLUS


CN 1-Piperazinecarboxylic acid, 3-[[[5-(2-methoxyphenyl)-1H-pyrazol-3-yl]oxy]methyl]-5-oxo-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 939054-01-0 CAPLUS

CN 1H-Pyrazole, 3-methoxy-5-(2-methoxyphenyl)- (CA INDEX NAME)




RN 939054-02-1 CAPLUS

CN 1H-Pyrazole, 3-ethoxy-5-(2-methoxyphenyl)- (CA INDEX NAME)




RN 939054-08-7 CAPLUS

CN 1H-Pyrazole, 3-(2-methoxyethoxy)-5-(2-methoxyphenyl)- (CA INDEX NAME)




RN 939054-10-1 CAPLUS

CN Ethanamine, 2-[[5-(2-methoxyphenyl)-1H-pyrazol-3-yl]oxy]-N,N-dimethyl-  
(CA INDEX NAME)




RN 939054-11-2 CAPLUS

CN 1-Propanamine, 3-[[5-(2-methoxyphenyl)-1H-pyrazol-3-yl]oxy]-N,N-dimethyl-  
(CA INDEX NAME)




RN 939054-14-5 CAPLUS


CN 1H-Pyrazole, 3-[(3-fluorophenyl)methoxy]-5-(2-methoxyphenyl)- (CA INDEX NAME)




RN 939054-15-6 CAPLUS  
 CN 1H-Pyrazole, 3-[(4-fluorophenyl)methoxy]-5-(2-methoxyphenyl)- (CA INDEX NAME)



RN 939054-16-7 CAPLUS  
 CN Benzonitrile, 4-[[[5-(2-methoxyphenyl)-1H-pyrazol-3-yl]oxy]methyl]- (CA INDEX NAME)




RN 939054-17-8 CAPLUS  
 CN 1H-Pyrazole, 3-[(2,4-difluorophenyl)methoxy]-5-(2-methoxyphenyl)- (CA INDEX NAME)




RN 939054-22-5 CAPLUS

CN Ethanamine, N,N-diethyl-2-[[5-(2-methoxyphenyl)-1H-pyrazol-3-yl]oxy]- (CA INDEX NAME)




RN 939054-24-7 CAPLUS

CN 2-Pyrrolidinone, 1-[3-[[5-(2-methoxyphenyl)-1H-pyrazol-3-yl]oxy]propyl]- (CA INDEX NAME)




RN 939054-25-8 CAPLUS


CN 2-Imidazolidinone, 1-[2-[[5-(2-methoxyphenyl)-1H-pyrazol-3-yl]oxy]ethyl]- (CA INDEX NAME)




RN 939054-26-9 CAPLUS  
CN Ethanone, 2-[[5-(2-methoxyphenyl)-1H-pyrazol-3-yl]oxy]-1-phenyl- (CA  
INDEX NAME)



RN 939054-27-0 CAPLUS  
CN Thiazole, 5-[2-[[5-(2-methoxyphenyl)-1H-pyrazol-3-yl]oxy]ethyl]-4-methyl-  
(CA INDEX NAME)



RN 939054-28-1 CAPLUS  
CN Thiazole, 2-[[[5-(2-methoxyphenyl)-1H-pyrazol-3-yl]oxy]methyl]- (CA INDEX  
NAME)



L3 ANSWER 8 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2006:1065917 CAPLUS Full-text  
DOCUMENT NUMBER: 145:389387  
TITLE: Dihydropyridines for the prevention and treatment of  
renal perfusion disorders  
INVENTOR(S): Owada, Shigeru; Murakami, Eiichi; Kamibayashi, Masato  
PATENT ASSIGNEE(S): Hetero Research Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 25pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006107059	A1	20061012	WO 2006-JP307166	20060329
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.:

JP 2005-105438

A 20050331

OTHER SOURCE(S): MARPAT 145:389387


AB Dihydropyridines, especially, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid Me 6-[(5-phenyl-1H-pyrazol-3-yl)oxy]hexyl ester (CV 159), are effective for the prevention and/or treatment of renal perfusion disorders and renal impairments, such as nephritis and renal insufficiency.

IT 86384-98-7, CV-159

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); BIOL (Biological study)  
 (dihydropyridines for treatment of renal perfusion disorders and impairments)

RN 86384-98-7 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 6-[(5-phenyl-1H-pyrazol-3-yl)oxy]hexyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:932791 CAPLUS Full-text

DOCUMENT NUMBER: 147:301090

TITLE: Utility of 4-{2-[2-(4-methoxyphenyl)vinyl]-4-oxo-4H-quinazolin-3-yl}benzoic acid hydrazide

AUTHOR(S): El-Shenawy, A. I.; Aly, A. A.

CORPORATE SOURCE: Chemistry Department, Faculty of Science, Benha University, Benha, Egypt



SOURCE: Egyptian Journal of Chemistry (2005), 48(6), 781-788  
 CODEN: EGJCA3; ISSN: 0449-2285

PUBLISHER: National Information and Documentation Centre

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 147:301090  
 AB The title compound was used as the starting material to prepare a number of heterocyclic derivs. Some of the products showed antimicrobial activity.  
 IT 947192-92-9P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation and antimicrobial activity of heterocyclic derivs. of 4-{2-[2-(4-methoxyphenyl)vinyl]-4-oxo-4H-quinazolin-3-yl}benzoic acid hydrazide)  
 RN 947192-92-9 CAPLUS  
 CN 4(3H)-Quinazolinone, 3-[4-[(3-ethoxy-5-phenyl-1H-pyrazol-1-yl)carbonyl]phenyl]-2-[2-(4-methoxyphenyl)ethenyl]- (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2006:193556 CAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 144:274266  
 TITLE: Preparation of 1-phenylpyrazole derivatives as sigma receptor inhibitors  
 INVENTOR(S): Laggner, Christian; Cuberes-Altisent, Maria Rosa; Holenz, Joerg; Berrocal-Romero, Juana Maria; Contijoch-Llobet, Maria Montserrat  
 PATENT ASSIGNEE(S): Laboratorios del Dr. Esteve, S. A., Spain  
 SOURCE: PCT Int. Appl., 75 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006021462	A1	20060302	WO 2005-EP9375	20050829
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,				





to pharmaceutical compns. comprising them, and to their use therapy and prophylaxis of a disease in which the sigma receptor is involved.


IT 878141-43-6P 878141-44-7P 878141-45-8P  
878141-46-9P 878141-47-0P 878141-48-1P  
878142-10-0P 878142-11-1P 878142-12-2P  
878142-13-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1-phenylpyrazoles as sigma receptor inhibitors)

RN 878141-43-6 CAPLUS


CN Morpholine, 4-[2-[[1-(3,4-dichlorophenyl)-5-phenyl-1H-pyrazol-3-yl]oxy]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 878141-44-7 CAPLUS


CN 1H-Pyrazole, 1-(3,4-dichlorophenyl)-5-phenyl-3-[2-(1-pyrrolidinyl)ethoxy]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 878141-45-8 CAPLUS


CN 1H-Pyrazole, 1-(3,4-dichlorophenyl)-5-phenyl-3-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



RN 878141-46-9 CAPLUS  
 CN Piperidine, 1-[2-[[1-(3,4-dichlorophenyl)-5-phenyl-1H-pyrazol-3-yl]oxy]ethyl]- (CA INDEX NAME)




RN 878141-47-0 CAPLUS  
 CN 1H-Pyrazole, 1-(3,4-dichlorophenyl)-3-[2-(1H-imidazol-1-yl)ethoxy]-5-phenyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 878141-48-1 CAPLUS  
 CN Isoquinoline, 2-[2-[[1-(3,4-dichlorophenyl)-5-phenyl-1H-pyrazol-3-yl]oxy]ethyl]-1,2,3,4-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 878142-10-0 CAPLUS  
 CN Morpholine, 4-[2-[[1-(3,4-dichlorophenyl)-5-phenyl-1H-pyrazol-3-yl]oxy]ethyl]- (CA INDEX NAME)




RN 878142-11-1 CAPLUS

CN 1H-Pyrazole, 1-(3,4-dichlorophenyl)-5-phenyl-3-[2-(1-pyrrolidinyl)ethoxy]-  
(CA INDEX NAME)




RN 878142-12-2 CAPLUS

CN 1H-Pyrazole, 1-(3,4-dichlorophenyl)-3-[2-(1H-imidazol-1-yl)ethoxy]-5-  
phenyl- (CA INDEX NAME)



RN 878142-13-3 CAPLUS

CN Isoquinoline, 2-[2-[[1-(3,4-dichlorophenyl)-5-phenyl-1H-pyrazol-3-  
yl]oxy]ethyl]-1,2,3,4-tetrahydro- (CA INDEX NAME)



REFERENCE COUNT:

9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2005:1345046 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 144:69823

TITLE: Preparation of heteroarylpyrazoles as p38 kinase inhibitors

INVENTOR(S): Naraian, Ashok S.; Clare, Michael; Collins, Paul W.; Crich, Joyce Zuowu; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Graneto, Matthew J.; Hanau, Cathleen E.; Hanson, Gunnar J.; Hartmann, Susan J.; Hepperle, Michael; Huang, He; Koszyk, Francis J.; Liao, Shuyuan; Metz, Suzanne; Partis, Richard A.; Perry, Thao D.; Rao, Shashidhar N.; Selness, Shaun Raj; South, Michael S.; Stealey, Michael A.; Talley, John Jeffrey; Vazquez, Michael L.; Weier, Richard M.; Xu, Xiangdong; Khanna, Ish K.; Yu, Yi; Naing, Win; Walker, John; Yang, Syaulan

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: U.S., 548 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6979686	B1	20051227	US 2001-21780	20011207
AU 2003200580	A1	20030501	AU 2003-200580	20030217
US 7071198	B2	20060704	US 2004-840734	20040505
US 20070078146	A1	20070405		
PRIORITY APPLN. INFO.:			US 1997-47570P	P 19970522
			AU 1998-75883	A3 19980522
			US 1998-196623	A2 19981120
			US 2000-513351	A3 20000224
			US 2001-21780	A3 20011207

OTHER SOURCE(S): MARPAT 144:69823

GI



AB Title compds. [I; R1 = H, OH, NH<sub>2</sub>, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = H, halo, mercapto, aryl, heterocyclyl, etc.; R3 = (un)substituted pyridinyl, pyrimidinyl, quinolinyl, etc.; R4 = H, alkyl, (un)substituted Ph, etc.; and pharmaceutically acceptable salts or tautomers thereof] were prepared by solution phase and solid phase parallel array reactions of ketones with hydrazines. Thus, R<sub>3</sub>CH<sub>2</sub>COMe (R<sub>3</sub> = 4-pyridinyl) was condensed with 3,4-F(MeO)C<sub>6</sub>H<sub>3</sub>CHO to give the butenone (80%), which was cyclocondensed with TsNHNH<sub>2</sub> to afford the title compound II (20.7%). The latter inhibited human


p38 kinase activity in vitro with IC50 of 4.6  $\mu$ M and inhibited tumor necrosis factor  $\alpha$  (TNF $\alpha$ ) and interleukin 1 $\beta$  (IL-1 $\beta$ ) release from human peripheral blood mononuclear cells following stimulation with lipopolysaccharide with IC50 of 0.5  $\mu$ M. Thus, I are useful for the treatment of inflammation, arthritis, asthma, and other disorders mediated by p38 kinase and TNF $\alpha$ . The pharmaceutical compns. comprising the compound I are disclosed.

IT 271575-72-5P 271575-77-0P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)  
(p38 kinase inhibitor; preparation of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones)


RN 271575-72-5 CAPLUS

CN Morpholine, 4-[2-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]oxy]ethyl]- (CA INDEX NAME)



RN 271575-77-0 CAPLUS

CN Carbamic acid, [2-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 87 THERE ARE 87 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1233272 CAPLUS Full-text

DOCUMENT NUMBER: 144:63897

TITLE: Synthesis and biological activity of  
N,N-dialkylaminoalkyl-substituted bisindolyl and  
diphenyl pyrazolone derivatives


AUTHOR(S): Brana, Miguel F.; Gradillas, Ana; Ovalles, Angel G.; Lopez, Berta; Acero, Nuria; Llinares, Francisco; Mingarro, Dolores Munoz  
CORPORATE SOURCE: Departamento de Quimica, Bioquimica y Biologia Molecular, Facultad de Farmacia, Universidad San Pablo CEU, Boadilla del Monte, Madrid, 28668, Spain  
SOURCE: Bioorganic & Medicinal Chemistry (2006), 14(1), 9-16  
CODEN: BMECEP; ISSN: 0968-0896  
PUBLISHER: Elsevier B.V.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 144:63897

AB New compds., structurally related to the potent protein kinase C inhibitor staurosporine, with a bisindolylpyrazolone framework and substituted on the pyrazolone nitrogens with N,N-dialkylaminoalkyl side chain, were synthesized and evaluated for growth-inhibitory properties in several human cell lines. Many showed inhibition of TNF- $\alpha$  production in response to the tumor promotor TPA on HL-60 cells. The apoptotic activity on HeLa cells has been examined for several of these compds.

IT 871843-21-9P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(N,N-dialkylaminoalkyl-substituted bisindolyl and di-Ph pyrazolone derivs. preparation and antitumor action)

RN 871843-21-9 CAPLUS

CN Ethanamine, 2-[(4,5-diphenyl-1H-pyrazol-3-yl)oxy]-N,N-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 13 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:232832 CAPLUS Full-text

DOCUMENT NUMBER: 143:367237

TITLE: Phase-transfer catalyzed alkylation and cycloalkylation of 3-substituted-1H-pyrazol-2-in-5-ones in the absence or presence of carbon disulphide

AUTHOR(S): Khalil, A. Kh.; Hassan, M. A.; Mohamed, M. M.; El-Sayed, A. M.

CORPORATE SOURCE: Chem. Dep., Fac. Sci., Ain Shams Univ., Cairo, Egypt

SOURCE: Phosphorus, Sulfur and Silicon and the Related Elements (2005), 180(2), 479-496  
CODEN: PSSLEC; ISSN: 1042-6507

PUBLISHER: Taylor & Francis, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:367237

AB PTC-alkylation of 3-substituted-1H-pyrazol-2-in-5-ones by different organohalogen reagents at 25°C in the presence of tetrabutylammonium bromide


as catalyst was investigated either in the absence or presence of CS<sub>2</sub>. This work aims to study the comparative reactivity of N-vs. O-vs. C-alkylation and cycloalkylation.

IT 39513-07-0P 103015-34-5P 866115-20-0P  
866115-34-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(phase-transfer catalyzed alkylation and cycloalkylation of  
3-substituted-1H-pyrazol-2-in-5-ones in the absence or presence of  
carbon disulfide)


RN 39513-07-0 CAPLUS

CN 1H-Pyrazole, 3-methoxy-5-phenyl- (CA INDEX NAME)




RN 103015-34-5 CAPLUS

CN Acetonitrile, [(5-phenyl-1H-pyrazol-3-yl)oxy]- (9CI) (CA INDEX NAME)




RN 866115-20-0 CAPLUS

CN Acetic acid, 2-[(5-phenyl-1H-pyrazol-3-yl)oxy]-, ethyl ester (CA INDEX NAME)



RN 866115-34-6 CAPLUS

CN 1H-Pyrazole, 3-(4-bromobutoxy)-5-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 14 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:757195 CAPLUS Full-text

DOCUMENT NUMBER: 141:410858

TITLE: Synthesis of 4,5-Diaryl-1H-pyrazole-3-ol Derivatives as Potential COX-2 Inhibitors

AUTHOR(S): Patel, Meena V.; Bell, Randy; Majest, Sandra; Henry, Rodger; Kolasa, Teodozyj

CORPORATE SOURCE: Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL, 60064-3500, USA

SOURCE: Journal of Organic Chemistry (2004), 69(21), 7058-7065  
CODEN: JOCEAH; ISSN: 0022-3263

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 141:410858


AB 4,5-Diaryl-1H-pyrazole-3-ol was utilized as a versatile template to synthesize several classes of compds. such as pyrazolooxazines, pyrazolobenzooxazines, pyrazolooxazoles, and annulated pyrazolooxazoles as potential COX-2 inhibitors. The pyrano- and thiopyranopyrazolooxazoles were successfully synthesized with use of pyridinium p-toluenesulfonate mediated cyclization of ketal intermediates. Diarylpyrazolobenzooxazepine analogs were synthesized by using Cu-mediated cyclization of O-alkylated aryl bromide intermediate. Arylsulfonamides were synthesized efficiently on a large scale with the 4-[4-(4-fluorophenyl)-5-hydroxy-2H-pyrazol-3-yl]benzenesulfonamide template readily synthesized from com. available 4-sulfamoylbenzoic acid. The structure of a representative compound from each class was confirmed by X-ray crystallog. Selected compds. tested for inhibitory activity against COX-1 and COX-2 enzymes showed good selectivity for COX-2 vs. COX-1 enzyme.

IT 329075-99-2P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation of 4,5-diaryl-1H-pyrazole-3-ol derivs. as potential COX-2 inhibitors)

RN 329075-99-2 CAPLUS

CN 2-Butanone, 1-[[1-ethyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]oxy]-3,3-dimethyl- (CA INDEX NAME)



IT 329075-80-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)


(preparation of 4,5-diaryl-1H-pyrazole-3-ol derivs. as potential COX-2



inhibitors)

RN 329075-80-1 CAPLUS

CN 1H-Pyrazole, 4-(4-fluorophenyl)-3-[(4-fluorophenyl)methoxy]-1-[(4-fluorophenyl)methyl]-5-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




IT 329076-00-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of 4,5-diaryl-1H-pyrazole-3-ol derivs. as potential COX-2 inhibitors)

RN 329076-00-8 CAPLUS

CN 1H-Pyrazole-1-acetonitrile, 3-(3,3-dimethyl-2-oxobutoxy)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)



IT 329075-93-6P 329075-97-0P



RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)

(preparation of 4,5-diaryl-1H-pyrazole-3-ol derivs. as potential COX-2 inhibitors)


RN 329075-93-6 CAPLUS

CN Ethanone, 2-[[1-ethyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]oxy]-1-(2-thienyl)- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A





RN 329075-97-0 CAPLUS  
 CN 2-Butanone, 1-[3-(3,3-dimethyl-2-oxobutoxy)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-3,3-dimethyl- (CA INDEX NAME)




IT 329076-08-6P 329076-88-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of 4,5-diaryl-1H-pyrazole-3-ol derivs. as potential COX-2 inhibitors)  
 RN 329076-08-6 CAPLUS  
 CN Ethanone, 1-(4-fluorophenyl)-2-[[4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]oxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 329076-88-2 CAPLUS


CN Ethanone, 1-(4-fluorophenyl)-2-[[5-(4-fluorophenyl)-4-[4-(methylthio)phenyl]-1H-pyrazol-3-yl]oxy]- (CA INDEX NAME)




IT 329075-85-6P 329075-90-3P 329075-92-5P  
329075-98-1P 329076-01-9P 329076-47-3P  
329076-50-8P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of 4,5-diaryl-1H-pyrazole-3-ol derivs. as potential COX-2 inhibitors)


RN 329075-85-6 CAPLUS  
 CN Ethanone, 1-(4-fluorophenyl)-2-[4-(4-fluorophenyl)-3-[2-(4-fluorophenyl)-2-oxoethoxy]-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]- (CA INDEX NAME)




RN 329075-90-3 CAPLUS  
 CN Ethanone, 2-[[1-ethyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]oxy]-1-(4-fluorophenyl)- (CA INDEX NAME)




PAGE 1-A



PAGE 2-A




RN 329075-92-5 CAPLUS  
 CN Ethanone, 2-[4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-[2-oxo-2-(2-thienyl)ethoxy]-1H-pyrazol-1-yl]-1-(2-thienyl)- (CA INDEX NAME)




RN 329075-98-1 CAPLUS

CN 2-Butanone, 1-[[1-(3,3-dichloro-2-propen-1-yl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]oxy]-3,3-dimethyl- (CA INDEX NAME)






RN 329076-01-9 CAPLUS

CN Benzenesulfonamide, 4-[3-(3,3-dimethyl-2-oxobutoxy)-1-ethyl-4-(4-fluorophenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 329076-47-3 CAPLUS

CN Ethanone, 1-(4-fluorophenyl)-2-[5-(4-fluorophenyl)-3-[2-(4-fluorophenyl)-2-oxoethoxy]-4-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 329076-50-8 CAPLUS

CN 2-Butanone, 1-[[1-ethyl-5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]oxy]-3,3-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 15 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:493684 CAPLUS Full-text


DOCUMENT NUMBER: 141:54327

TITLE: Preparation of pyrazole derivatives useful as COX-1 inhibitors

INVENTOR(S): Shirai, Fumiyuki; Azami, Hidenori; Kayakiri, Natsuko;  
 Okumura, Kazuo; Nakamura, Katsuya  
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 436 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050632	A1	20040617	WO 2003-JP14489	20031114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2505945	A1	20040617	CA 2003-2505945	20031114
AU 2003302635	A1	20040623	AU 2003-302635	20031114
EP 1567503	A1	20050831	EP 2003-812289	20031114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016332	A	20050927	BR 2003-16332	20031114
CN 1717393	A	20060104	CN 2003-80104548	20031114
JP 2006514095	T	20060427	JP 2004-570721	20031114
NZ 540515	A	20080131	NZ 2003-540515	20031114
MX 2005PA05742	A	20050816	MX 2005-PA5742	20050530
IN 2005CN01453	A	20070622	IN 2005-CN1453	20050629
NO 2005003215	A	20050901	NO 2005-3215	20050630
PRIORITY APPLN. INFO.:			AU 2002-953019	A 20021202
			AU 2002-953602	A 20021230
			AU 2003-902015	A 20030429
			WO 2003-JP14489	W 20031114

OTHER SOURCE(S): MARPAT 141:54327  
 GI



AB The compds. [I; R1 = H, alkyl; R2 = alkyl, haloalkyl, hydroxyalkyl, etc.; R3 = alkoxy, halo, CN, etc. ; R4 = H, CN, OH, etc.; X = O, S, SO, SO2; Y = CH, N; Z = alkylene, alkenylene; m = 0-1], were prepared E.g., a 3-step synthesis of 4-[3-isopropyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenol, was given. The


compds. I have an inhibiting activity against COX, particularly a selective inhibiting activity against COX-1 (data for representative compds. I is given). The pharmaceutical composition comprising the compound I is claimed.

IT 705934-39-0P 705936-97-6P 705937-04-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of pyrazole derivs. useful as COX-1 inhibitors)


RN 705934-39-0 CAPLUS

CN 1H-Pyrazole, 3-methoxy-1-(4-methoxyphenyl)-5-[4-(phenylmethoxy)phenyl]-  
(CA INDEX NAME)



RN 705936-97-6 CAPLUS


CN Acetic acid, 2-[4-[3-methoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]-  
(CA INDEX NAME)



RN 705937-04-8 CAPLUS

CN Ethanamine, 2-[4-[3-methoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]-,  
hydrochloride (1:1) (CA INDEX NAME)





● HCl


IT 705936-98-7P 705937-05-9P 705937-06-0P  
 705937-07-1P 705937-08-2P 705937-09-3P  
 705937-10-6P 705937-19-5P 705937-20-8P  
 705937-21-9P 705937-22-0P 705937-38-8P  
 705937-39-9P 705937-40-2P 705937-41-3P  
 705937-42-4P 705937-43-5P 705937-44-6P  
 705937-45-7P 705937-57-1P 705937-58-2P  
 705937-59-3P 705937-60-6P 705937-71-9P  
 705937-73-1P 705937-81-1P 705937-82-2P  
 705937-98-0P 705937-99-1P 705938-00-7P  
 705938-01-8P 705938-02-9P 705938-03-0P  
 705938-04-1P 705938-06-3P 705938-07-4P  
 705938-08-5P 705938-09-6P 705938-14-3P  
 705938-17-6P 705938-18-7P 705938-19-8P  
 705938-20-1P 705938-21-2P 705938-26-7P  
 705938-27-8P 705938-28-9P 705938-29-0P  
 705938-36-9P 705938-47-2P 705938-48-3P  
 705938-49-4P 705938-50-7P 705938-51-8P  
 705938-52-9P 705938-56-3P 705938-57-4P  
 705938-58-5P 705938-59-6P 705938-63-2P  
 705938-64-3P 705938-65-4P 705938-66-5P  
 705938-67-6P 705938-68-7P 705938-69-8P  
 705938-70-1P 705938-72-3P 705938-73-4P  
 705938-74-5P 705938-75-6P 705938-76-7P  
 705938-85-8P 705939-25-9P 705939-33-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of pyrazole derivs. useful as COX-1 inhibitors)

RN 705936-98-7 CAPLUS

CN Ethanol, 2-[4-[3-methoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]-(CA INDEX NAME)




RN 705937-05-9 CAPLUS  
CN Ethanamine, 2-[4-[3-ethoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 705937-06-0 CAPLUS  
CN Ethanamine, 2-[4-[1-(4-methoxyphenyl)-3-(2-methylpropoxy)-1H-pyrazol-5-yl]phenoxy]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 705937-07-1 CAPLUS  
CN Ethanamine, 2-[4-[3-(2-methoxyethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 705937-08-2 CAPLUS


CN Ethanamine, 2-[4-[3-(2-ethoxyethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 705937-09-3 CAPLUS


CN Ethanamine, 2-[4-[3-methoxy-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 705937-10-6 CAPLUS


CN Ethanamine, 2-[4-[3-ethoxy-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 705937-19-5 CAPLUS


CN Ethanamine, 2-[4-[1-(4-methoxyphenyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]phenoxy]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 705937-20-8 CAPLUS


CN Ethanamine, 2-[4-[3-(2,2-difluoroethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 705937-21-9 CAPLUS


CN Ethanamine, 2-[4-[1-(6-methoxy-3-pyridinyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]phenoxy]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 705937-22-0 CAPLUS


CN Ethanamine, 2-[4-[3-(2,2-difluoroethoxy)-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 705937-38-8 CAPLUS


CN Methanesulfonamide, N-[2-[4-[3-methoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)



RN 705937-39-9 CAPLUS


CN Ethanesulfonamide, N-[2-[4-[3-methoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-

yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 705937-40-2 CAPLUS

CN Methanesulfonamide, N-[2-[4-[3-ethoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 705937-41-3 CAPLUS

CN Methanesulfonamide, N-[2-[4-[1-(4-methoxyphenyl)-3-(2-methylpropoxy)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 705937-42-4 CAPLUS

CN Methanesulfonamide, N-[2-[4-[3-(2-methoxyethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 705937-43-5 CAPLUS

CN Methanesulfonamide, N-[2-[4-[3-(2-ethoxyethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 705937-44-6 CAPLUS

CN Methanesulfonamide, N-[2-[4-[3-methoxy-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 705937-45-7 CAPLUS

CN Methanesulfonamide, N-[2-[4-[3-ethoxy-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 705937-57-1 CAPLUS

CN Methanesulfonamide, N-[2-[4-[1-(4-methoxyphenyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)



RN 705937-58-2 CAPLUS


CN Methanesulfonamide, N-[2-[4-[3-(2,2-difluoroethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)



RN 705937-59-3 CAPLUS


CN Methanesulfonamide, N-[2-[4-[1-(6-methoxy-3-pyridinyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)






RN 705937-60-6 CAPLUS

CN Methanesulfonamide, N-[2-[4-[3-(2,2-difluoroethoxy)-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 705937-71-9 CAPLUS

CN Methanesulfonamide, N-[[4-[3-methoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenyl]methyl]- (CA INDEX NAME)




RN 705937-73-1 CAPLUS

CN Methanesulfonamide, N-[[4-[1-(6-methoxy-3-pyridinyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]phenyl]methyl]- (CA INDEX NAME)




RN 705937-81-1 CAPLUS

CN Urea, N-[2-[4-[3-methoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 705937-82-2 CAPLUS

CN Urea, N-[2-[4-[3-ethoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 705937-98-0 CAPLUS

CN Ethanol, 2-[4-[3-ethoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]- (CA INDEX NAME)




RN 705937-99-1 CAPLUS

CN Ethanol, 2-[4-[1-(4-methoxyphenyl)-3-(2-methylpropoxy)-1H-pyrazol-5-yl]phenoxy]- (CA INDEX NAME)




RN 705938-00-7 CAPLUS

CN Ethanol, 2-[4-[3-(2-methoxyethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]- (CA INDEX NAME)




RN 705938-01-8 CAPLUS

CN Ethanol, 2-[4-[3-(2-ethoxyethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]- (CA INDEX NAME)




RN 705938-02-9 CAPLUS

CN Acetamide, 2-[[5-[4-(2-hydroxyethoxy)phenyl]-1-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 705938-03-0 CAPLUS

CN Ethanol, 2-[4-[3-methoxy-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]- (CA INDEX NAME)




RN 705938-04-1 CAPLUS

CN Ethanol, 2-[4-[3-ethoxy-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]- (CA INDEX NAME)




RN 705938-06-3 CAPLUS

CN Ethanol, 2-[4-[1-(4-methoxyphenyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]phenoxy]- (CA INDEX NAME)




RN 705938-07-4 CAPLUS

CN Ethanol, 2-[4-[3-(2,2-difluoroethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]- (CA INDEX NAME)




RN 705938-08-5 CAPLUS

CN Ethanol, 2-[4-[1-(6-methoxy-3-pyridinyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]phenoxy]- (CA INDEX NAME)




RN 705938-09-6 CAPLUS

CN Ethanol, 2-[4-[3-(2,2-difluoroethoxy)-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]- (CA INDEX NAME)



RN 705938-14-3 CAPLUS


CN Acetamide, 2-[[5-[4-(2-aminoethoxy)phenyl]-1-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]-N,N-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 705938-17-6 CAPLUS

CN Urea, N-[2-[4-[3-(2-methoxyethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 705938-18-7 CAPLUS

CN Urea, N-[2-[4-[3-(2-ethoxyethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 705938-19-8 CAPLUS

CN Acetamide, 2-[[5-[4-[2-[(aminocarbonyl)amino]ethoxy]phenyl]-1-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 705938-20-1 CAPLUS

CN Urea, N-[2-[4-[3-methoxy-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 705938-21-2 CAPLUS

CN Urea, N-[2-[4-[3-ethoxy-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)



RN 705938-26-7 CAPLUS


CN Urea, N-[2-[4-[1-(4-methoxyphenyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)



RN 705938-27-8 CAPLUS


CN Urea, N-[2-[4-[3-(2,2-difluoroethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)






RN 705938-28-9 CAPLUS

CN Urea, N-[2-[4-[1-(6-methoxy-3-pyridinyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 705938-29-0 CAPLUS

CN Urea, N-[2-[4-[3-(2,2-difluoroethoxy)-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 705938-36-9 CAPLUS

CN Urea, N-[2-[4-[3-methoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenyl]methyl]- (CA INDEX NAME)




RN 705938-47-2 CAPLUS

CN Carbamic acid, [2-[4-[3-methoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 705938-48-3 CAPLUS

CN Carbamic acid, [2-[4-[1-(4-methoxyphenyl)-3-(2-methylpropoxy)-1H-pyrazol-5-yl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 705938-49-4 CAPLUS

CN Carbamic acid, [2-[4-[3-(2-methoxyethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 705938-50-7 CAPLUS

CN Carbamic acid, [2-[4-[3-(2-ethoxyethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 705938-51-8 CAPLUS

CN Carbamic acid, [2-[4-[3-methoxy-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 705938-52-9 CAPLUS

CN Carbamic acid, [2-[4-[3-ethoxy-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 705938-56-3 CAPLUS

CN Carbamic acid, [2-[4-[1-(4-methoxyphenyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 705938-57-4 CAPLUS

CN Carbamic acid, [2-[4-[3-(2,2-difluoroethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 705938-58-5 CAPLUS

CN Carbamic acid, [2-[4-[1-(6-methoxy-3-pyridinyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 705938-59-6 CAPLUS

CN Carbamic acid, [2-[4-[3-(2,2-difluoroethoxy)-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 705938-63-2 CAPLUS

CN Methanesulfonamide, 1,1,1-trifluoro-N-[2-[4-[3-methoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 705938-64-3 CAPLUS

CN 1H-Pyrazole, 3-ethoxy-1-(4-methoxyphenyl)-5-[4-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 705938-65-4 CAPLUS

CN Pyridine, 5-[3-ethoxy-5-[4-(phenylmethoxy)phenyl]-1H-pyrazol-1-yl]-2-methoxy- (CA INDEX NAME)




RN 705938-66-5 CAPLUS

CN Carbamic acid, [2-[4-[3-ethoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 705938-67-6 CAPLUS

CN 1H-Pyrazole, 1-(4-methoxyphenyl)-3-(2-methylpropoxy)-5-[4-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 705938-68-7 CAPLUS

CN 1H-Pyrazole, 3-(2-methoxyethoxy)-1-(4-methoxyphenyl)-5-[4-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 705938-69-8 CAPLUS

CN 1H-Pyrazole, 3-(2-ethoxyethoxy)-1-(4-methoxyphenyl)-5-[4-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 705938-70-1 CAPLUS

CN Acetamide, 2-[[1-(4-methoxyphenyl)-5-[4-(phenylmethoxy)phenyl]-1H-pyrazol-3-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 705938-72-3 CAPLUS

CN 1H-Pyrazole, 1-(4-methoxyphenyl)-5-[4-(phenylmethoxy)phenyl]-3-(2,2,2-trifluoroethoxy)- (CA INDEX NAME)



RN 705938-73-4 CAPLUS


CN 1H-Pyrazole, 3-(2,2-difluoroethoxy)-1-(4-methoxyphenyl)-5-[4-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 705938-74-5 CAPLUS


CN Pyridine, 2-methoxy-5-[5-[4-(phenylmethoxy)phenyl]-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-1-yl]- (CA INDEX NAME)






RN 705938-75-6 CAPLUS

CN Pyridine, 5-[3-(2,2-difluoroethoxy)-5-[4-(phenylmethoxy)phenyl]-1H-pyrazol-1-yl]-2-methoxy- (CA INDEX NAME)




RN 705938-76-7 CAPLUS

CN Pyridine, 2-methoxy-5-[3-methoxy-5-[4-(phenylmethoxy)phenyl]-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 705938-85-8 CAPLUS


CN Benzenemethanamine, 4-[3-methoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 705939-25-9 CAPLUS

CN Benzenemethanamine, 4-[1-(6-methoxy-3-pyridinyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]- (CA INDEX NAME)



RN 705939-33-9 CAPLUS

CN Thiourea, N-[2-[4-[3-methoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




IT 705939-75-9P 705939-79-3P 705939-80-6P  
 705939-81-7P 705939-82-8P 705939-83-9P  
 705939-84-0P 705939-85-1P 705939-89-5P  
 705939-90-8P 705939-91-9P 705939-92-0P  
 705939-98-6P 705940-01-8P 705940-03-0P  
 705940-06-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrazole derivs. useful as COX-1 inhibitors)


RN 705939-75-9 CAPLUS

CN Phenol, 4-[3-methoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 705939-79-3 CAPLUS

CN Phenol, 4-[3-ethoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 705939-80-6 CAPLUS

CN Phenol, 4-[1-(4-methoxyphenyl)-3-(2-methylpropoxy)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 705939-81-7 CAPLUS

CN Phenol, 4-[3-(2-methoxyethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 705939-82-8 CAPLUS

CN Phenol, 4-[3-(2-ethoxyethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 705939-83-9 CAPLUS

CN Acetamide, 2-[[5-(4-hydroxyphenyl)-1-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 705939-84-0 CAPLUS

CN Phenol, 4-[3-methoxy-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 705939-85-1 CAPLUS

CN Phenol, 4-[3-ethoxy-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 705939-89-5 CAPLUS

CN Phenol, 4-[1-(4-methoxyphenyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 705939-90-8 CAPLUS

CN Phenol, 4-[3-(2,2-difluoroethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 705939-91-9 CAPLUS

CN Phenol, 4-[1-(6-methoxy-3-pyridinyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 705939-92-0 CAPLUS

CN Phenol, 4-[3-(2,2-difluoroethoxy)-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 705939-98-6 CAPLUS

CN Methanesulfonic acid, 1,1,1-trifluoro-, 4-[3-methoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenyl ester (CA INDEX NAME)




RN 705940-01-8 CAPLUS


CN Benzonitrile, 4-[3-methoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)



RN 705940-03-0 CAPLUS  
 CN Benzonitrile, 4-[1-(6-methoxy-3-pyridinyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]- (CA INDEX NAME)



RN 705940-06-3 CAPLUS  
 CN Methanesulfonic acid, 1,1,1-trifluoro-, 4-[1-(6-methoxy-3-pyridinyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]phenyl ester (CA INDEX NAME)




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 16 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:493568 CAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 141:54325  
 TITLE: Preparation of pyrazole derivatives useful as COX-1 inhibitors  
 INVENTOR(S): Shirai, Fumiyuki; Azami, Hidenori; Kayakiri, Natsuko; Okumura, Kazuo; Nakamura, Katsuya

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan  
 SOURCE: U.S. Pat. Appl. Publ., 142 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 20040116475	A1	20040617	US 2003-706999	20031114
US 7183306	B2	20070227		
CN 1717393	A	20060104	CN 2003-80104548	20031114
US 20070112037	A1	20070517	US 2006-610230	20061213
PRIORITY APPLN. INFO.:			AU 2002-953019	A 20021202
			AU 2002-953602	A 20021230
			AU 2003-902015	A 20030429
			US 2003-706999	A3 20031114

OTHER SOURCE(S): MARPAT 141:54325  
 GI




AB The compds. [I; R1 = H, alkyl; R2 = alkyl, haloalkyl, hydroxyalkyl, etc.; R3 = alkoxy, halo, CN, etc. ; R4 = H, CN, OH, etc.; X = O, S, SO, SO<sub>2</sub>; Y = CH, N; Z = alkylene, alkenylene; m = 0-1], were prepared E.g., a 3-step synthesis of 4-[3-isopropyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenol, was given. The compds. I have an inhibiting activity against COX, particularly a selective inhibiting activity against COX-1 (data for representative compds. I is given). The pharmaceutical composition comprising the compound I is claimed.

IT 705934-39-0P 705936-97-6P 705937-04-8P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of pyrazole derivs. useful as COX-1 inhibitors)

RN 705934-39-0 CAPLUS


CN 1H-Pyrazole, 3-methoxy-1-(4-methoxyphenyl)-5-[4-(phenylmethoxy)phenyl]-  
 (CA INDEX NAME)






RN 705936-97-6 CAPLUS

CN Acetic acid, 2-[4-[3-methoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]-  
(CA INDEX NAME)



RN 705937-04-8 CAPLUS

CN Ethanamine, 2-[4-[3-methoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]-,  
hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 705936-98-7P 705937-05-9P 705937-06-0P  
705937-07-1P 705937-08-2P 705937-09-3P  
705937-10-6P 705937-19-5P 705937-20-8P  
705937-21-9P 705937-22-0P 705937-38-8P  
705937-39-9P 705937-40-2P 705937-41-3P  
705937-42-4P 705937-43-5P 705937-44-6P  
705937-45-7P 705937-57-1P 705937-58-2P  
705937-59-3P 705937-60-6P 705937-71-9P  
705937-73-1P 705937-81-1P 705937-82-2P


705937-98-0P 705937-99-1P 705938-00-7P  
 705938-01-8P 705938-02-9P 705938-03-0P  
 705938-04-1P 705938-06-3P 705938-07-4P  
 705938-08-5P 705938-09-6P 705938-14-3P  
 705938-17-6P 705938-18-7P 705938-19-8P  
 705938-20-1P 705938-21-2P 705938-26-7P  
 705938-27-8P 705938-28-9P 705938-29-0P  
 705938-36-9P 705938-47-2P 705938-48-3P  
 705938-49-4P 705938-50-7P 705938-51-8P  
 705938-52-9P 705938-56-3P 705938-57-4P  
 705938-58-5P 705938-59-6P 705938-63-2P  
 705938-64-3P 705938-65-4P 705938-66-5P  
 705938-67-6P 705938-68-7P 705938-69-8P  
 705938-70-1P 705938-72-3P 705938-73-4P  
 705938-74-5P 705938-75-6P 705938-76-7P  
 705938-85-8P 705939-25-9P 705939-33-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazole derivs. useful as COX-1 inhibitors)


RN 705936-98-7 CAPLUS

CN Ethanol, 2-[4-[3-methoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]-(CA INDEX NAME)



RN 705937-05-9 CAPLUS

CN Ethanamine, 2-[4-[3-ethoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 705937-06-0 CAPLUS

CN Ethanamine, 2-[4-[1-(4-methoxyphenyl)-3-(2-methylpropoxy)-1H-pyrazol-5-


yl]phenoxy]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 705937-07-1 CAPLUS


CN Ethanamine, 2-[4-[3-(2-methoxyethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 705937-08-2 CAPLUS


CN Ethanamine, 2-[4-[3-(2-ethoxyethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 705937-09-3 CAPLUS


CN Ethanamine, 2-[4-[3-methoxy-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 705937-10-6 CAPLUS


CN Ethanamine, 2-[4-[3-ethoxy-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 705937-19-5 CAPLUS

CN Ethanamine, 2-[4-[1-(4-methoxyphenyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]phenoxy]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


RN 705937-20-8 CAPLUS  
 CN Ethanamine, 2-[4-[3-(2,2-difluoroethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]-, hydrochloride (1:1) (CA INDEX NAME)



RN 705937-21-9 CAPLUS  
 CN Ethanamine, 2-[4-[1-(6-methoxy-3-pyridinyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]phenoxy]-, hydrochloride (1:2) (CA INDEX NAME)




RN 705937-22-0 CAPLUS  
 CN Ethanamine, 2-[4-[3-(2,2-difluoroethoxy)-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 705937-38-8 CAPLUS

CN Methanesulfonamide, N-[2-[4-[3-methoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 705937-39-9 CAPLUS

CN Ethanesulfonamide, N-[2-[4-[3-methoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 705937-40-2 CAPLUS

CN Methanesulfonamide, N-[2-[4-[3-ethoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 705937-41-3 CAPLUS

CN Methanesulfonamide, N-[2-[4-[1-(4-methoxyphenyl)-3-(2-methylpropoxy)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 705937-42-4 CAPLUS

CN Methanesulfonamide, N-[2-[4-[3-(2-methoxyethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 705937-43-5 CAPLUS

CN Methanesulfonamide, N-[2-[4-[3-(2-ethoxyethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 705937-44-6 CAPLUS

CN Methanesulfonamide, N-[2-[4-[3-methoxy-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)



RN 705937-45-7 CAPLUS


CN Methanesulfonamide, N-[2-[4-[3-ethoxy-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)



RN 705937-57-1 CAPLUS


CN Methanesulfonamide, N-[2-[4-[1-(4-methoxyphenyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)






RN 705937-58-2 CAPLUS

CN Methanesulfonamide, N-[2-[4-[3-(2,2-difluoroethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)






RN 705937-59-3 CAPLUS


CN Methanesulfonamide, N-[2-[4-[1-(6-methoxy-3-pyridinyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)



RN 705937-60-6 CAPLUS


CN Methanesulfonamide, N-[2-[4-[3-(2,2-difluoroethoxy)-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)






RN 705937-82-2 CAPLUS

CN Urea, N-[2-[4-[3-ethoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]-  
(CA INDEX NAME)




RN 705937-98-0 CAPLUS

CN Ethanol, 2-[4-[3-ethoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]- (CA  
INDEX NAME)




RN 705937-99-1 CAPLUS

CN Ethanol, 2-[4-[1-(4-methoxyphenyl)-3-(2-methylpropoxy)-1H-pyrazol-5-yl]phenoxy]-  
(CA INDEX NAME)




RN 705938-00-7 CAPLUS

CN Ethanol, 2-[4-[3-(2-methoxyethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]- (CA INDEX NAME)




RN 705938-01-8 CAPLUS

CN Ethanol, 2-[4-[3-(2-ethoxyethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]- (CA INDEX NAME)




RN 705938-02-9 CAPLUS

CN Acetamide, 2-[[5-[4-(2-hydroxyethoxy)phenyl]-1-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 705938-03-0 CAPLUS

CN Ethanol, 2-[4-[3-methoxy-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]- (CA INDEX NAME)




RN 705938-04-1 CAPLUS

CN Ethanol, 2-[4-[3-ethoxy-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]- (CA INDEX NAME)




RN 705938-06-3 CAPLUS

CN Ethanol, 2-[4-[1-(4-methoxyphenyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]phenoxy]- (CA INDEX NAME)




RN 705938-07-4 CAPLUS

CN Ethanol, 2-[4-[3-(2,2-difluoroethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]- (CA INDEX NAME)




RN 705938-08-5 CAPLUS

CN Ethanol, 2-[4-[1-(6-methoxy-3-pyridinyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]phenoxy]- (CA INDEX NAME)




RN 705938-09-6 CAPLUS

CN Ethanol, 2-[4-[3-(2,2-difluoroethoxy)-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]- (CA INDEX NAME)



RN 705938-14-3 CAPLUS


CN Acetamide, 2-[[5-[4-(2-aminoethoxy)phenyl]-1-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]-N,N-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 705938-17-6 CAPLUS

CN Urea, N-[2-[4-[3-(2-methoxyethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 705938-18-7 CAPLUS

CN Urea, N-[2-[4-[3-(2-ethoxyethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 705938-19-8 CAPLUS

CN Acetamide, 2-[[5-[4-[2-[(aminocarbonyl)amino]ethoxy]phenyl]-1-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 705938-20-1 CAPLUS


CN Urea, N-[2-[4-[3-methoxy-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)



RN 705938-21-2 CAPLUS


CN Urea, N-[2-[4-[3-ethoxy-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)






RN 705938-26-7 CAPLUS

CN Urea, N-[2-[4-[1-(4-methoxyphenyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 705938-27-8 CAPLUS

CN Urea, N-[2-[4-[3-(2,2-difluoroethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 705938-28-9 CAPLUS

CN Urea, N-[2-[4-[1-(6-methoxy-3-pyridinyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 705938-29-0 CAPLUS

CN Urea, N-[2-[4-[3-(2,2-difluoroethoxy)-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 705938-36-9 CAPLUS

CN Urea, N-[[4-[3-methoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenyl]methyl]- (CA INDEX NAME)




RN 705938-47-2 CAPLUS

CN Carbamic acid, [2-[4-[3-methoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 705938-48-3 CAPLUS

CN Carbamic acid, [2-[4-[1-(4-methoxyphenyl)-3-(2-methylpropoxy)-1H-pyrazol-5-yl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 705938-49-4 CAPLUS

CN Carbamic acid, [2-[4-[3-(2-methoxyethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 705938-50-7 CAPLUS

CN Carbamic acid, [2-[4-[3-(2-ethoxyethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 705938-51-8 CAPLUS

CN Carbamic acid, [2-[4-[3-methoxy-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 705938-52-9 CAPLUS

CN Carbamic acid, [2-[4-[3-ethoxy-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 705938-56-3 CAPLUS

CN Carbamic acid, [2-[4-[1-(4-methoxyphenyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 705938-57-4 CAPLUS

CN Carbamic acid, [2-[4-[3-(2,2-difluoroethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 705938-58-5 CAPLUS

CN Carbamic acid, [2-[4-[1-(6-methoxy-3-pyridinyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 705938-59-6 CAPLUS

CN Carbamic acid, [2-[4-[3-(2,2-difluoroethoxy)-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 705938-63-2 CAPLUS

CN Methanesulfonamide, 1,1,1-trifluoro-N-[2-[4-[3-methoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 705938-64-3 CAPLUS

CN 1H-Pyrazole, 3-ethoxy-1-(4-methoxyphenyl)-5-[4-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 705938-65-4 CAPLUS

CN Pyridine, 5-[3-ethoxy-5-[4-(phenylmethoxy)phenyl]-1H-pyrazol-1-yl]-2-methoxy- (CA INDEX NAME)




RN 705938-66-5 CAPLUS

CN Carbamic acid, [2-[4-[3-ethoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 705938-67-6 CAPLUS

CN 1H-Pyrazole, 1-(4-methoxyphenyl)-3-(2-methylpropoxy)-5-[4-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 705938-68-7 CAPLUS

CN 1H-Pyrazole, 3-(2-methoxyethoxy)-1-(4-methoxyphenyl)-5-[4-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 705938-69-8 CAPLUS

CN 1H-Pyrazole, 3-(2-ethoxyethoxy)-1-(4-methoxyphenyl)-5-[4-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 705938-70-1 CAPLUS


CN Acetamide, 2-[[1-(4-methoxyphenyl)-5-[4-(phenylmethoxy)phenyl]-1H-pyrazol-3-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 705938-72-3 CAPLUS


CN 1H-Pyrazole, 1-(4-methoxyphenyl)-5-[4-(phenylmethoxy)phenyl]-3-(2,2,2-trifluoroethoxy)- (CA INDEX NAME)






RN 705938-73-4 CAPLUS

CN 1H-Pyrazole, 3-(2,2-difluoroethoxy)-1-(4-methoxyphenyl)-5-[4-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 705938-74-5 CAPLUS

CN Pyridine, 2-methoxy-5-[5-[4-(phenylmethoxy)phenyl]-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-1-yl]- (CA INDEX NAME)




RN 705938-75-6 CAPLUS

CN Pyridine, 5-[3-(2,2-difluoroethoxy)-5-[4-(phenylmethoxy)phenyl]-1H-pyrazol-1-yl]-2-methoxy- (CA INDEX NAME)




RN 705938-76-7 CAPLUS

CN Pyridine, 2-methoxy-5-[3-methoxy-5-[4-(phenylmethoxy)phenyl]-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 705938-85-8 CAPLUS


CN Benzenemethanamine, 4-[3-methoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 705939-25-9 CAPLUS

CN Benzenemethanamine, 4-[1-(6-methoxy-3-pyridinyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]- (CA INDEX NAME)



RN 705939-33-9 CAPLUS

CN Thiourea, N-[2-[4-[3-methoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




IT 705939-75-9P 705939-79-3P 705939-80-6P  
 705939-81-7P 705939-82-8P 705939-83-9P  
 705939-84-0P 705939-85-1P 705939-89-5P  
 705939-90-8P 705939-91-9P 705939-92-0P  
 705939-98-6P 705940-01-8P 705940-03-0P  
 705940-06-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrazole derivs. useful as COX-1 inhibitors)


RN 705939-75-9 CAPLUS

CN Phenol, 4-[3-methoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 705939-79-3 CAPLUS


CN Phenol, 4-[3-methoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 705939-80-6 CAPLUS  
 CN Phenol, 4-[1-(4-methoxyphenyl)-3-(2-methylpropoxy)-1H-pyrazol-5-yl]- (CA  
 INDEX NAME)



RN 705939-81-7 CAPLUS  
 CN Phenol, 4-[3-(2-methoxyethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]- (CA  
 INDEX NAME)




RN 705939-82-8 CAPLUS  
 CN Phenol, 4-[3-(2-ethoxyethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]- (CA  
 INDEX NAME)




RN 705939-83-9 CAPLUS

CN Acetamide, 2-[[5-(4-hydroxyphenyl)-1-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 705939-84-0 CAPLUS

CN Phenol, 4-[3-methoxy-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 705939-85-1 CAPLUS

CN Phenol, 4-[3-ethoxy-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 705939-89-5 CAPLUS

CN Phenol, 4-[1-(4-methoxyphenyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]-  
(CA INDEX NAME)




RN 705939-90-8 CAPLUS

CN Phenol, 4-[3-(2,2-difluoroethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]-  
(CA INDEX NAME)




RN 705939-91-9 CAPLUS

CN Phenol, 4-[1-(6-methoxy-3-pyridinyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]-  
(CA INDEX NAME)




RN 705939-92-0 CAPLUS

CN Phenol, 4-[3-(2,2-difluoroethoxy)-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]-  
(CA INDEX NAME)




RN 705939-98-6 CAPLUS

CN Methanesulfonic acid, 1,1,1-trifluoro-, 4-[3-methoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenyl ester (CA INDEX NAME)




RN 705940-01-8 CAPLUS

CN Benzonitrile, 4-[3-methoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)




RN 705940-03-0 CAPLUS

CN Benzonitrile, 4-[1-(6-methoxy-3-pyridinyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]- (CA INDEX NAME)



RN 705940-06-3 CAPLUS  
 CN Methanesulfonic acid, 1,1,1-trifluoro-, 4-[1-(6-methoxy-3-pyridinyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]phenyl ester (CA INDEX NAME)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 17 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:311011 CAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 140:321649  
 TITLE: Preparation of pyrazolyl glycoside derivatives as inhibitors of 1,5-anhydroglucitol/fructose/mannose transporters  
 INVENTOR(S): Fujikura, Hideki; Kikuchi, Norihiko; Tazawa, Shigeki; Yamato, Tokuhisa; Isaji, Masayuki  
 PATENT ASSIGNEE(S): Kissei Pharmaceutical Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 159 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004031203	A1	20040415	WO 2003-JP12477	20030930
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				



RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2500873	A1	20040415	CA 2003-2500873	20030930
AU 2003272903	A1	20040423	AU 2003-272903	20030930
EP 1550668	A1	20050706	EP 2003-753967	20030930

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK


US 20060128635	A1	20060615	US 2005-529895	20050919
----------------	----	----------	----------------	----------

PRIORITY APPLN. INFO.:

			JP 2002-293090	A	20021004
			JP 2002-330694	A	20021114
			JP 2002-378959	A	20021227
			WO 2003-JP12477	W	20030930

OTHER SOURCE(S): MARPAT 140:321649

GI



AB The title compds. [I; R = each (un)substituted C3-8 cycloalkyl, C6-10 aryl, C2-9 heterocycloalkyl, or C1-9 heteroaryl; R<sup>1</sup> = H, each (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, C6-10 aryl, C2-9 heterocycloalkyl, or C1-9 heteroaryl; one of Q<sup>0</sup> and T<sup>0</sup> =  $\alpha$ - or  $\beta$ -D-glucopyranosyloxy or -mannopyranosyloxy or  $\beta$ -D-deoxyglucopyranosyloxy- and the other = (CH<sub>2</sub>)<sub>n</sub>Ar; wherein Ar = each (un)substituted C6-10 aryl or C1-9 heteroaryl; n = an integer of 0-2] or pharmacol. acceptable salts or prodrugs thereof are prepared Also disclosed are medicinal composition containing the compound I, medicinal use thereof, and intermediates in producing the same. These compds. exerts an excellent effect of inhibiting human 1,5-anhydroglucitol/fructose/mannose transporters and inhibit reabsorption or cellular uptake of glucose, fructose, and mannose in kidney or absorption of these saccharide small intestine and inhibit the increase in blood sugar. Therefore, they are useful as preventives, progress inhibitors or remedies for a disease caused by the over intake of at least one saccharide selected from among glucose, fructose, and mannose or a disease caused by hyperglycemia (diabetic complication, diabetes, or diabetic nephropathy). Thus, glycosidation of 1-isopropyl-5-(4-methoxyphenyl)-4-[(4-methoxyphenyl)methyl]-1,2-dihydro-3H-pyrazol-3-one by acetobromo- $\alpha$ -D- glucose in the presence of benzyltributylammonium bromide in a mixture of CH<sub>2</sub>Cl<sub>2</sub> and 5 N aqueous NaOH at room temperature for 1.5 h followed by treatment of the product with NaOMe in MeOH gave 3-( $\beta$ -D-glucopyranosyloxy)-1- isopropyl-5-(4-methoxyphenyl)-4-[(4-methoxyphenyl)methyl]-1H-pyrazole (II). II in vitro inhibited the uptake of

[14C]methyl  $\alpha$ -D-glucopyranoside in COS-7 cells transfected with human SMINT/PME18S-FL expression plasmid with IC50 of 92 nM.


IT 678994-79-1P 678994-80-4P 678994-81-5P  
678994-97-3P 678994-99-5P 678995-08-9P  
678995-11-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrazolyl glycoside derivs. as inhibitors of 1,5-anhydroglucitol/fructose/mannose transporters and preventives, progress inhibitors or remedies for diabetic complication, diabetes, or diabetic nephropathy)


RN 678994-79-1 CAPLUS

CN 1H-Pyrazole, 5-(4-methoxyphenyl)-1-(1-methylethyl)-3-(phenylmethoxy)- (CA INDEX NAME)




RN 678994-80-4 CAPLUS

CN 1H-Pyrazole-4-carboxaldehyde, 5-(4-methoxyphenyl)-1-(1-methylethyl)-3-(phenylmethoxy)- (CA INDEX NAME)




RN 678994-81-5 CAPLUS

CN 1H-Pyrazole-4-methanol,  $\alpha$ ,5-bis(4-methoxyphenyl)-1-(1-methylethyl)-3-(phenylmethoxy)- (CA INDEX NAME)




RN 678994-97-3 CAPLUS

CN 1H-Pyrazole, 4-bromo-5-(4-methoxyphenyl)-1-(1-methylethyl)-3-(phenylmethoxy)- (CA INDEX NAME)




RN 678994-99-5 CAPLUS

CN 1H-Pyrazole-4-methanol,  $\alpha$ -(2,4-dimethoxyphenyl)-5-(4-methoxyphenyl)-1-(1-methylethyl)-3-(phenylmethoxy)- (CA INDEX NAME)




RN 678995-08-9 CAPLUS

CN Methanone, [5-[4-(dimethylamino)phenyl]-1-(1-methylethyl)-3-(phenylmethoxy)-1H-pyrazol-4-yl](4-methoxyphenyl)- (CA INDEX NAME)



RN 678995-11-4 CAPLUS

CN 1H-Pyrazole-4-methanol, 5-(4-methoxyphenyl)- $\alpha$ -[2-methoxy-4-[[tris(1-methylethyl)silyl]oxy]phenyl]-1-(1-methylethyl)-3-(phenylmethoxy)- (CA INDEX NAME)



REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 18 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:182871 CAPLUS Full-text

DOCUMENT NUMBER: 140:235706

TITLE: Preparation of substituted pyrazole derivatives as GnRH inhibitors

INVENTOR(S): Bird, Thomas Geoffrey Colerick; Maudet, Mickael Louis Pierre

PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited

SOURCE: PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018459	A1	20040304	WO 2003-GB3623	20030819
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003255811	A1	20040311	AU 2003-255811	20030819
EP 1539743	A1	20050615	EP 2003-792484	20030819
EP 1539743	B1	20070530		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006501231	T	20060112	JP 2004-530359	20030819
AT 363481	T	20070615	AT 2003-792484	20030819
ES 2286493	T3	20071201	ES 2003-792484	20030819
US 20050239858	A1	20051027	US 2005-525111	20050218
US 7253290	B2	20070807		
PRIORITY APPLN. INFO.:			EP 2002-292075	A 20020821
			WO 2003-GB3623	W 20030819
OTHER SOURCE(S):	MARPAT 140:235706			
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [A = bond, alkylene; B = C(:X)R11; R1 = alkyl, etc.; R2 = mono- or bicyclic aromatic ring, etc.; R5 = 3-8 membered heterocyclic ring, etc.; R6-6a = H, alkyl, together equal CO; R7 = H, alkyl; X = N, CH; R8 = CN, H, OH, alkoxy, etc.; R11 = substituted amino, etc.] are prepared For instance, II (prepared in 4 steps from Me 3,5-dimethylbenzoate, butyrolactone and hydrazine) is reacted with 4-nitrophenyl chloroformate and 4-(pyrrolidin-3-yl)pyridine to give III. In an assay of GnRH-induced LH release, compds. of the invention are active at 1nM to 5µM.


IT 667466-15-1P 667466-16-2P 667466-17-3P  
667466-18-4P 667466-19-5P 667466-20-8P  
667466-21-9P 667466-22-0P 667466-23-1P  
667466-24-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted pyrazole derivs. as GnRH inhibitors)


RN 667466-15-1 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[2-[3-[2,2-dimethyl-3-oxo-3-(1-pyrrolidinyl)propoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]ethyl]-3-(4-pyridinyl)- (CA INDEX NAME)




RN 667466-16-2 CAPLUS

CN Carbamic acid, [[[2-[3-[2,2-dimethyl-3-oxo-3-(1-pyrrolidinyl)propoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]ethyl]amino][3-(4-pyridinyl)-1-pyrrolidinyl]methylene]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 667466-17-3 CAPLUS

CN Carbamic acid, [[[2-[3-[3-(diethylamino)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]ethyl]amino][3-(4-pyridinyl)-1-pyrrolidinyl]methylene]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 667466-18-4 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[2-[3-[3-(diethylamino)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]ethyl]-3-(4-pyridinyl)- (CA INDEX NAME)




RN 667466-19-5 CAPLUS

CN Carbamic acid, [[[(2S)-2-[3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]ethyl]-3-(4-pyridinyl)-1-pyrrolidinyl]methylene]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]propyl]amino][3-(4-pyridinyl)-1-pyrrolidinyl]methylene]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667466-20-8 CAPLUS

CN Carbamic acid, [[[2S)-2-[3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]propyl]amino][4-(tetrahydro-2H-pyran-4-yl)-1-piperidinyl]methylene]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667466-21-9 CAPLUS

CN Carbamic acid, [[[2S)-2-[3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]propyl]amino][4-(4-pyridinyl)-1-piperidinyl]methylene]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667466-22-0 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(2S)-2-[3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]propyl]-3-(4-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 667466-23-1 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(2S)-2-[3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]propyl]-3-(2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 667466-24-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(2S)-2-[3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]propyl]-4-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



Absolute stereochemistry.



IT 667461-05-4


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of substituted pyrazole derivs. as GnRH inhibitors)

RN 667461-05-4 CAPLUS

CN 1-Propanone, 2-[[[4-[(1S)-2-amino-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]methyl]-1-(7-azabicyclo[2.2.1]hept-7-yl)-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



IT 667460-74-4P 667460-75-5P 667466-26-4P

667466-27-5P 667466-29-7P 667466-30-0P


667466-31-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of substituted pyrazole derivs. as GnRH inhibitors)


RN 667460-74-4 CAPLUS

CN 1-Propanone, 3-[[[5-(3,5-dimethylphenyl)-4-(2-hydroxyethyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 667460-75-5 CAPLUS

CN 1-Propanone, 3-[[4-(2-aminoethyl)-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 667466-26-4 CAPLUS

CN Carbamic acid, [[[2-[3-[2,2-dimethyl-3-oxo-3-(1-pyrrolidinyl)propoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]ethyl]amino]thioxomethyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 667466-27-5 CAPLUS

CN Carbamic acid, [[[2-[3-[3-(diethylamino)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]ethyl]amino]thioxomethyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 667466-29-7 CAPLUS

CN Propanamide, 3-[[5-(3,5-dimethylphenyl)-4-(2-hydroxyethyl)-1H-pyrazol-3-yl]oxy]-N,N-diethyl-2,2-dimethyl- (CA INDEX NAME)



RN 667466-30-0 CAPLUS


CN Propanamide, 3-[[4-(2-aminoethyl)-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-N,N-diethyl-2,2-dimethyl- (CA INDEX NAME)



RN 667466-31-1 CAPLUS

CN Carbamic acid, [[[2S]-2-[3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]propyl]amino]thioxomethyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 19 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:182700 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 140:235705


TITLE: Preparation of pyrazole derivatives as antagonists of gonadotropin releasing hormone (gnrh) for treating sex hormone related conditions

INVENTOR(S): Bird, Thomas Geoffrey Colerick; Herdemann, Matthias Ferdinand; Maudet, Mickael Louis Pierre

PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited

SOURCE: PCT Int. Appl., 156 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004017961	A2	20040304	WO 2003-GB3633	20030819
WO 2004017961	A3	20040408		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003255820	A1	20040311	AU 2003-255820	20030819
EP 1531811	A2	20050525	EP 2003-792487	20030819
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006505528	T	20060216	JP 2004-530361	20030819
US 20060287379	A1	20061221	US 2005-524977	20051128
PRIORITY APPLN. INFO.:			EP 2002-292077	A 20020821
			WO 2003-GB3633	W 20030819
OTHER SOURCE(S):	MARPAT 140:235705			
GI				



AB Title compds. I [R1 = H, (un)substituted-alkyl, aryl, or arylalkyl; R2 = (un)substituted mono or bicyclic aromatic ring; R3 = arylalkylaminoalkyl,

heterocyclylalkylaminoalkyl, etc.; M = -(CH<sub>2</sub>)<sub>0-20</sub>-, or -CONH-; R<sub>5</sub> = H, halo, heterocyclylcarbonylalkyl, etc.] and their pharmaceutically acceptable salts are prepared and disclosed as gonadotropin releasing hormone antagonists. Thus, e.g., II, was prepared in a multistep synthesis from Me 3,5-dimethylbenzoate and butyrolactone. In test assays, I possessed activity at concns. from 1 nM to 5 μM.

IT 667459-73-6P 667459-74-7P 667459-75-8P  
 667459-76-9P 667459-77-0P 667459-78-1P  
 667459-79-2P 667459-80-5P 667459-81-6P  
 667459-82-7P 667459-83-8P 667459-84-9P  
 667459-85-0P 667459-86-1P 667459-87-2P  
 667459-88-3P 667459-89-4P 667459-90-7P  
 667459-91-8P 667459-92-9P 667459-93-0P  
 667459-94-1P 667459-95-2P 667459-96-3P  
 667459-97-4P 667459-98-5P 667459-99-6P  
 667460-00-6P 667460-01-7P 667460-02-8P  
 667460-03-9P 667460-04-0P 667460-05-1P  
 667460-06-2P 667460-07-3P 667460-08-4P  
 667460-09-5P 667460-10-8P 667460-11-9P  
 667460-12-0P 667460-13-1P 667460-14-2P  
 667460-15-3P 667460-16-4P 667460-17-5P  
 667460-18-6P 667460-19-7P 667460-20-0P  
 667460-21-1P 667460-22-2P 667460-23-3P  
 667460-24-4P 667460-25-5P 667460-26-6P  
 667460-27-7P 667460-28-8P 667460-29-9P  
 667460-30-2P 667460-31-3P 667460-32-4P  
 667460-33-5P 667460-34-6P 667460-35-7P  
 667460-36-8P 667460-37-9P 667460-38-0P  
 667460-39-1P 667460-40-4P 667460-41-5P  
 667460-42-6P 667460-43-7P 667460-44-8P  
 667460-45-9P 667460-46-0P 667460-47-1P  
 667460-48-2P 667460-49-3P 667460-50-6P  
 667460-51-7P 667460-52-8P 667460-53-9P  
 667460-54-0P 667460-55-1P 667460-56-2P  
 667460-57-3P 667460-58-4P 667460-59-5P  
 667460-60-8P 667460-61-9P 667460-62-0P  
 667460-63-1P 667460-64-2P 667460-65-3P  
 667460-66-4P 667460-67-5P 667460-68-6P  
 667460-69-7P 667460-70-0P 667460-71-1P



RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrazoles as antagonists of gonadotropin releasing hormone)


RN 667459-73-6 CAPLUS

CN 1-Propanone, 3-[[[5-(3,5-dimethylphenyl)-4-[2-[[2-(4-pyridinyl)ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-(1-pyrrolidinyl)- (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 667459-74-7 CAPLUS  
CN 1-Propanone, 3-[[5-(3,5-dimethylphenyl)-4-[2-[[3-(4-pyridinyl)propyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-(1-pyrrolidinyl)- (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 667459-75-8 CAPLUS  
 CN 1-Propanone, 3-[[5-(3,5-dimethylphenyl)-4-[2-[[3-(3-pyridinyl)propyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-(1-pyrrolidinyl)- (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 667459-76-9 CAPLUS  
 CN Benzonitrile, 4-[2-[[2-[3-[2,2-dimethyl-3-oxo-3-(1-pyrrolidinyl)propoxy]-5-

(3,5-dimethylphenyl)-1H-pyrazol-4-yl]ethyl]amino]ethyl]- (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 667459-77-0 CAPLUS  
 CN 1-Propanone, 3-[[5-(3,5-dimethylphenyl)-4-[2-[[2-(4-methoxyphenyl)ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-(1-pyrrolidinyl)- (CA INDEX NAME)

PAGE 1-A








PAGE 2-A






RN 667459-78-1 CAPLUS  
 CN 1-Propanone, 3-[[5-(3,5-dimethylphenyl)-4-[2-[[3-(4-methoxyphenoxy)propyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-(1-pyrrolidinyl)- (CA INDEX NAME)

PAGE 1-A






RN 667459-79-2 CAPLUS  
 CN 1-Propanone, 3-[[5-(3,5-dimethylphenyl)-4-[2-[[4-(4-pyridinyl)butyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 667459-80-5 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[2-[[4-(4-pyridinyl)butyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-  
(CA INDEX NAME)




RN 667459-81-6 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-2-[[[5-(3,5-dimethylphenyl)-4-[2-[[2-(4-pyridinyl)ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]methyl]-2-methyl- (CA INDEX NAME)




RN 667459-82-7 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[2-[[2-(1H-1,2,4-triazol-1-yl)ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)




RN 667459-83-8 CAPLUS

CN 1-Propanone, 3-[[4-[2-[[3-(4-acetyl-1-piperazinyl)propyl]amino]ethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-1-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl- (CA INDEX NAME)




RN 667459-84-9 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[2-[[3-(4-morpholinyl)propyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)




RN 667459-85-0 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[2-[[3-(1,1-dioxido-4-thiomorpholinyl)propyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)



RN 667459-86-1 CAPLUS


CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[4-[(1S)-2-[[2-(1,3-benzodioxol-5-yl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)



RN 667459-87-2 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[2-(4-pyridinyl)ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667459-88-3 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[4-(4-pyridinyl)butyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667459-89-4 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[3-(4-pyridinyl)propyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667459-90-7 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[4-phenylbutyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667459-91-8 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[4-(4-methoxyphenyl)butyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667459-92-9 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[4-(4-nitrophenyl)butyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667459-93-0 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[4-(2-pyrimidinyl)butyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667459-94-1 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[4-(2-pyrazinyl)butyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.






RN 667459-95-2 CAPLUS

CN Benzonitrile, 4-[2-[[ (2S)-2-[3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]propyl]amino]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 667459-96-3 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[2-(2-naphthalenyl)ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667459-97-4 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[2-(phenylmethoxy)ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667459-98-5 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[(2-phenylethyl)amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667459-99-6 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[2-[3-(trifluoromethyl)phenyl]ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-00-6 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[4-[(1S)-2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-01-7 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[4-[(1S)-2-[[2-[4-(dimethylamino)phenyl]ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-02-8 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[2-(4-fluorophenyl)ethyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-03-9 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[4-[(1S)-2-[[2-(3,5-difluorophenyl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-04-0 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[4-[(1S)-2-[[2-[4-(1,1-dimethylethyl)phenyl]ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-05-1 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[2-(2,5-dimethylphenyl)ethyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-06-2 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[4-[(1S)-2-[[2-(2-chloro-6-fluorophenyl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-07-3 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[4-[(1S)-2-[[2-(4-chloro-2-fluorophenyl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-08-4 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[4-[(1S)-2-[[2-(3,4-dichlorophenyl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-09-5 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[4-[(1S)-2-[[2-(2,6-dichlorophenyl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-10-8 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[2-oxo-2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-11-9 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-12-0 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[2-(3-fluorophenyl)ethyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-13-1 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[4-[(1S)-2-[[2-(3-chlorophenyl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-14-2 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[2-(3-methoxyphenyl)ethyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-15-3 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[2-(3-methylphenyl)ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-16-4 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[4-[(1S)-2-[[2-(4-chlorophenyl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-17-5 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[2-(4-methylphenyl)ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-18-6 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[2-(4-methoxyphenyl)ethyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 667460-19-7 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-



[(1S)-2-[[2-(2-fluorophenyl)ethyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-20-0 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[4-[(1S)-2-[[2-(3,4-difluorophenyl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-21-1 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[4-[(1S)-2-[[2-(3,5-dimethoxyphenyl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 667460-22-2 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[2-(3,4,5-trimethoxyphenyl)ethyl]amino]ethyl]-1H-pyrazol-

3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-23-3 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[3-(4-methoxyphenoxy)propyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-24-4 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[4-[(1S)-2-[[[5-(dimethylamino)methyl]-2-furanyl]methyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-25-5 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[2-(phenylamino)ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 667460-26-6 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[(3-phenyl-2-propen-1-yl)amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 667460-27-7 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[[(4-methoxyphenyl)methyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 667460-28-8 CAPLUS

CN Urea, N-[4-[2-[[[(2S)-2-[3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-

yl]propyl]amino]ethyl]phenyl]-N'-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-29-9 CAPLUS

CN 1-Propanone, 3-[[4-[(1S)-2-[[2-(4-aminophenyl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-1-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-30-2 CAPLUS

CN Cyclopentanecarboxamide, N-[4-[2-[[[(2S)-2-[3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]propyl]amino]ethyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-31-3 CAPLUS

CN Methanesulfonamide, N-[4-[2-[[[(2S)-2-[3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]propyl]amino]ethyl]phenyl]-N-(methanesulfonyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-32-4 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[(1S)-1-methyl-2-[[2-(2-thienyl)ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-33-5 CAPLUS

CN Methanesulfonamide, N-[4-[2-[[[(2S)-2-[3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]propyl]amino]ethyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-34-6 CAPLUS

CN Carbamic acid, [4-[2-[[[(2S)-2-[3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]propyl]amino]ethyl]phenyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-35-7 CAPLUS

CN Urea, N-[4-[2-[[ (2S)-2-[3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]propyl]amino]ethyl]phenyl]-N'-cyclohexyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-36-8 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[4-[(1S)-2-[(2-cyclohexylethyl)amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 667460-37-9 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[[ (2S)-2-[3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]propyl]amino]ethyl]-1-methyl- (CA INDEX NAME)


RN 667460-40-4 CAPLUS

CN Acetamide, 2-[[[(2S)-2-[3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]propyl]amino]-N-1H-benzotriazol-6-yl- (CA INDEX NAME)



RN 667460-41-5 CAPLUS


CN Ethanone, 2-[4-[2-[3-[2,2-dimethyl-3-oxo-3-(1-pyrrolidinyl)propoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]ethyl]-1-piperazinyl]-1-(1-pyrrolidinyl)- (CA INDEX NAME)



RN 667460-42-6 CAPLUS


CN 1-Propanone, 3-[[5-(3,5-dimethylphenyl)-4-[2-[3-(4-pyridinyl)-1-pyrrolidinyl]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-(1-pyrrolidinyl)- (CA INDEX NAME)






RN 667460-43-7 CAPLUS

CN 1-Propanone, 3-[[5-(3,5-dimethylphenyl)-4-[2-[4-(2-(1-pyrrolidinyl)ethyl)-1-piperazinyl]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-(1-pyrrolidinyl)-  
(CA INDEX NAME)





RN 667460-44-8 CAPLUS


CN 1-Propanone, 3-[[5-(3,5-dimethylphenyl)-4-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-(1-pyrrolidinyl)-  
(CA INDEX NAME)



RN 667460-45-9 CAPLUS  
 CN Ethanone, 2-[4-[2-[3-[2,2-dimethyl-3-oxo-3-(1-pyrrolidinyl)propoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]ethyl]-1-piperazinyl]-1-(4-morpholinyl)-  
 (CA INDEX NAME)


PAGE 1-A






RN 667460-46-0 CAPLUS

CN 1-Piperazineacetamide, 4-[2-[3-[2,2-dimethyl-3-oxo-3-(1-pyrrolidinyl)propoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]ethyl]-N-methyl-N-phenyl- (CA INDEX NAME)



RN 667460-47-1 CAPLUS



CN 1-Propanone, 3-[[5-(3,5-dimethylphenyl)-4-[2-[4-(2-phenylethyl)-1-piperazinyl]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 667460-48-2 CAPLUS

CN 1-Propanone, 3-[[5-(3,5-dimethylphenyl)-4-[2-[4-(4-pyridinylmethyl)-1-piperazinyl]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-(1-pyrrolidinyl)-  
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 667460-49-3 CAPLUS

CN 1-Propanone, 3-[[5-(3,5-dimethylphenyl)-4-[2-[4-(3-phenylpropyl)-1-piperazinyl]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-(1-pyrrolidinyl)-  
(CA INDEX NAME)



RN 667460-50-6 CAPLUS



CN 1-Propanone, 3-[[5-(3,5-dimethylphenyl)-4-[2-[4-(4-phenylbutyl)-1-piperazinyl]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-(1-pyrrolidinyl)-  
(CA INDEX NAME)




RN 667460-51-7 CAPLUS

CN 1-Propanone, 3-[[5-(3,5-dimethylphenyl)-4-[2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperidinyl]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-(1-pyrrolidinyl)-  
(CA INDEX NAME)

PAGE 1-A






PAGE 2-A



RN 667460-52-8 CAPLUS  
 CN 1-Propanone, 3-[[5-(3,5-dimethylphenyl)-4-[2-[3-[4-(trifluoromethyl)phenyl]-1-piperidinyl]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-(1-pyrrolidinyl)- (CA INDEX NAME)


PAGE 1-A





RN 667460-53-9 CAPLUS


CN 1-Propanone, 3-[[5-(3,5-dimethylphenyl)-4-[2-[methyl(2-phenylethyl)amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-(1-pyrrolidinyl)- (CA INDEX NAME)



RN 667460-54-0 CAPLUS

CN 1-Propanone, 1-(2-azabicyclo[2.2.2]oct-2-yl)-3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[2-(3-methoxyphenyl)ethyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667460-55-1 CAPLUS


CN 1-Propanone, 1-(2-azabicyclo[2.2.2]oct-2-yl)-3-[[4-[(1S)-2-[[2-(1,3-benzodioxol-5-yl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 667460-56-2 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[1-[[2-(3-methoxyphenyl)ethyl]amino]methyl]cyclopropyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)



RN 667460-57-3 CAPLUS


CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[(4-phenyl-1-piperidinyl)methyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)



RN 667460-58-4 CAPLUS


CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[[4-(4-phenylbutyl)-1-piperazinyl]methyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)





RN 667460-59-5 CAPLUS


CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[[methyl(3-phenylpropyl)amino]methyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)




RN 667460-60-8 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[[methyl(2-(2-pyridinyl)ethyl)amino]methyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)


PAGE 1-A






RN 667460-61-9 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[4-[[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]methyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)




RN 667460-62-0 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[[4-(4-pyridinyl)-1-piperidinyl]methyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)




RN 667460-63-1 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[[4-(tetrahydro-2H-pyran-4-yl)-1-piperidinyl]methyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)




RN 667460-64-2 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[[methyl(4-phenylbutyl)amino]methyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)




RN 667460-65-3 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[[4-phenylbutyl)amino]methyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)




RN 667460-66-4 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[5-(3,5-dimethylphenyl)-4-[[methyl(5-phenylpentyl)amino]methyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)




RN 667460-67-5 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-2-[[[5-(3,5-dimethylphenyl)-4-[(3-phenylpropyl)amino]methyl]-1H-pyrazol-3-yl]oxy]methyl]-2-methyl- (CA INDEX NAME)




RN 667460-68-6 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[[5-(3,5-dimethylphenyl)-4-[(5-phenylpentyl)amino]methyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)



RN 667460-69-7 CAPLUS


CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[[5-(3,5-dimethylphenyl)-4-[(3-phenyl-1-pyrrolidinyl)methyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)



RN 667460-70-0 CAPLUS

CN 1-Propanol, 3-[[4-[(1S)-2-[[2-(1,3-benzodioxol-5-yl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 667460-71-1 CAPLUS

CN Propanoic acid, 3-[[4-[(1S)-2-[[2-(1,3-benzodioxol-5-yl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-,  
1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 667460-74-4P 667460-75-5P 667460-76-6P  
667460-77-7P 667460-79-9P 667460-80-2P  
667460-81-3P 667460-82-4P 667460-83-5P  
667460-87-9P 667460-88-0P 667460-89-1P


667460-90-4P 667460-91-5P 667460-92-6P  
 667460-94-8P 667460-95-9P 667460-97-1P  
 667460-98-2P 667460-99-3P 667461-00-9P  
 667461-01-0P 667461-03-2P 667461-04-3P  
 667461-05-4P 667461-06-5P 667461-07-6P  
 667461-08-7P 667461-09-8P 667461-10-1P  
 667461-11-2P 667461-12-3P 667461-13-4P  
 667461-14-5P 667461-15-6P 667461-16-7P  
 667461-17-8P 667461-18-9P 667461-19-0P  
 667461-20-3P 667461-21-4P 667461-22-5P  
 667461-23-6P 667461-24-7P 667461-25-8P  
 667461-26-9P 667461-27-0P 667461-28-1P  
 667461-29-2P 667461-30-5P 667461-31-6P  
 667461-32-7P 667461-33-8P 667461-34-9P  
 667461-38-3P 667461-39-4P 667461-40-7P  
 667461-41-8P 667461-43-0P 667461-44-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyrazoles as antagonists of gonadotropin releasing hormone)


RN 667460-74-4 CAPLUS

CN 1-Propanone, 3-[[5-(3,5-dimethylphenyl)-4-(2-hydroxyethyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 667460-75-5 CAPLUS

CN 1-Propanone, 3-[[4-(2-aminoethyl)-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-(1-pyrrolidinyl)- (CA INDEX NAME)



RN 667460-76-6 CAPLUS



CN Pyrrolidine, 1-[3-[[5-(3,5-dimethylphenyl)-4-[2-[(2,4-dinitrophenyl)sulfonyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 667460-77-7 CAPLUS

CN Benzenesulfonamide, N-[2-[3-[2,2-dimethyl-3-oxo-3-(1-pyrrolidinyl)propoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]ethyl]-2,4-dinitro-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 667460-79-9 CAPLUS  
 CN Benzenesulfonamide, N-[2-[3-[2,2-dimethyl-3-oxo-3-(1-pyrrolidinyl)propoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]ethyl]-2,4-dinitro-N-[3-(4-pyridinyl)propyl]- (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 667460-80-2 CAPLUS  
 CN Benzenesulfonamide, N-[2-[3-[2,2-dimethyl-3-oxo-3-(1-pyrrolidinyl)propoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]ethyl]-2,4-dinitro-N-[3-(3-pyridinyl)propyl]- (CA INDEX NAME)



PAGE 1-A





PAGE 2-A




RN 667460-81-3 CAPLUS  
 CN Pyrrolidine, 1-[3-[[4-[2-[[2-(4-cyanophenyl)ethyl][(2,4-dinitrophenyl)sulfonyl]amino]ethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 667460-82-4 CAPLUS  
 CN Pyrrolidine, 1-[3-[[5-(3,5-dimethylphenyl)-4-[2-[[ (2,4-dinitrophenyl)sulfonyl][2-(4-methoxyphenyl)ethyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 667460-83-5 CAPLUS  
 CN Pyrrolidine, 1-[3-[[5-(3,5-dimethylphenyl)-4-[2-[[ (2,4-dinitrophenyl)sulfonyl][3-(4-methoxyphenoxy)propyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 667460-87-9 CAPLUS  
 CN 1-Propanone, 3-[[5-(3,5-dimethylphenyl)-4-(2-propen-1-yl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 667460-88-0 CAPLUS

CN 1H-Pyrazole-1-carboxylic acid, 3-[2,2-dimethyl-3-oxo-3-(1-pyrrolidinyl)propoxy]-5-(3,5-dimethylphenyl)-4-(2-propen-1-yl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 667460-89-1 CAPLUS


CN 1H-Pyrazole-1-carboxylic acid, 3-[2,2-dimethyl-3-oxo-3-(1-pyrrolidinyl)propoxy]-5-(3,5-dimethylphenyl)-4-(2-oxoethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 667460-90-4 CAPLUS


CN 1H-Pyrazole-1-carboxylic acid, 3-[2,2-dimethyl-3-oxo-3-(1-pyrrolidinyl)propoxy]-5-(3,5-dimethylphenyl)-4-[2-[[4-(4-pyridinyl)butyl]amino]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)






RN 667460-91-5 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-2-[[[5-(3,5-dimethylphenyl)-4-(2-hydroxyethyl)-1H-pyrazol-3-yl]oxy]methyl]-2-methyl- (CA INDEX NAME)




RN 667460-92-6 CAPLUS

CN 1-Propanone, 2-[[[4-(2-aminoethyl)-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]methyl]-1-(7-azabicyclo[2.2.1]hept-7-yl)-2-methyl- (CA INDEX NAME)




RN 667460-94-8 CAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[2-[[[(2,4-dinitrophenyl)sulfonyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 667460-95-9 CAPLUS

CN Benzenesulfonamide, N-[2-[3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]ethyl]-2,4-dinitro-N-[4-(4-pyridinyl)butyl]- (CA INDEX NAME)




RN 667460-97-1 CAPLUS

CN Benzenesulfonamide, N-[2-[3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]ethyl]-2,4-dinitro-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)




RN 667460-98-2 CAPLUS

CN Benzenesulfonamide, N-[2-[3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]ethyl]-2,4-dinitro-N-[2-(1H-1,2,4-triazol-1-yl)ethyl]- (CA INDEX NAME)




RN 667460-99-3 CAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[2-[[3-(4-acetyl-1-piperazinyl)propyl][(2,4-dinitrophenyl)sulfonyl]amino]ethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 667461-00-9 CAPLUS


CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[2-[[[(2,4-dinitrophenyl)sulfonyl][3-(4-morpholinyl)propyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 667461-01-0 CAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[2-[[[(2,4-dinitrophenyl)sulfonyl][3-(1,1-dioxido-4-thiomorpholinyl)propyl]amino]ethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)






RN 667461-03-2 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-2-[[[5-(3,5-dimethylphenyl)-4-[(1S)-2-hydroxy-1-methylethyl]-1H-pyrazol-3-yl]oxy]methyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667461-04-3 CAPLUS

CN 1H-Pyrazole-1-carboxylic acid, 3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-4-[(1S)-2-hydroxy-1-methylethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 667461-05-4 CAPLUS

CN 1-Propanone, 2-[[[4-[(1S)-2-amino-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-

pyrazol-3-yl]oxy)methyl]-1-(7-azabicyclo[2.2.1]hept-7-yl)-2-methyl- (CA  
INDEX NAME)


Absolute stereochemistry.



RN 667461-06-5 CAPLUS


CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[2,4-dinitrophenyl)sulfonyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 667461-07-6 CAPLUS


CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[[2-(1,3-benzodioxol-5-yl)ethyl][(2,4-dinitrophenyl)sulfonyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 667461-08-7 CAPLUS

CN Benzenesulfonamide, N-[(2S)-2-[3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]propyl]-2,4-dinitro-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 667461-09-8 CAPLUS

CN Benzenesulfonamide, N-[(2S)-2-[3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]propyl]-2,4-dinitro-N-[4-(4-pyridinyl)butyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 667461-10-1 CAPLUS

CN Benzenesulfonamide, N-[(2S)-2-[3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]propyl]-2,4-dinitro-N-[3-(4-pyridinyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 667461-11-2 CAPLUS

CN Benzenesulfonamide, N-[(2S)-2-[3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]propyl]-2,4-dinitro-N-(4-phenylbutyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 667461-12-3 CAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[2,4-dinitrophenyl)sulfonyl][4-(4-methoxyphenyl)butyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667461-13-4 CAPLUS

CN Benzenesulfonamide, N-[(2S)-2-[3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]propyl]-2,4-dinitro-N-[4-(4-nitrophenyl)butyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 667461-14-5 CAPLUS

CN Benzenesulfonamide, N-[(2S)-2-[3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]propyl]-2,4-dinitro-N-[4-(2-pyrimidinyl)butyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 667461-15-6 CAPLUS

CN Benzenesulfonamide, N-[(2S)-2-[3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]propyl]-2,4-dinitro-N-[4-(2-pyrazinyl)butyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 667461-16-7 CAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[[2-(4-cyanophenyl)ethyl][(2,4-dinitrophenyl)sulfonyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 667461-17-8 CAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[2-(4-cyanophenyl)ethyl][(2,4-dinitrophenyl)sulfonyl][2-(2-naphthalenyl)ethyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667461-18-9 CAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[[(2,4-dinitrophenyl)sulfonyl][2-(phenylmethoxy)ethyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667461-19-0 CAPLUS

CN Benzenesulfonamide, N-[(2S)-2-[3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]propyl]-2,4-dinitro-N-(2-phenylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 667461-20-3 CAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[2-(4-fluorophenyl)ethyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667461-21-4 CAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[[2-(3,5-difluorophenyl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 667461-22-5 CAPLUS


CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[2,4-dinitrophenyl]sulfonyl][2-[4-[[[(1-methylethyl)amino]carbonyl]amino]phenyl]ethyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 667461-23-6 CAPLUS  
 CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[[2-(4-aminophenyl)ethyl][(2,4-dinitrophenyl)sulfonyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 667461-24-7 CAPLUS  
 CN Carbamic acid, [4-[2-[[[(2S)-2-[3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-1H-pyrazol-4-yl]propyl][(2,4-dinitrophenyl)sulfonyl]amino]ethyl]phenyl]-, 1-methylethyl ester (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A




RN 667461-25-8 CAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[4-[(1S)-2-[[2-(1,2-dihydro-1-methyl-2-oxo-7-quinolinyl)ethyl][(2,4-dinitrophenyl)sulfonyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 667461-26-9 CAPLUS

CN 1H-Pyrazole-1-carboxylic acid, 3-[2,2-dimethyl-3-oxo-3-(1-pyrrolidinyl)propoxy]-5-(3,5-dimethylphenyl)-4-[2-[4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1-piperazinyl]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 667461-27-0 CAPLUS

CN 1H-Pyrazole-1-carboxylic acid, 3-[2,2-dimethyl-3-oxo-3-(1-pyrrolidinyl)propoxy]-5-(3,5-dimethylphenyl)-4-[2-[3-(4-pyridinyl)-1-pyrrolidinyl]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 667461-28-1 CAPLUS

CN 1H-Pyrazole-1-carboxylic acid, 3-[2,2-dimethyl-3-oxo-3-(1-pyrrolidinyl)propoxy]-5-(3,5-dimethylphenyl)-4-[2-[4-[2-(1-pyrrolidinyl)ethyl]-1-piperazinyl]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 667461-29-2 CAPLUS

CN 1H-Pyrazole-1-carboxylic acid, 3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-4-(2-hydroxyethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 667461-30-5 CAPLUS


CN 1H-Pyrazole-1-carboxylic acid, 3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-4-(2-bromoethyl)-5-(3,5-dimethylphenyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 667461-31-6 CAPLUS

CN 1-Propanone, 1-(2-azabicyclo[2.2.2]oct-2-yl)-2-[[[5-(3,5-dimethylphenyl)-4-[(1S)-2-hydroxy-1-methylethyl]-1H-pyrazol-3-yl]oxy]methyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667461-32-7 CAPLUS

CN 1H-Pyrazole-1-carboxylic acid, 3-[3-(2-azabicyclo[2.2.2]oct-2-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-4-[(1S)-2-hydroxy-1-methylethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 667461-33-8 CAPLUS

CN 1-Propanone, 2-[[[4-[(1S)-2-amino-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]methyl]-1-(2-azabicyclo[2.2.2]oct-2-yl)-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 667461-34-9 CAPLUS


CN 2-Azabicyclo[2.2.2]octane, 2-[3-[[5-(3,5-dimethylphenyl)-4-[(1S)-2-[[[(2,4-dinitrophenyl)sulfonyl]amino]-1-methylethyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667461-38-3 CAPLUS

CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-3-[[[5-(3,5-dimethylphenyl)-4-[1-(hydroxymethyl)cyclopropyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)




RN 667461-39-4 CAPLUS

CN 1H-Pyrazole-1-carboxylic acid, 3-[3-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl-3-oxopropoxy]-5-(3,5-dimethylphenyl)-4-[1-(hydroxymethyl)cyclopropyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 667461-40-7 CAPLUS

CN 1-Propanone, 3-[[4-[1-(aminomethyl)cyclopropyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-1-(7-azabicyclo[2.2.1]hept-7-yl)-2,2-dimethyl- (CA INDEX NAME)




RN 667461-41-8 CAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[3-[[5-(3,5-dimethylphenyl)-4-[1-[[[(2,4-dinitrophenyl)sulfonyl]amino]methyl]cyclopropyl]-1H-pyrazol-3-yl]oxy]-2,2-dimethyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 667461-43-0 CAPLUS


CN 1-Propanone, 1-(7-azabicyclo[2.2.1]hept-7-yl)-2-[[[5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]methyl]-2-methyl- (CA INDEX NAME)



RN 667461-44-1 CAPLUS

CN Propanoic acid, 3-[[4-[(1S)-2-[[2-(1,3-benzodioxol-5-yl)ethyl]amino]-1-methylethyl]-5-(3,5-dimethylphenyl)-1H-pyrazol-3-yl]oxy]-2,2-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 20 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:166009 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 141:367640

TITLE: Surface active agents containing heterocyclic moiety

AUTHOR(S): Eissa, A. M. F.

CORPORATE SOURCE: Chemistry Department, Faculty of Science, Benha University, Benha, Egypt

SOURCE: Chemistry (Rajkot, India) (2003), 1(4), 303-312



PUBLISHER: Trade Science Inc.  
DOCUMENT TYPE: Journal  
LANGUAGE: English


AB Sodium salt of  $\alpha$ -sulfonated fatty acid hydrazide (I) was used as starting material to synthesis some important heterocycles as pyrazoles, thiazoles, oxadiazoles, benzoxazoles, pyridazines, and phthalazines to produce a novel groups of anionic surfactants having a double function, antimicrobial and surface active agents. All these compds. were investigated by IR,  $^1\text{H}$  NMR and Mass spectra. The phys. properties as surface and interfacial tension, Krafft point, foaming height, wetting time, emulsification power, calcium stability, stability to hydrolysis and the critical micelle concentration (CMC), as well as antimicrobial activity and biodegradability were determined

IT 512193-26-9P 512193-27-0P 512193-28-1P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation, properties, biodegradability, and antimicrobial activities of surface active agents containing heterocyclic moiety)

RN 512193-26-9 CAPLUS


CN 1H-Pyrazole-1-ethanesulfonic acid,  $\alpha$ -dodecyl-3-ethoxy- $\beta$ -oxo-5-phenyl-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 512193-27-0 CAPLUS


CN 1H-Pyrazole-1-ethanesulfonic acid, 3-ethoxy- $\beta$ -oxo-5-phenyl- $\alpha$ -tetradecyl-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 512193-28-1 CAPLUS

CN 1H-Pyrazole-1-ethanesulfonic acid, 3-ethoxy- $\alpha$ -hexadecyl- $\beta$ -oxo-5-phenyl-, sodium salt (1:1) (CA INDEX NAME)



● Na

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 21 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:100955 CAPLUS Full-text  
 DOCUMENT NUMBER: 140:157441  
 TITLE: Cyclooxygenase- 2 selective inhibitors, compositions and methods of use  
 INVENTOR(S): Garvey, David S.; Khanapure, Subhash P.; Ranatunge, Ramani R.; Richardson, Stewart K.; Schroeder, Joseph D.  
 PATENT ASSIGNEE(S): Nitromed, Inc., USA  
 SOURCE: PCT Int. Appl., 140 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004010945	A2	20040205	WO 2003-US23605	20030729
WO 2004010945	A3	20040422		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2493156	A1	20040205	CA 2003-2493156	20030729
AU 2003261281	A1	20040216	AU 2003-261281	20030729
US 20040072883	A1	20040415	US 2003-628375	20030729
US 7244753	B2	20070717		
EP 1542972	A2	20050622	EP 2003-772004	20030729
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005538110	T	20051215	JP 2004-524981	20030729
US 20070238735	A1	20071011	US 2007-802161	20070521
PRIORITY APPLN. INFO.:			US 2002-398829P	P 20020729
			US 2003-628375	A3 20030729
			WO 2003-US23605	W 20030729
OTHER SOURCE(S):			MARPAT 140:157441	

AB The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors and novel compns. comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.

IT 654058-50-1P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (antiinflammatory cyclooxygenase-2 selective inhibitors)

RN 654058-50-1 CAPLUS

CN Ethanol, 2-[[1-(cyclohexylmethyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]oxy]- (CA INDEX NAME)



L3 ANSWER 22 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:150531 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 138:187765

TITLE: Preparation of heteroarylpyrazoles as p38 kinase inhibitors

INVENTOR(S): Anantanarayan, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce Zuowu; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Graneto, Matthew J.; Hanau, Cathleen E.; Hanson, Gunnar J.; Hartmann, Susan J.; Hepperle, Michael; Huang, He; Koszyk, Francis J.; Liao, Shuyuan; Metz, Suzanne; Partis, Richard A.; Perry, Thao D.; Rao, Shashidhar N.; Selness, Shaun Raj; South, Michael S.; Stealey, Michael A.; Talley, John Jeffrey; Vazquez, Michael L.; Weier, Richard M.; Xu, Xiangdong; Khanna, Ish K.; Yu, Yi

PATENT ASSIGNEE(S): G.D. Searle and Co., USA

SOURCE: U.S., 415 pp., Cont.-in-part of U.S. Ser. No. 196,623. CODEN: USXXAM


DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 5  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6525059	B1	20030225	US 2000-513351	20000224
US 6514977	B1	20030204	US 1998-196623	19981120
WO 2000031063	A1	20000602	WO 1999-US26007	19991117
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2003200580	A1	20030501	AU 2003-200580	20030217
US 7071198	B2	20060704	US 2004-840734	20040505
US 20070078146	A1	20070405		


PRIORITY APPLN. INFO.:

US 1998-196623	A2 19981120
WO 1999-US26007	A1 19991117
US 1997-47570P	P 19970522
AU 1998-75883	A3 19980522
US 1998-83670	A2 19980522
US 2000-513351	A3 20000224
US 2001-21780	A3 20011207

OTHER SOURCE(S): MARPAT 138:187765  
 GI



I



II

AB Title compds. [I; R1 = H, OH, NH<sub>2</sub>, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = (un)substituted piperidinyl; R3 = (un)substituted pyrimidinyl; R4 = (un)substituted Ph; and pharmaceutically acceptable salts or tautomers thereof] were prepared by solution phase and solid phase parallel array reactions of ketones with hydrazines. Thus, R<sub>3</sub>CH<sub>2</sub>COMe (R<sub>3</sub> = 4-pyridinyl) was condensed with 3,4-F(MeO)C<sub>6</sub>H<sub>3</sub>CHO to give the butenone (80%), which was cyclocondensed with TsNHNH<sub>2</sub> to afford the title compound II (20.7%). The latter inhibited human p38 kinase activity in vitro with IC<sub>50</sub> of 4.6 μM and inhibited tumor necrosis factor α (TNFα) and interleukin 1β (IL-1β) release from human peripheral blood mononuclear cells following stimulation with lipopolysaccharide with IC<sub>50</sub> of 0.5 μM. Thus, I are useful for the treatment of inflammation, arthritis, asthma, and other disorders mediated by p38 kinase and TNFα.


IT 271575-72-5P 271575-77-0P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);

CMBI (Combinatorial study); PREP (Preparation); USES (Uses)  
(p38 kinase inhibitor; preparation of heteroarylpyrazole p38 kinase  
inhibitors by cyclocondensation of hydrazines with ketones)


RN 271575-72-5 CAPLUS

CN Morpholine, 4-[2-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]oxy]ethyl]- (CA INDEX NAME)



RN 271575-77-0 CAPLUS

CN Carbamic acid, [2-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 75 THERE ARE 75 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 23 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:92403 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 138:137307

TITLE: Preparation of heteroarylpyrazoles as p38 kinase inhibitors

INVENTOR(S): Anantanarayan, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce Zuowu; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Graneto, Matthew J.; Hanau, Cathleen E.; Hanson, Gunnar J.; Hartmann, Susan J.; Hepperle, Michael; Huang, He; Koszyk, Francis J.; Liao, Shuyuan; Metz, Suzanne; Partis, Richard A.; Perry, Thao D.; Rao, Shashidhar N.; Selness, Shaun Raj; South, Michael S.; Stealey, Michael A.; Talley, John Jeffrey; Vazquez, Michael L.; Weier, Richard M.; Xu, Xiangdong; Khanna, Ish K.; Yu, Yi

PATENT ASSIGNEE(S): G.D. Searle and Co., USA

SOURCE: U.S., 541 pp., Cont.-in-part of U.S. Ser. No. 83,670.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 5  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6514977	B1	20030204	US 1998-196623	19981120
CA 2351725	A1	20000602	CA 1999-2351725	19991117
WO 2000031063	A1	20000602	WO 1999-US26007	19991117
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1144403	A1	20011017	EP 1999-965756	19991117
EP 1144403	B1	20041006		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200102001	T2	20011221	TR 2001-2001	19991117
BR 9915420	A	20020122	BR 1999-15420	19991117
HU 2002000130	A2	20020629	HU 2002-130	19991117
EE 200100268	A	20021216	EE 2001-268	19991117
NZ 512344	A	20031128	NZ 1999-512344	19991117
AU 774262	B2	20040624	AU 2000-21454	19991117
AT 278685	T	20041015	AT 1999-965756	19991117
EP 1500657	A1	20050126	EP 2004-23186	19991117
EP 1500657	B1	20070919		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
PT 1144403	T	20050131	PT 1999-965756	19991117
ES 2229809	T3	20050416	ES 1999-965756	19991117
AT 373649	T	20071015	AT 2004-23186	19991117
ES 2289411	T3	20080201	ES 2004-23186	19991117
US 6525059	B1	20030225	US 2000-513351	20000224
ZA 2001003882	A	20021014	ZA 2001-3882	20010514
MX 2001PA05043	A	20010710	MX 2001-PA5043	20010518
NO 2001002456	A	20010719	NO 2001-2456	20010518
BG 105620	A	20020131	BG 2001-105620	20010619
US 6423713	B1	20020723	US 2001-918481	20010731
HK 1040705	A1	20050304	HK 2002-102213	20020322
US 6617324	B1	20030909	US 2002-114297	20020402
AU 2003200580	A1	20030501	AU 2003-200580	20030217
US 20040176433	A1	20040909	US 2003-374781	20030225
US 7153959	B2	20061226		
US 7071198	B2	20060704	US 2004-840734	20040505
US 20070078146	A1	20070405		
PRIORITY APPLN. INFO.:			US 1997-47570P	P 19970522
			US 1998-83670	A2 19980522
			AU 1998-75883	A3 19980522
			US 1998-196623	A 19981120
			EP 1999-965756	A3 19991117
			WO 1999-US26007	W 19991117
			US 2000-513351	A3 20000224
			US 2001-918481	A3 20010731

US 2001-21780  
US 2002-114297


A3 20011207  
A3 20020402

OTHER SOURCE(S):  
GI

MARPAT 138:137307



I



II

AB Title compds. [I; R1 = H, OH, NH<sub>2</sub>, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = (un)substituted piperidinyl or piperazinyl; R3 = (un)substituted pyrimidinyl; R4 = (un)substituted Ph; and pharmaceutically acceptable salts or tautomers thereof] were prepared by solution phase and solid phase parallel array reactions of ketones with hydrazines. Thus, R<sub>3</sub>CH<sub>2</sub>COMe (R<sub>3</sub> = 4-pyridinyl) was condensed with 3,4-F(MeO)C<sub>6</sub>H<sub>3</sub>CHO to give the butenone (80%), which was cyclocondensed with TsNHNH<sub>2</sub> to afford the title compound II (20.7%). The latter inhibited human p38 kinase activity in vitro with IC<sub>50</sub> of 4.6 μM and inhibited tumor necrosis factor α (TNFα) and interleukin 1β (IL-1β) release from human peripheral blood mononuclear cells following stimulation with lipopolysaccharide with IC<sub>50</sub> of 0.5 μM. Thus, I are useful for the treatment of inflammation, arthritis, asthma, and other disorders mediated by p38 kinase and TNFα.


IT 271575-72-5P 271575-77-0P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; preparation of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones)


RN 271575-72-5 CAPLUS

CN Morpholine, 4-[2-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]oxy]ethyl]- (CA INDEX NAME)



RN 271575-77-0 CAPLUS

CN Carbamic acid, [2-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 76 THERE ARE 76 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 24 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2002:877598 CAPLUS Full-text  
DOCUMENT NUMBER: 138:323042  
TITLE: Anionic surface active agents from fatty acid hydrazides containing heterocyclic moiety  
AUTHOR(S): Eissa, A. M.  
CORPORATE SOURCE: Chem. Dep., Fac. of Sci., Benha Univ., Benha, Egypt  
SOURCE: Olaj, Szappan, Kozmetika (2002), 51(4), 155-160  
CODEN: OSZKAT; ISSN: 0472-8602  
PUBLISHER: METE  
DOCUMENT TYPE: Journal  
LANGUAGE: English


AB Sodium salt of  $\alpha$ -sulfonated fatty acid hydrazide (1) was used as starting material to synthesis some important heterocycles as pyrazoles, thiazoles, oxadiazoles, benzoxazoles, pyridazines, and phthalazines to produce novel groups of anionic surfactants having a double function, antimicrobial and surface active agents. The structure of these compds. was investigated by IR,  $^1\text{H}$  NMR and Mass spectra. The phys. properties as surface and interfacial tension, Krafft point, foaming height, wetting time, emulsification power, calcium stability, stability to hydrolyzes and the critical micelle concentration (cmc) were determined, antimicrobial and biodegradability were also determined

IT 512193-26-9P 512193-27-0P 512193-28-1P  
RL: SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)  
(preparation of anionic surfactants containing heterocyclic moiety from fatty acid hydrazides)

RN 512193-26-9 CAPLUS

CN 1H-Pyrazole-1-ethanesulfonic acid,  $\alpha$ -dodecyl-3-ethoxy- $\beta$ -oxo-5-phenyl-, sodium salt (1:1) (CA INDEX NAME)






● Na

RN 512193-27-0 CAPLUS


CN 1H-Pyrazole-1-ethanesulfonic acid, 3-ethoxy-β-oxo-5-phenyl-α-tetradecyl-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 512193-28-1 CAPLUS

CN 1H-Pyrazole-1-ethanesulfonic acid, 3-ethoxy-α-hexadecyl-β-oxo-5-phenyl-, sodium salt (1:1) (CA INDEX NAME)



● Na

L3 ANSWER 25 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:855864 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 139:214344

TITLE: Product class 1: pyrazoles

AUTHOR(S): Stanovnik, B.; Svete, J.

CORPORATE SOURCE: Faculty of Chemistry and Chemical Technology, Division of Organic Chemistry, Ljubljana, 61000, Slovenia


SOURCE: Science of Synthesis (2002), 12, 15-225

CODEN: SSCYJ9


PUBLISHER: Georg Thieme Verlag

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English  
AB A review. Methods for preparing pyrazoles are reviewed including cyclization, ring transformation, aromatization and substituent modifications.  
IT 16105-56-9P 58876-83-8P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of pyrazoles via cyclization, ring transformation, aromatization and substituent modifications)  
RN 16105-56-9 CAPLUS  
CN 1H-Pyrazole, 3-ethoxy-5-phenyl- (CA INDEX NAME)



RN 58876-83-8 CAPLUS  
CN 1H-Pyrazole, 3-ethoxy-5-(4-methoxyphenyl)- (CA INDEX NAME)



REFERENCE COUNT: 909 THERE ARE 909 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L3 ANSWER 26 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2002:720124 CAPLUS Full-text  
DOCUMENT NUMBER: 137:379678  
TITLE: Inhibitory Mode of 1,5-Diarylpyrazole Derivatives against Cyclooxygenase-2 and Cyclooxygenase-1: Molecular Docking and 3D QSAR Analyses  
AUTHOR(S): Liu, Hong; Huang, Xiaoqin; Shen, Jianhua; Luo, Xiaomin; Li, Minghui; Xiong, Bing; Chen, Gang; Shen, Jingkan; Yang, Yimin; Jiang, Hualiang; Chen, Kaixian  
CORPORATE SOURCE: Shanghai Institutes for Biological Sciences, Center for Drug Discovery and Design, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, State Key Laboratory of Drug Research, Shanghai, 200031, Peop. Rep. China  
SOURCE: Journal of Medicinal Chemistry (2002), 45(22), 4816-4827  
CODEN: JMCMAR; ISSN: 0022-2623  
PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB The Lamarckian genetic algorithm of AutoDock 3.0 has been employed to dock 40 1,5-diarylpyrazole class compds. into the active sites of cyclooxygenase-2 (COX-2) and cyclooxygenase-1 (COX-1). The binding models were demonstrated in the aspects of inhibitor's conformation, subsite interaction, and hydrogen

bonding. The data of geometrical parameters and RMSD values compared with the known inhibitor, SC-558 (43), show that these inhibitors interact resp. with COX-2 and COX-1 in a very similar way. The  $r^2$  values of 0.648 for COX-2 and 0.752 for COX-1 indicate that the calculated binding free energies correlate well with the inhibitory activities. The structural and energetic differences in inhibitory potencies of 1,5-diarylpyrazoles were reasonably explored, and the COX-2/COX-1 selectivity was demonstrated by the three-dimensional (3D) interaction models of inhibitors complexing with these two enzymes. Using the binding conformations of 1,5-diarylpyrazoles, consistent and highly predictive 3D quant. structure-activity relation (QSAR) models were developed by performing comparative mol. field analyses (CoMFA) and comparative mol. similarity analyses (CoMSIA). The  $q^2$  values are 0.635 and 0.641 for CoMFA and CoMSIA models, resp. The predictive ability of these models was validated by SC-558 (43) and a set of 10 other compds. that were not included in the training set. Mapping these models back to the topol. of the active site of COX-2 leads to a better understanding of vital diarylpyrazole compds. and COX-2 interactions. Structure-based investigations and the final 3D QSAR results provided possible guidelines and accurate activity predictions for novel inhibitor design.


IT 476322-47-1

RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)

(inhibitory mode of diarylpyrazole derivs. against cyclooxygenase-2 and cyclooxygenase-1: mol. docking and 3D QSAR analyses)

RN 476322-47-1 CAPLUS

CN Benzenesulfonamide, 4-[3-methoxy-5-phenyl-4-(trifluoromethyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 27 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:361409 CAPLUS Full-text

DOCUMENT NUMBER: 137:294902

TITLE: An efficient synthesis of tetra-substituted pyrazoles

AUTHOR(S): Cottineau, Bertrand; Chenault, Jacques

CORPORATE SOURCE: Institut de Chimie Organique et Analytique, Universite d'Orleans, Orleans, 45067, Fr.

SOURCE: Synlett (2002), (5), 769-770

CODEN: SYNLES; ISSN: 0936-5214


PUBLISHER: Georg Thieme Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 137:294902

GI



AB An efficient method for the preparation of 1,3,4,5-tetra-substituted pyrazoles, e.g. I, promoted by butyllithium and palladium(0) cross-coupling reactions is described. Advantages of this new method include high yields and mild reaction conditions, which tolerate functional groups such as esters.

IT 462126-28-9P 462126-29-0P 462126-30-3P


462126-31-4P

RL: SPN (Synthetic preparation); PREP (Preparation)

(synthesis of tetra-substituted pyrazoles via palladium-catalyzed cross-coupling with arylboronic acids and alkenes)


RN 462126-28-9 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 3-methoxy-1-methyl-5-phenyl-, ethyl ester  
(CA INDEX NAME)




RN 462126-29-0 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 3-methoxy-5-(4-methoxyphenyl)-1-methyl-, ethyl ester (CA INDEX NAME)




RN 462126-30-3 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 3-methoxy-1-methyl-5-(3-nitrophenyl)-, ethyl ester (CA INDEX NAME)



RN 462126-31-4 CAPLUS  
 CN 1H-Pyrazole-4-carboxylic acid, 3-methoxy-1-methyl-5-(4-methylphenyl)-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 28 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:699248 CAPLUS Full-text

DOCUMENT NUMBER: 136:2171

TITLE: QSAR and k-Nearest Neighbor Classification Analysis of Selective Cyclooxygenase-2 Inhibitors Using Topologically-Based Numerical Descriptors

AUTHOR(S): Kauffman, Gregory W.; Jurs, Peter C.

CORPORATE SOURCE: Department of Chemistry, The Pennsylvania State University, University Park, PA, 16802, USA

SOURCE: Journal of Chemical Information and Computer Sciences (2001), 41(6), 1553-1560

CODEN: JCISD8; ISSN: 0095-2338

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Exptl. IC50 data for 314 selective cyclooxygenase-2 (COX-2) inhibitors are used to develop quantitation and classification models as a potential screening mechanism for larger libraries of target compds. Exptl. log(IC50) values ranged from 0.23 to  $\geq 5.00$ . Numerical descriptors encoding solely topol. information are calculated for all structures and are used as inputs for linear regression, computational neural network, and classification anal. routines. Evolutionary optimization algorithms are then used to search the descriptor space for information-rich subsets which minimize the rms error of a diverse training set of compds. An eight-descriptor model was identified as a robust predictor of exptl. log(IC50) values, producing a root-mean-square error of 0.625 log units for an external prediction set of inhibitors which took no part in model development. A k-nearest neighbor classification study of the data set discriminating between active and inactive members produced a


nine-descriptor model able to accurately classify 83.3% of the prediction set compds. correctly.

IT 188816-96-8

RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (cyclooxygenase-2 inhibitor; QSAR and k-nearest neighbor classification anal. of selective cyclooxygenase-2 inhibitors using topol.-based numerical descriptors)

RN 188816-96-8 CAPLUS

CN Benzenesulfonamide, 4-(3-methoxy-5-phenyl-1H-pyrazol-1-yl)- (CA INDEX NAME)



REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 29 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:167997 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 134:207814

TITLE: Preparation of sulfonylphenylpyrazoles as COX-2 inhibitors

INVENTOR(S): Kolasa, Teodozyj; Patel, Meena V.

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: PCT Int. Appl., 101 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001016138	A1	20010308	WO 2000-US23214	20000824
W: CA, JP, MX				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2379421	A1	20010308	CA 2000-2379421	20000824
EP 1206474	A1	20020522	EP 2000-955867	20000824
EP 1206474	B1	20040526		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
AT 267830	T	20040615	AT 2000-955867	20000824
PT 1206474	T	20041029	PT 2000-955867	20000824
ES 2222919	T3	20050216	ES 2000-955867	20000824
US 6472416	B1	20021029	US 2000-648202	20000825
MX 2002PA02111	A	20021031	MX 2002-PA2111	20020227
PRIORITY APPLN. INFO.:			US 1999-151247P	P 19990827
			US 1999-384954	A 19990827
			WO 2000-US23214	W 20000824

OTHER SOURCE(S):            MARPAT 134:207814  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*



AB    The title compds. [I-III; one of R1 and R2 = IV, V (wherein R7 = alkyl, NH2, (di)alkylamino; X4 = SO2, SO(NR8); R8 = H, alkyl, cycloalkyl; R9 = H, halo) and the other of R1 and R2 = hydroxyalkyl, halo, alkyl, etc.; R3 = alkyl, alkenyl, aryl, etc.; R4 = H, alkyl, alkenyl, etc.; X1 = O, NR4, S; X2 = O(CH2)n, S(CH2)n, NR4(CH2)n (n = 0-1), etc.; X3 = absent, CH2, CR15R16 (R15, R16 = H, alkyl); R5, R6 = H, alkyl, aryl, etc.; R5 and R6 taken together with the atoms to which they are attached = (un)substituted 5-7 membered ring, optionally aromatic, and optionally containing 1-2 heteroatoms selected from O, N, and S], useful in the treatment of cyclooxygenase-2 mediated diseases, were prepared E.g., a multi-step synthesis of the pyrazolooxazine VI which showed IC50 of 720 nM against COX-2, was given.

IT    329076-53-1P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
      (preparation of sulfonylphenylpyrazoles as COX-2 inhibitors)


RN    329076-53-1    CAPLUS

CN    Ethanone, 2-[[4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]oxy]-1-(2-thienyl)-    (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




IT 329075-79-8P 329075-80-1P 329075-81-2P  
 329075-84-5P 329075-85-6P 329075-90-3P  
 329075-91-4P 329075-92-5P 329075-93-6P  
 329075-94-7P 329075-97-0P 329075-98-1P  
 329075-99-2P 329076-00-8P 329076-01-9P  
 329076-02-0P 329076-03-1P 329076-04-2P  
 329076-05-3P 329076-06-4P 329076-07-5P  
 329076-08-6P 329076-36-0P 329076-39-3P  
 329076-47-3P 329076-49-5P 329076-50-8P  
 329076-52-0P 329076-54-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of sulfonylphenylpyrazoles as COX-2 inhibitors)


RN 329075-79-8 CAPLUS

CN 1H-Pyrazole, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-(phenylmethoxy)-1-(phenylmethyl)- (CA INDEX NAME)



RN 329075-80-1 CAPLUS


CN 1H-Pyrazole, 4-(4-fluorophenyl)-3-[(4-fluorophenyl)methoxy]-1-[(4-fluorophenyl)methyl]-5-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)



RN 329075-81-2 CAPLUS


CN 1H-Pyrazole, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-(2-propen-1-yl)-3-(2-propen-1-yloxy)- (CA INDEX NAME)






RN 329075-84-5 CAPLUS

CN Ethanone, 2-[4-(4-fluorophenyl)-5-[4-(methanesulfonyl)phenyl]-3-(2-oxo-2-phenylethoxy)-1H-pyrazol-1-yl]-1-phenyl- (CA INDEX NAME)



RN 329075-85-6 CAPLUS



CN Ethanone, 1-(4-fluorophenyl)-2-[4-(4-fluorophenyl)-3-[2-(4-fluorophenyl)-2-oxoethoxy]-5-[4-(methanesulfonyl)phenyl]-1H-pyrazol-1-yl]- (CA INDEX NAME)




RN 329075-90-3 CAPLUS

CN Ethanone, 2-[[1-ethyl-4-(4-fluorophenyl)-5-[4-(methanesulfonyl)phenyl]-1H-pyrazol-3-yl]oxy]-1-(4-fluorophenyl)- (CA INDEX NAME)

PAGE 1-A






PAGE 2-A



RN 329075-91-4 CAPLUS  
CN Ethanone, 1-(4-fluorophenyl)-2-[[4-(4-fluorophenyl)-1-(1-methylethyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]oxy]- (CA INDEX NAME)


PAGE 1-A







RN 329075-92-5 CAPLUS


CN Ethanone, 2-[4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-[2-oxo-2-(2-thienyl)ethoxy]-1H-pyrazol-1-yl]-1-(2-thienyl)- (CA INDEX NAME)



RN 329075-93-6 CAPLUS


CN Ethanone, 2-[[1-ethyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]oxy]-1-(2-thienyl)- (CA INDEX NAME)






RN 329075-94-7 CAPLUS

CN Ethanone, 2-[[4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-(2-propen-1-yl)-1H-pyrazol-3-yl]oxy]-1-(2-thienyl)- (CA INDEX NAME)




RN 329075-97-0 CAPLUS

CN 2-Butanone, 1-[3-(3,3-dimethyl-2-oxobutoxy)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-3,3-dimethyl- (CA INDEX NAME)




RN 329075-98-1 CAPLUS

CN 2-Butanone, 1-[[1-(3,3-dichloro-2-propen-1-yl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]oxy]-3,3-dimethyl- (CA INDEX NAME)




RN 329075-99-2 CAPLUS

CN 2-Butanone, 1-[[1-ethyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]oxy]-3,3-dimethyl- (CA INDEX NAME)




RN 329076-00-8 CAPLUS

CN 1H-Pyrazole-1-acetonitrile, 3-(3,3-dimethyl-2-oxobutoxy)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 329076-01-9 CAPLUS

CN Benzenesulfonamide, 4-[3-(3,3-dimethyl-2-oxobutoxy)-1-ethyl-4-(4-fluorophenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)





RN 329076-02-0 CAPLUS

CN Benzenesulfonamide, 4-[3-(3,3-dimethyl-2-oxobutoxy)-1-ethyl-4-(4-fluorophenyl)-1H-pyrazol-5-yl]-N-ethyl- (CA INDEX NAME)




RN 329076-03-1 CAPLUS

CN 1H-Pyrazole, 1-ethyl-4-(4-fluorophenyl)-3-[(4-fluorophenyl)methoxy]-5-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




PAGE 1-A




RN 329076-04-2 CAPLUS

CN 2-Butanone, 1-[[1-acetyl-5-[4-(methylsulfonyl)phenyl]-4-phenyl-1H-pyrazol-3-yl]oxy]-3,3-dimethyl- (CA INDEX NAME)




RN 329076-05-3 CAPLUS

CN 2-Butanone, 1-[[1-ethyl-5-[4-(methylsulfonyl)phenyl]-4-phenyl-1H-pyrazol-3-yl]oxy]-3,3-dimethyl- (CA INDEX NAME)





RN 329076-06-4 CAPLUS

CN 2-Butanone, 1-[4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-(2-oxobutoxy)-1H-pyrazol-1-yl]- (CA INDEX NAME)




RN 329076-07-5 CAPLUS  
 CN Ethanone, 1-(4-fluorophenyl)-2-[[4-(4-fluorophenyl)-1-methyl-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]oxy]- (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 329076-08-6 CAPLUS  
 CN Ethanone, 1-(4-fluorophenyl)-2-[[4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]oxy]- (CA INDEX NAME)


PAGE 1-A










RN 329076-36-0 CAPLUS  
 CN 1H-Pyrazole, 3-[(2-chloro-6-fluorophenyl)methoxy]-1-[(2-chloro-6-fluorophenyl)methyl]-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)



RN 329076-39-3 CAPLUS  
 CN Benzenesulfonamide, 4-[3-[(2-bromophenyl)methoxy]-1-[(2-bromophenyl)methyl]-4-(4-fluorophenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)





PAGE 2-A




RN 329076-47-3 CAPLUS

CN Ethanone, 1-(4-fluorophenyl)-2-[5-(4-fluorophenyl)-3-[2-(4-fluorophenyl)-2-oxoethoxy]-4-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 329076-49-5 CAPLUS

CN 2-Butanone, 1-[5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-3-(2-oxobutoxy)-1H-pyrazol-1-yl]- (CA INDEX NAME)




RN 329076-50-8 CAPLUS

CN 2-Butanone, 1-[[1-ethyl-5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]oxy]-3,3-dimethyl- (CA INDEX NAME)




RN 329076-52-0 CAPLUS

CN 1H-Pyrazole, 1-(3,4-difluorophenyl)-4-(4-fluorophenyl)-3-methoxy-5-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)





RN 329076-54-2 CAPLUS

CN Benzenesulfonamide, 4-[3-(3,3-dimethyl-2-oxobutoxy)-1-ethyl-4-(4-fluorophenyl)-1H-pyrazol-5-yl]-N,N-diethyl- (CA INDEX NAME)




IT 329076-67-7P 329076-70-2P 329076-72-4P  
 329076-75-7P 329076-88-2P 329076-90-6P  
 329076-91-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of sulfonylphenylpyrazoles as COX-2 inhibitors)  
 RN 329076-67-7 CAPLUS  
 CN 1H-Pyrazole, 4-(4-fluorophenyl)-3-[(4-fluorophenyl)methoxy]-5-[4-  
 (methylsulfonyl)phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 329076-70-2 CAPLUS  
 CN 2-Butanone, 1-[[4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-  
 3-yl]oxy]-3,3-dimethyl- (CA INDEX NAME)




RN 329076-72-4 CAPLUS

CN 2-Butanone, 3,3-dimethyl-1-[[5-[4-(methylsulfonyl)phenyl]-4-phenyl-1H-pyrazol-3-yl]oxy]- (CA INDEX NAME)




RN 329076-75-7 CAPLUS

CN 2-Propanone, 1,1,1-trifluoro-3-[[4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]oxy]- (CA INDEX NAME)




RN 329076-88-2 CAPLUS

CN Ethanone, 1-(4-fluorophenyl)-2-[[5-(4-fluorophenyl)-4-[4-(methylthio)phenyl]-1H-pyrazol-3-yl]oxy]- (CA INDEX NAME)




RN 329076-90-6 CAPLUS

CN 2-Butanone, 1-[[5-(4-fluorophenyl)-4-[4-(methylthio)phenyl]-1H-pyrazol-3-yl]oxy]-3,3-dimethyl- (CA INDEX NAME)



RN 329076-91-7 CAPLUS

CN 2-Butanone, 1-[[1-ethyl-5-(4-fluorophenyl)-4-[4-(methylthio)phenyl]-1H-pyrazol-3-yl]oxy]-3,3-dimethyl- (CA INDEX NAME)




IT 329076-66-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of sulfonylphenylpyrazoles as COX-2 inhibitors)

RN 329076-66-6 CAPLUS

CN 1H-Pyrazole, 3-[(2-bromophenyl)methoxy]-1-[(2-bromophenyl)methyl]-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 30 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:818587 CAPLUS Full-text

DOCUMENT NUMBER: 134:131458

TITLE: Synthesis and Biological Evaluation of Novel Pyrazoles and Indazoles as Activators of the Nitric Oxide Receptor, Soluble Guanylate Cyclase

AUTHOR(S): Selwood, David L.; Brummell, David G.; Budworth, Joanna; Burtin, Guillaume E.; Campbell, Richard O.; Chana, Surinder S.; Charles, Ian G.; Fernandez, Patricia A.; Glen, Robert C.; Goggin, Maria C.; Hobbs, Adrian J.; Kling, Marcel R.; Liu, Qian; Madge, David J.; Millerais, Sylvie; Powell, Kenneth L.; Reynolds, Karen; Spacey, Graham D.; Stables, Jeremy N.; Tatlock, Mark A.; Wheeler, Kerry A.; Wishart, Grant; Woo, Chi-Kit

CORPORATE SOURCE: Biological & Medicinal Chemistry and Molecular & Cellular Biology The Wolfson Institute for Biomedical Research, University College London, London, WC1E 6BT, UK

SOURCE: Journal of Medicinal Chemistry (2001), 44(1), 78-93  
CODEN: JMCMAR; ISSN: 0022-2623


PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 134:131458

GI



AB Database searching and compound screening identified 1-benzyl-3-(3-dimethylaminopropoxy)indazole (benzydamine) as a potent activator of the nitric oxide receptor, soluble guanylate cyclase. A comprehensive structure-activity relationship study surrounding benzydamine clearly showed that the indazole C-3 dimethylaminopropoxy substituent was critical for enzyme


activity. However replacement of the indazole ring of benzydamine by appropriately substituted pyrazoles maintained enzyme activity. Compds. were evaluated for inhibition of platelet aggregation and showed a general lipophilicity requirement. Aryl-substituted pyrazoles I (R = CH<sub>2</sub>Ph, R<sub>1</sub> = CONHC<sub>6</sub>H<sub>4</sub>OMe-p; R = CH<sub>2</sub>Ph, R<sub>1</sub> = Ph; R = Ph, R<sub>1</sub> = Ph) demonstrated potent activation of soluble guanylate cyclase and potent inhibition of platelet aggregation. Pharmacokinetic studies in rats showed that I (R = CH<sub>2</sub>Ph, R<sub>1</sub> = CONHC<sub>6</sub>H<sub>4</sub>OMe-p) exhibits modest oral bioavailability (12%). Furthermore I (R = CH<sub>2</sub>Ph, R<sub>1</sub> = CONHC<sub>6</sub>H<sub>4</sub>OMe-p) has an excellent selectivity profile notably showing no significant inhibition of phosphodiesterases or nitric oxide synthases.

IT 86871-56-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and biol. evaluation of dimethylaminopropoxy substituted pyrazoles and indazoles)

RN 86871-56-9 CAPLUS

CN 1-Propanamine, N,N-dimethyl-3-[(5-phenyl-1H-pyrazol-3-yl)oxy]- (CA INDEX NAME)




IT 268725-58-2P 268725-60-6P 268725-79-7P  
321747-41-5P 321747-42-6P 321747-43-7P  
321747-45-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation and biol. evaluation of dimethylaminopropoxy substituted pyrazoles and indazoles)

RN 268725-58-2 CAPLUS


CN Piperidine, 1-methyl-3-[[5-phenyl-1H-pyrazol-3-yl)oxy]methyl]- (CA INDEX NAME)



RN 268725-60-6 CAPLUS


CN 1-Propanamine, N,N-dimethyl-3-[[5-phenyl-1-(phenylmethyl)-1H-pyrazol-3-yl]oxy]- (CA INDEX NAME)






RN 268725-79-7 CAPLUS

CN 1-Propanamine, 3-[(1,5-diphenyl-1H-pyrazol-3-yl)oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 321747-41-5 CAPLUS

CN 1-Propanamine, N,N-dimethyl-3-[[5-(3,4,5-trimethoxyphenyl)-1H-pyrazol-3-yl]oxy]- (CA INDEX NAME)




RN 321747-42-6 CAPLUS

CN 1-Propanamine, N,N-diethyl-3-[(5-phenyl-1H-pyrazol-3-yl)oxy]- (CA INDEX NAME)




RN 321747-43-7 CAPLUS

CN 2-Pyridinamine, 3-[[[(5-phenyl-1H-pyrazol-3-yl)oxy]methyl]- (CA INDEX NAME)



RN 321747-45-9 CAPLUS  
 CN 2-Pyridinamine, 4-[[5-phenyl-1H-pyrazol-3-yl]oxy]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 31 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:556480 CAPLUS Full-text

DOCUMENT NUMBER: 133:281728

TITLE: Synthesis of 3-Ethoxyisoxazole Derivatives and 3-Ethoxy-1H-pyrazole Derivatives from  $\beta$ -Oxo Thionoesters

AUTHOR(S): Ohta, Tetsuo; Fujisawa, Hironori; Nakai, Yasuto; Furukawa, Isao

CORPORATE SOURCE: Dep. Mol. Sci. Technol., Fac. Eng., Doshisha University, Kyotanabe, Kyoto, 610-0394, Japan

SOURCE: Bulletin of the Chemical Society of Japan (2000), 73(8), 1861-1864

CODEN: BCSJA8; ISSN: 0009-2673

PUBLISHER: Chemical Society of Japan

DOCUMENT TYPE: Journal

LANGUAGE: English

AB 3-Ethoxyisoxazoles and 3-ethoxy-1H-pyrazoles were obtained in high yields from  $\beta$ -oxo thionoesters. The reaction of the Et  $\beta$ -oxo thionoesters with hydroxylamine hydrochloride in the presence of triethylamine at room temperature for 2 h gave the Et 3-oxopropiohydroximates and their hemiacetals, which were easily converted to the 3-ethoxyisoxazoles by refluxing for 3 h at pH 3-5. On the other hand, the reaction of the Et  $\beta$ -oxo thionoesters with hydrazine derivs. in the presence of triethylamine for 3-8 h at room temperature directly yielded the 3-ethoxy-1H-pyrazoles.


IT 16105-56-9P 300543-30-0P 300543-33-3P

RL: SPN (Synthetic preparation); PREP (Preparation)


(3-ethoxyisoxazoles and 3-ethoxy-1H-pyrazoles from  $\beta$ -oxo thionoesters)

RN 16105-56-9 CAPLUS


CN 1H-Pyrazole, 3-ethoxy-5-phenyl- (CA INDEX NAME)



RN 300543-30-0 CAPLUS  
CN 1H-Pyrazole, 3-ethoxy-1-methyl-5-phenyl- (CA INDEX NAME)



RN 300543-33-3 CAPLUS  
CN 1H-Pyrazole, 3-ethoxy-1,5-diphenyl- (CA INDEX NAME)




REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 32 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2000:368351 CAPLUS Full-text  
DOCUMENT NUMBER: 133:4657  
TITLE: Preparation of heteroarylpyrazoles using dithietanes  
INVENTOR(S): Graneto, Matthew J.; Hartmann, Susan J.; Metz, Suzanne; Talley, John Jeffrey; Vazquez, Michael L.; Brown, David L.; Weier, Richard M.; Stealey, Michael A.; Xu, Xiangdong  
PATENT ASSIGNEE(S): G.D. Searle and Co., USA  
SOURCE: PCT Int. Appl., 95 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000031072	A1	20000602	WO 1999-US26011	19991118
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2350081	A1	20000602	CA 1999-2350081	19991118
US 6143892	A	20001107	US 1999-442971	19991118
EP 1131318	A1	20010912	EP 1999-961578	19991118
EP 1131318	B1	20040324		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002530404	T	20020917	JP 2000-583900	19991118
NZ 511594	A	20030131	NZ 1999-511594	19991118
AU 758811	B2	20030403	AU 2000-18126	19991118
EP 1380584	A1	20040114	EP 2003-21671	19991118
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
AT 262523	T	20040415	AT 1999-961578	19991118
PT 1131318	T	20040730	PT 1999-961578	19991118
ES 2219092	T3	20041116	ES 1999-961578	19991118
US 6242612	B1	20010605	US 2000-633726	20000807
US 6342608	B1	20020129	US 2001-772743	20010130
ZA 2001003759	A	20020909	ZA 2001-3759	20010509
MX 2001PA05053	A	20020108	MX 2001-PA5053	20010518
US 20020115868	A1	20020822	US 2001-922819	20010806
US 6482955	B2	20021119		
US 20030135057	A1	20030717	US 2002-268818	20021010
US 6750338	B2	20040615		
US 20040220232	A1	20041104	US 2004-778432	20040214
PRIORITY APPLN. INFO.:			US 1998-109177P	P 19981120
			EP 1999-961578	A3 19991118
			US 1999-442971	A3 19991118
			WO 1999-US26011	W 19991118
			US 2000-633726	A3 20000807
			US 2001-772743	A1 20010130
			US 2001-922819	A1 20010806
			US 2002-268818	A1 20021010
OTHER SOURCE(S):	MARPAT 133:4657			
GI				



AB This invention relates to a novel process of preparing title compds. [I; R1 = H, (cyclo)alk(en)yl, acyl, substituted Ph or heterocyclyl, etc.; R2 = H, halo, alkyl, pyridyl, pyrimidinyl, triazinyl, substituted Ph or heterocyclyl, etc.; R3 = H or (un)substituted alkyl or Ph; R4 and R5 = independently (un)subsubstituted (cyclo)alkyl, Ph, or heterocyclyl(alkyl)] by reaction of dithietanes with amines, followed by cycloaddn. with hydrazines. This method requires fewer steps and provides the desired pyrazoles in significantly

higher yield and with higher purity than standard literature methods. In addition, the process does not rely on the preparation of unstable  $\alpha$ -chloroketones, which dechlorinate upon treatment with thiosemicarbizides. Thus, 1-tolyl-2-(4-pyridyl)ethanone (preparation given with 67% yield) was treated with K<sub>2</sub>CO<sub>3</sub>, CS<sub>2</sub>, and CH<sub>2</sub>Br<sub>2</sub> in acetone to form the 1,3-dithietanylidene derivative (80%). Addition of N-methylpiperazine gave the thioamide (82%), which reacted with hydrazine to produce the title pyrazole (II) in 97% yield. I are useful as p38 kinase and cyclooxygenase-2 (COX-2) inhibitors for the treatment of antiinflammatory diseases (no data).


IT 271575-72-5P 271575-77-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heteroarylpyrazole p38 kinase and COX-2 inhibitors by reaction of dithietanes with amines, followed by cycloaddn. with hydrazines)


RN 271575-72-5 CAPLUS

CN Morpholine, 4-[2-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]oxy]ethyl]- (CA INDEX NAME)



RN 271575-77-0 CAPLUS

CN Carbamic acid, [2-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 33 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2000:368337 CAPLUS Full-text

DOCUMENT NUMBER: 133:4656  
 TITLE: Preparation of heteroarylpyrazoles as p38 kinase inhibitors  
 INVENTOR(S): Anantanarayan, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce Z.; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Graneto, Matthew J.; Hanau, Cathleen E.; Hanson, Gunnar J.; Hartmann, Susan J.; Hepperle, Michael; Huang, He; Khanna, Ish K.; Koszyk, Francis J.; Liao, Shuyuan; Metz, Suzanne; Partis, Richard A.; Perry, Thao D.; Rao, Shashidhar N.; Selness, Shaun Raj; South, Michael S.; Stealey, Michael A.; Talley, John Jeffrey; Vazquez, Michael L.; Weier, Richard M.; Xu, Xiangdong; Yu, Yi  
 PATENT ASSIGNEE(S): G.D. Searle and Co., USA  
 SOURCE: PCT Int. Appl., 1210 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 5  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000031063	A1	20000602	WO 1999-US26007	19991117
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6514977	B1	20030204	US 1998-196623	19981120
CA 2351725	A1	20000602	CA 1999-2351725	19991117
EP 1144403	A1	20011017	EP 1999-965756	19991117
EP 1144403	B1	20041006		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9915420	A	20020122	BR 1999-15420	19991117
EE 200100268	A	20021216	EE 2001-268	19991117
NZ 512344	A	20031128	NZ 1999-512344	19991117
AU 774262	B2	20040624	AU 2000-21454	19991117
AT 278685	T	20041015	AT 1999-965756	19991117
ES 2229809	T3	20050416	ES 1999-965756	19991117
US 6525059	B1	20030225	US 2000-513351	20000224
MX 2001PA05043	A	20010710	MX 2001-PA5043	20010518
NO 2001002456	A	20010719	NO 2001-2456	20010518
BG 105620	A	20020131	BG 2001-105620	20010619
HK 1040705	A1	20050304	HK 2002-102213	20020322
AU 2003200580	A1	20030501	AU 2003-200580	20030217
PRIORITY APPLN. INFO.:			US 1998-196623	A 19981120
			US 1997-47570P	P 19970522
			AU 1998-75883	A3 19980522
			US 1998-83670	A2 19980522
			WO 1999-US26007	W 19991117
OTHER SOURCE(S):			MARPAT 133:4656	
GI				




AB Title compds. [I; R1 = H, OH, NH<sub>2</sub>, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = H, halo, alkyl, alkoxy, (un)substituted piperidinyl, etc.; R3 = pyridyl, pyrimidinyl, quinolyl, etc.; R4 = H, alkyl, heterocyclyl, aryl, etc.] were prepared by reaction of ketones with hydrazines. Thus, R<sub>3</sub>CH<sub>2</sub>COMe (R<sub>3</sub> = 4-pyridinyl) was condensed with 3,4-F(MeO)C<sub>6</sub>H<sub>3</sub>CHO and the product cyclocondensed with TsNHNH<sub>2</sub> to give title compound II. Data for biol. activity of I were given.

IT 271575-72-5P 271575-77-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones)


RN 271575-72-5 CAPLUS

CN Morpholine, 4-[2-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]oxy]ethyl]- (CA INDEX NAME)



RN 271575-77-0 CAPLUS


CN Carbamic acid, [2-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 34 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2000:335243 CAPLUS Full-text  
DOCUMENT NUMBER: 132:347565  
TITLE: Preparation of pyrazoles and indazoles as activators of soluble guanylate cyclase  
INVENTOR(S): Selwood, David; Glen, Robert; Liu, Qian; Kling, Marcel; Madge, David; Reynolds, Karen; Wishart, Grant; Powell, Ken  
PATENT ASSIGNEE(S): University College London, UK  
SOURCE: PCT Int. Appl., 100 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000027394	A1	20000518	WO 1999-GB3663	19991105
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9964816	A	20000529	AU 1999-64816	19991105
PRIORITY APPLN. INFO.:			GB 1998-24310	A 19981105
			WO 1999-GB3663	W 19991105
OTHER SOURCE(S):	MARPAT 132:347565			
GI				



I



II

AB The title compds. [I or II; Y = O, CH<sub>2</sub>, NH; R<sub>1</sub> = H, aryl, heteroaryl, etc.; when Y = O then R<sub>2</sub> = XNMe<sub>2</sub>, XNHMe (wherein X = alkylene), 2-hydroxymethylfuran-5-ylmethyl, WB (W = alkylene; B = N-containing heterocyclyl); when Y = CH<sub>2</sub> then R<sub>2</sub> = XNMe<sub>2</sub>, XNHMe (X is as defined above); when Y = NH then R<sub>2</sub> = XNMe<sub>2</sub>, XNHMe (X = propylene); R<sub>3</sub>, R<sub>4</sub> = CO<sub>2</sub>A (A = H, alkyl, aryl, etc.), CF<sub>3</sub>, halo, etc.; R<sub>3</sub> and R<sub>4</sub> together form the (un)substituted divalent group, (CH<sub>2</sub>)<sub>4</sub>], activators of soluble guanylate cyclase which are vasodilators and/or inhibit platelet aggregation and are therefore useful in the treatment of peripheral vascular diseases such as hypertension, angina pectoris or atherosclerosis, or in the treatment of



prevention of glaucoma, preeclampsia, Raynaud's syndrome, stroke or erectile disfunctions, were prepared E.g., a 2-step synthesis of II [Y = CH<sub>2</sub>; R<sub>1</sub> = H; R<sub>2</sub> = Ph; R<sub>3</sub> = H; R<sub>4</sub> = O(CH<sub>2</sub>)<sub>3</sub>NMe<sub>2</sub>] which showed IC<sub>50</sub> of 35 μM against platelet aggregation, was given.


IT 86871-56-9F

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of pyrazoles and indazoles as activators of soluble guanylate cyclase)

RN 86871-56-9 CAPLUS

CN 1-Propanamine, N,N-dimethyl-3-[(5-phenyl-1H-pyrazol-3-yl)oxy]- (CA INDEX NAME)




IT 268725-57-1F 268725-58-2F 268725-59-3F  
268725-60-6F 268725-79-7F 268725-83-3F

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazoles and indazoles as activators of soluble guanylate cyclase)


RN 268725-57-1 CAPLUS

CN 1H-Pyrazole, 3-[2-(1-methyl-2-pyrrolidiny)ethoxy]-5-phenyl- (CA INDEX NAME)




RN 268725-58-2 CAPLUS

CN Piperidine, 1-methyl-3-[[5-(5-phenyl-1H-pyrazol-3-yl)oxy]methyl]- (CA INDEX NAME)




RN 268725-59-3 CAPLUS

CN Pyridine, 4-[[5-phenyl-1H-pyrazol-3-yl]oxy]methyl]- (CA INDEX NAME)




RN 268725-60-6 CAPLUS

CN 1-Propanamine, N,N-dimethyl-3-[[5-phenyl-1-(phenylmethyl)-1H-pyrazol-3-yl]oxy]- (CA INDEX NAME)




RN 268725-79-7 CAPLUS

CN 1-Propanamine, 3-[(1,5-diphenyl-1H-pyrazol-3-yl)oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 268725-83-3 CAPLUS

CN 1-Propanamine, N,N-dimethyl-3-[[5-(2,4,6-trimethylphenyl)-1H-pyrazol-3-yl]oxy]- (CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 35 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:97883 CAPLUS Full-text

DOCUMENT NUMBER: 132:273796

TITLE: Primary porcine enterocyte and hepatocyte cultures to


study drug oxidation reactions  
AUTHOR(S): Bader, A.; Hansen, T.; Kirchner, G.; Allmeling, C.;  
Haverich, A.; Borlak, J. T.  
CORPORATE SOURCE: Leibniz Research Laboratories for Biotechnology and  
Artificial Organs, Leibniz Research Laboratories for  
Biotechnology and Artificial Organs, Forschungszentrum  
der MHH, Hannover, D-30659, Germany  
SOURCE: British Journal of Pharmacology (2000), 129(2),  
331-342  
CODEN: BJPCBM; ISSN: 0007-1188  
PUBLISHER: Nature Publishing Group  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Primary porcine hepatocytes and enterocytes were isolated and cultured in Williams' E medium for up to 10 days to investigate potential organ differences in the metabolism of the immunosuppressive compound tacrolimus (FK 506) and of two investigational drugs (KC11346 and KC12291). Using LC-MS (FK506) and HPLC-FL (KC 11346/12291) a number of metabolites with identical mass and/or identical retention time could be detected. In the case of tacrolimus hepatocytes and enterocytes produced the same spectrum of metabolites, e.g. bisdemethyl-tacrolimus, demethyl-tacrolimus, demethyl-hydroxy-tacrolimus and hydroxy-tacrolimus, albeit at varying intensities. Treatment of enterocyte cultures with dexamethasone increased the overall metabolite formation very significantly (up to 36 fold). The metabolism of tacrolimus was also studied with prepns. of insect cells, that express specifically high levels of individual human cytochrome P 450 (CYP) isoenzymes. All metabolites could be generated with microsomal prepns. specifically expressing CYP3A4, but hydroxytacrolimus was exclusively produced by CYP3A5. In the case of the investigational drugs KC 11346 and KC 12291 only three metabolites were formed by cultured enterocytes whereas hepatocytes produced 10 and 20 metabolites, resp. When assessed at the protein level CYP1A and CYP3A were expressed in cultures of porcine enterocytes for up to 10 days but porcine hepatocytes expressed addnl. CYP2C9/10. In conclusion, primary enterocytes and hepatocytes can be successfully cultured for several days while maintaining mono-oxygenase activity and may therefore be used as a tool for studying intestinal and hepatic metabolism

IT 165741-64-0, KC 11346  
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
(biotransformation of tacrolimus and other drugs in primary porcine enterocyte vs. hepatocyte cultures)

RN 165741-64-0 CAPLUS

CN Benzeneethanamine, N-[3-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]propyl]-3,4-dimethoxy-N-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 36 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:3379 CAPLUS Full-text

DOCUMENT NUMBER: 132:35697

TITLE: Preparation and fungicidal activity of pyrazole derivatives

INVENTOR(S): Desbordes, Philippe; Ellwood, Charles; Perez, Joseph; Vors, Jean Pierre

PATENT ASSIGNEE(S): Rhone Poulenc Agrochimie, Fr.

SOURCE: Fr. Demande, 54 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2773155	A1	19990702	FR 1997-16835	19971229
FR 2773155	B1	20000128		
WO 9933812	A1	19990708	WO 1998-FR2842	19981223
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9918819	A	19990719	AU 1999-18819	19981223
ZA 9811915	A	19991105	ZA 1998-11915	19981229
PRIORITY APPLN. INFO.:			FR 1997-16835	A 19971229
			WO 1998-FR2842	W 19981223


OTHER SOURCE(S): MARPAT 132:35697

GI




- AB The title compds. I [G = R5OQ1:CMcC(:Q2)R4, R5SQ1:CMcC(:Q2)R4, R6CH:CMcC(:Q2)R4, etc.; Q1 = N, CN, Q2 = O, S; Z = H, alkyl, haloalkyl, etc.; W = bond, O, S, SO, SO2, etc.; X1, X2, X3 = H, halo, OH, NO2, etc.; X4 = H, halo, alkyl, etc.; R3 = H, halo, alkyl, haloalkyl, etc.], possessing fungicidal activity, were prepared E.g., Me (E)-2-[2-[(4-methoxycarbonyl-1-methyl-5-phenoxy-1H-pyrazol-3-yl)oxymethyl]phenyl]-3-methoxyacrylate was prepared Fungicidal activity of I was tested against Plasmopora viticola, Puccinia recondita, Septoria tritici, etc.
- IT 252280-47-0P 252280-48-1P 252280-49-2P  
252280-50-5P 252280-51-6P 252280-52-7P  
252280-53-8P  
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and fungicidal activity of pyrazole derivs.)
- RN 252280-47-0 CAPLUS
- CN Benzeneacetic acid,  $\alpha$ -(methoxymethylene)-2-[[[(1-methyl-5-phenyl-1H-pyrazol-3-yl)oxy]methyl]-, methyl ester, ( $\alpha$ E)- (CA INDEX NAME)

Double bond geometry as shown.



- RN 252280-48-1 CAPLUS
- CN Benzeneacetic acid,  $\alpha$ -(methoxyimino)-2-[[[(5-phenyl-1H-pyrazol-3-yl)oxy]methyl]-, methyl ester, ( $\alpha$ E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 252280-49-2 CAPLUS

CN Benzeneacetamide,  $\alpha$ -(methoxyimino)-N-methyl-2-[[ (5-phenyl-1H-pyrazol-3-yl)oxy]methyl]-, ( $\alpha$ E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 252280-50-5 CAPLUS


CN Benzeneacetic acid,  $\alpha$ -ethylidene-2-[[ (5-phenyl-1H-pyrazol-3-yl)oxy]methyl]-, methyl ester, ( $\alpha$ E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 252280-51-6 CAPLUS

CN Carbamic acid, methoxy[2-[[ (5-phenyl-1H-pyrazol-3-yl)oxy]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 252280-52-7 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -methoxy-2-[[ (5-phenyl-1H-pyrazol-3-yl)oxy]methyl]-, methyl ester (CA INDEX NAME)



RN 252280-53-8 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 2,4-dihydro-5-methoxy-2-methyl-4-[2-[(5-phenyl-1H-pyrazol-3-yl)oxy]methyl]phenyl]- (CA INDEX NAME)



L3 ANSWER 37 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:431880 CAPLUS Full-text

DOCUMENT NUMBER: 131:54033

TITLE: Dihydropyridine derivatives for treatment of brain ischemic neuron injury

INVENTOR(S): Nomura, Yasuyuki; Miyazaki, Hiroyuki; Uehara, Takashi; Tanaka, Shinji; Okuma, Yasunobu; Kamibayashi, Masato

PATENT ASSIGNEE(S): Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.

CODEN: JKXXAF


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 11189535	A	19990713	JP 1997-366303	19971225
JP 3365732	B2	20030114		
PRIORITY APPLN. INFO.:			JP 1997-366303	19971225
GI				




AB Dihydropyridine derivs. (I; R1, R2 = H, nitro, Cl; R3 = H, Cl, F; n = 2-8) and their optic isomers are claimed for treatment of brain ischemic neuron injury. The neuroprotective effect of I (CV 159) on exptl. brain ischemia was tested in rats.

IT 86384-98-7, CV 159  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (dihydropyridine derivs. for treatment of brain ischemic neuron injury)

RN 86384-98-7 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 6-[(5-phenyl-1H-pyrazol-3-yl)oxy]hexyl ester (9CI) (CA INDEX NAME)



L3 ANSWER 38 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:104883 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 130:291479

TITLE: Neuroprotective effects of a dihydropyridine derivative, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl-6-(5-phenyl-3-pyrazolyloxy)hexyl ester (CV-159), on rat ischemic brain injury

AUTHOR(S): Miyazaki, Hiroyuki; Tanaka, Shinji; Fujii, Yukiko; Shimizu, Kazuko; Nagashima, Kazuo; Kamibayashi, Masato; Uehara, Takashi; Okuma, Yasunobu; Nomura, Yasuyuki

CORPORATE SOURCE: Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, 060-0812, Japan

SOURCE: Life Sciences (1999), 64(10), 869-878  
 CODEN: LIFSAK; ISSN: 0024-3205

PUBLISHER: Elsevier Science Inc.

DOCUMENT TYPE: Journal



LANGUAGE: English

AB CV-159 is a dihydropyridine derivative that blocks the L-type  $\text{Ca}^{2+}$  channel and inhibits the calmodulin (CaM)-dependent pathway. In this study, we examined the effects of CV-159 on rat ischemic brain injury. CV-159 (5 and 10 mg/kg, p.o.) gave significant protection against delayed neuronal death in the hippocampal CA1 region after 15-min transient forebrain ischemia. In contrast, the  $\text{Ca}^{2+}$  antagonists nicardipine (1 and 10 mg/kg, p.o.) and nifedipine (1 mg/kg, i.p.) and the CaM antagonist N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7, 500 ng, i.c.v.) had no effect on this hippocampal neuronal death. CV-159 also diminished the size of the brain infarct after permanent middle cerebral artery (MCA) occlusion, although physiol. variables, including regional cerebral blood flow, were not affected. The increase in the water content of the infarcted cortex induced by MCA occlusion was significantly reduced by CV-159. Neither nicardipine nor nifedipine affected the brain infarct size, volume or increased water content induced by MCA occlusion, as previously reported (A. Sauter and M. Rudin, 1991). These findings indicate that  $\text{Ca}^{2+}$  antagonists, such as nicardipine and nifedipine, and W-7 have no effect on rat ischemic brain injury. The results suggest that CV-159 protects against ischemic brain injury. This might be mediated by both blocking the L-type  $\text{Ca}^{2+}$  channel and inhibiting CaM-dependent function via  $\text{Ca}^{2+}$ /CaM binding at a different binding site from that of W-7 to CaM (H. Umekawa, K. Yamakawa, K. Nunoki, N. Taira, T. Tanaka, and H. Hidaka, 1988).


IT 86384-98-7, CV-159

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(neuroprotective effects of a dihydropyridine derivative (CV-159), on rat ischemic brain injury)

RN 86384-98-7 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 6-[(5-phenyl-1H-pyrazol-3-yl)oxy]hexyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 39 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:60452 CAPLUS Full-text

DOCUMENT NUMBER: 130:281689

TITLE: An experimental (flash vacuum pyrolysis) and theoretical study of the tautomerism of pyrazolinones at high temperatures

AUTHOR(S): Yranzo, Gloria I.; Moyano, Elizabeth L.; Rozas, Isabel; Dardonville, Christophe; Elguero, Jose

CORPORATE SOURCE: Facultad de Ciencias Quimicas, I.N.F.I.Q.C. - Departamento de Quimica Organica, Universidad Nacional

de Cordoba, Cordoba, 5016, Spain

SOURCE: Journal of the Chemical Society, Perkin Transactions  
2: Physical Organic Chemistry (1999), (2), 211-216  
CODEN: JCPKBH; ISSN: 0300-9580

PUBLISHER: Royal Society of Chemistry

DOCUMENT TYPE: Journal


LANGUAGE: English

AB Flash vacuum pyrolysis expts. were carried out between 500 and 800° on 3(5)-phenyl- and 3(5)-methyl-pyrazolinones and on 3(5)-methoxy-5(3)-phenylpyrazole. The origin of the isolated products (mainly indanone, hydroxyalkynes and  $\alpha,\beta$ -unsatd. aldehydes) can be explained as arising from the hydroxy tautomers of pyrazolinones. Temperature effects on the tautomeric equilibrium of 1-phenyl-3-methylpyrazolinone in solution show that the percentage of the CH tautomer increases with the temperature MP2 ab initio calcns. on the model compound, pyrazolinone itself, have been used to rationalize these findings. The problem of the aromaticity of the four tautomers of pyrazolinone has been examined through Schleyer's NICS (nuclear independent chemical shifts) calcns.

IT 39513-07-0, 5-Methoxy-3-phenyl-1H-pyrazole  
RL: PEP (Physical, engineering or chemical process); RCT (Reactant); PROC (Process); RACT (Reactant or reagent)  
(flash vacuum pyrolysis of pyrazolinones)

RN 39513-07-0 CAPLUS

CN 1H-Pyrazole, 3-methoxy-5-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 40 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:231026 CAPLUS Full-text

DOCUMENT NUMBER: 126:264035

ORIGINAL REFERENCE NO.: 126:51141a,51144a

TITLE: Synthesis and Biological Evaluation of the  
1,5-Diarylpyrazole Class of Cyclooxygenase-2  
Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide  
(SC-58635, Celecoxib)


AUTHOR(S): Penning, Thomas D.; Talley, John J.; Bertenshaw,  
Stephen R.; Carter, Jeffery S.; Collins, Paul W.;  
Docter, Stephen; Graneto, Matthew J.; Lee, Len F.;  
Malecha, James W.; Miyashiro, Julie M.; Rogers, Roland  
S.; Rogier, D. J.; Yu, Stella S.; Anderson, Gary D.;  
Burton, Earl G.; Cogburn, J. Nita; Gregory, Susan A.;  
Koboldt, Carol M.; Perkins, William E.; Seibert,  
Karen; Veenhuizen, Amy W.; Zhang, Yan Y.; Isakson,  
Peter C.

CORPORATE SOURCE: Departments of Chemistry Inflammatory Diseases  
Research and Molecular Pharmacology, Searle Research  
and Development, Skokie, IL, 60077, USA

SOURCE: Journal of Medicinal Chemistry (1997), 40(9),

1347-1365  
CODEN: JMCMAR; ISSN: 0022-2623  
American Chemical Society  
Journal  
English

PUBLISHER:  
DOCUMENT TYPE:  
LANGUAGE:  
GI




AB Sulfonamide-containing 1,5-diarylpyrazole derivs. were prepared and evaluated for their ability to block cyclooxygenase-2 (COX-2) in vitro and in vivo. Extensive structure-activity relationship work was carried out within this series, and a number of potent and selective inhibitors of COX-2 were identified. Since an early structural lead exhibited an unacceptably long plasma half-life, a number of pyrazole analogs containing potential metabolic sites were evaluated further in vivo in an effort to identify compds. with acceptable pharmacokinetic profiles. This work led to the identification of SC-58635 (celecoxib, I), which is currently in phase III clin. trials for the treatment of rheumatoid arthritis and osteoarthritis.

IT 188816-96-8F

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(diarylpyrazoles as cyclooxygenase 2 inhibitors)

RN 188816-96-8 CAPLUS

CN Benzenesulfonamide, 4-(3-methoxy-5-phenyl-1H-pyrazol-1-yl)- (CA INDEX NAME)



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 41 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:748761 CAPLUS Full-text

DOCUMENT NUMBER: 126:98771

ORIGINAL REFERENCE NO.: 126:18897a,18900a

TITLE: Determination of 1-(5-(3,4-dimethoxyphenyl)-pyrazol-3-yl-oxypropyl)-3-[N-methyl-N-2-(3,4-dimethoxyphenyl)ethylamino]propane hydrochloride and

AUTHOR(S): its two metabolites in dog plasma by high performance liquid chromatography with fluorescence detection  
 Lau, Yi; Wagner, Colette A.; Hanson, Glenn D.; Borlak, J.  
 CORPORATE SOURCE: Corning Hazleton Wisconsin, Madison, WI, 53704, USA  
 SOURCE: Journal of Liquid Chromatography & Related Technologies (1996), 19(20), 3279-3292  
 CODEN: JLCTFC; ISSN: 1082-6076  
 PUBLISHER: Dekker  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB A simple specific and sensitive high-performance liquid chromatog. (HPLC) method was developed for the determination of 1-(5-(3,4-dimethoxyphenyl)-pyrazol-3-yl-oxypropyl)-3-[n-methyl-n-[2-(3,4-dimethoxyphenyl)ethyl]amino]propane hydrochloride (KC11346) and two of its metabolites (KC12795, KC12816) in dog plasma. KC11346, KC12795, KC12816 and KC11294 (internal standard) are extracted from dog plasma by Me t-Bu ether (MTBE) following an alkalization of plasma. MTBE is removed from the extract with a gentle stream of nitrogen at 40 °C and reconstituted in 200 µL of mobile phase. Separation of the reconstituted extract is achieved by HPLC on a Zorbax SB-CN column with a mobile phase composed of (56:44) 50 mM sodium acetate/acetonitrile. The analytes were detected by fluorescence detection with a Corion UG-11 cut off filter and an excitation wavelength of 265 nm. The mean retention times of KC12816, KC12795, K11346, and the internal standard were 4.8, 8.1, 9.0, and 14.4 min, resp. The assay is linear over the concentration range 3 to 350 ng/mL. The anal. of pooled quality control samples (8, 30, and 300 ng/mL) demonstrates excellent precision with relative standard deviations (RSD) (n= 18) ≤ 7.5% for all three compds. The method is accurate with all intraday (n = 6) and overall mean values ≤ 15.7% from theor. at all control concns. for all compds.


IT 165741-64-0, KC 11346 185912-89-4, KC 12795  
 185912-90-7, KC 12816

RL: ANT (Analyte); ANST (Analytical study)

(KC11346 and its metabolites KC12795 and KC12816 determination in dog plasma by HPLC with fluorescence detection)

RN 165741-64-0 CAPLUS

CN Benzeneethanamine, N-[3-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]propyl]-3,4-dimethoxy-N-methyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 185912-89-4 CAPLUS

CN Benzeneethanamine, N-[3-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]propyl]-3,4-dimethoxy-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 185912-90-7 CAPLUS  
CN 1-Propanamine, 3-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]-N-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

DOCUMENT NUMBER: 125:247807  
ORIGINAL REFERENCE NO.: 125:46325a,46328a  
TITLE: (Phenylalkylaminoalkyloxy)-heteroaryl compounds having heart-rate-lowering and anti-ischemic effects  
INVENTOR(S): Kehrbach, Wolfgang; Mlinaric, Michael; Ziegler, Dieter; Brueckner, Reinhard; Bielenberg, Willi  
PATENT ASSIGNEE(S): Kali-Chemie Pharma GmbH, Germany  
SOURCE: U.S., 34 pp., Cont.-in-part of U.S. Ser. No. 352, 353, abandoned.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5547967	A	19960820	US 1995-476118	19950607
DE 4341749	A1	19950614	DE 1993-4341749	19931208
DE 19513503	A1	19961017	DE 1995-19513503	19950410
US 5679699	A	19971021	US 1995-576699	19951221
EP 737680	A1	19961016	EP 1996-105335	19960403
EP 737680	B1	20040303		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 260905	T	20040315	AT 1996-105335	19960403
ES 2213165	T3	20040816	ES 1996-105335	19960403
JP 09151180	A	19970610	JP 1996-88590	19960410
PRIORITY APPLN. INFO.:			DE 1993-4341749	A 19931208
			US 1994-352353	B2 19941208
			DE 1995-19513503	A 19950410
			US 1995-476118	A3 19950607
OTHER SOURCE(S):	MARPAT 125:247807			
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB 3-(Phenylalkylaminoalkyloxy)heteroaryl compds. having heart rate lowering and/or anti-ischemic effects, methods for their preparation and pharmaceutical compns. containing them are described. The compds. correspond to the general formula I in which n is an integer from 1-5, A = NR<sub>1</sub>Q in which R<sub>1</sub> represents hydrogen or a lower alkyl group and Q represents a (CH<sub>2</sub>)<sub>m</sub> group in which m is 2 to 8 and which may optionally be substituted in the α position to the oxygen atom by 1 or 2 lower alkyl groups, or Q represents a 2-hydroxypropylene chain, or A = [cyclic N(CH<sub>2</sub>)<sub>p</sub>]-B in which p is 4 to 6 and B represents a (CH<sub>2</sub>)<sub>r</sub> group in which r is 1 to 3 and which may optionally be substituted in the α position to the oxygen atom by 1 or 2 lower alkyl groups; R<sub>2</sub> = e.g., H, halogen, lower alkyl; R<sub>3</sub> = e.g., H, halogen, lower alkyl; R<sub>4</sub> = H or lower alkyl; R<sub>5</sub> is disposed in the 1 or 2 position and represents hydrogen, lower alkyl or a phenyl-lower alkyl group; R<sub>6</sub> = e.g., H, lower alkyl, lower alkoxy; R<sub>7</sub> = e.g., H, lower alkyl, lower alkoxy, and their acid addition salts. The compds. also correspond to the general formula II wherein R<sub>1</sub> = H or lower alkyl; R<sub>2</sub> = e.g., H, halo, lower alkyl; R<sub>3</sub> = e.g., H, halo, lower alkyl; R<sub>4</sub> = thienyl or R<sub>5</sub>R<sub>6</sub>-substituted Ph wherein R<sub>5</sub> = e.g., H, halo, lower alkyl and R<sub>6</sub> = e.g., H, halo, lower alkyl; A = N or R<sub>7</sub>C in which R<sub>7</sub> = H or lower alkyl; B = O or, if A = N, also S; n = an integer from 1-5; and Q = (CH<sub>2</sub>)<sub>m</sub> where m is an integer from 2-8 and which may optionally be substituted by a lower alkyl, or represents the 2-hydroxypropylene chain, or a physiol. acceptable acid addition salt thereof.


Thus, e.g., alkylation of 5-(3,4-dimethoxyphenyl)pyrazolin-3-one (preparation given) with 3-[N-(2-(3,4-dimethoxyphenyl)ethyl)-N-methylamino]propyl chloride (preparation given) afforded aminoalkoxy pyrazole III which exhibited FRQ 75 (that concentration, in  $\mu\text{mol/L}$ , at which 20 min after the administration of the substance there is a reduction in the heart rate to 75% of the initial value) = 1.6. Data were also presented for cytoprotective effect on atrial contraction induced by hypoxia (as low as  $0.55 \mu\text{M}$ ), and for corresponding force recovery after hypoxia (up to 80%). Pharmaceutical formulations were given.

IT 165741-63-9P 165741-64-0P 165741-80-0P  
 165741-85-5P 165741-89-9P 165741-97-9P  
 165741-99-1P 165742-00-7P 165742-11-0P  
 165742-22-3P 165742-25-6P 165742-26-7P  
 165742-27-8P 165742-32-5P 165742-33-6P  
 165742-38-1P 165742-39-2P 165742-40-5P  
 165742-41-6P 165742-42-7P 165742-44-9P  
 165742-47-2P 165742-48-3P 165742-50-7P  
 165742-54-1P 165742-57-4P 165742-60-9P  
 181934-98-5P 181935-07-9P 181935-13-7P  
 181935-22-8P 181935-79-5P 181935-83-1P  
 181935-96-6P 181936-26-5P 181936-30-1P  
 181936-47-0P 181936-57-2P 181936-70-9P  
 181936-71-0P 181936-74-3P 181936-78-7P  
 181936-83-4P 181936-86-7P 181936-96-9P  
 181954-86-9P 181955-81-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 ((phenylalkylaminoalkyloxy)-heteroaryl compds. having  
 heart-rate-lowering and anti-ischemic effects)


RN 165741-63-9 CAPLUS

CN Benzeneethanamine, N-[3-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]propyl]-3,4-dimethoxy-N-methyl- (CA INDEX NAME)



RN 165741-64-0 CAPLUS


CN Benzeneethanamine, N-[3-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]propyl]-3,4-dimethoxy-N-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 165741-80-0 CAPLUS

CN Piperidine, 1-[2-(3,4-dimethoxyphenyl)ethyl]-3-[[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]methyl]- (CA INDEX NAME)



RN 165741-85-5 CAPLUS


CN Benzeneethanamine, N-[6-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]hexyl]-3,4-dimethoxy-N-methyl- (CA INDEX NAME)




RN 165741-89-9 CAPLUS

CN Benzeneethanamine, N-[3-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]propyl]-3,4-dimethoxy- (CA INDEX NAME)






RN 165741-97-9 CAPLUS  
 CN Benzeneethanamine, 3,4-dimethoxy-N-methyl-N-[3-[[5-(4-nitrophenyl)-1H-pyrazol-3-yl]oxy]propyl]- (CA INDEX NAME)




RN 165741-99-1 CAPLUS  
 CN Benzeneethanamine, N-[3-[[5-(3,4-dichlorophenyl)-1H-pyrazol-3-yl]oxy]propyl]-3,4-dimethoxy-N-methyl- (CA INDEX NAME)



RN 165742-00-7 CAPLUS  
 CN Benzeneethanamine, N-[3-[[5-(3,4-dichlorophenyl)-1H-pyrazol-3-yl]oxy]propyl]-3,4-dimethoxy-N-methyl-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1


CRN 165741-99-1  
 CMF C23 H27 Cl2 N3 O3




CM 2

CRN 110-17-8  
 CMF C4 H4 O4

Double bond geometry as shown.



RN 165742-11-0 CAPLUS  
 CN Benzeneethanamine, N-[3-[[5-(2-fluorophenyl)-1-methyl-1H-pyrazol-3-yl]oxy]propyl]-N-methyl- (CA INDEX NAME)




RN 165742-22-3 CAPLUS

CN Benzeneethanamine, 3,4-dimethoxy-N-methyl-N-[3-[(5-phenyl-4-propyl-1H-pyrazol-3-yl)oxy]propyl]-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 165742-21-2


CMF C26 H35 N3 O3



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 165742-25-6 CAPLUS

CN Benzeneethanamine, N-[2-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]ethyl]-N-methyl-4-nitro-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 165742-24-5


CMF C22 H26 N4 O5



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 165742-26-7 CAPLUS

CN Benzeneethanamine, 3,4-dimethoxy-N-methyl-N-[3-[[5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]oxy]propyl]- (CA INDEX NAME)




RN 165742-27-8 CAPLUS

CN Benzeneethanamine, 3,4-dimethoxy-N-methyl-N-[3-[[5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]oxy]propyl]-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 165742-26-7

CMF C24 H28 F3 N3 O3




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.



RN 165742-32-5 CAPLUS

CN Benzeneethanamine, 3,4-dimethoxy-N-methyl-N-[3-[(1-methyl-5-phenyl-1H-pyrazol-3-yl)oxy]propyl]- (CA INDEX NAME)




RN 165742-33-6 CAPLUS

CN Benzeneethanamine, 3,4-dimethoxy-N-methyl-N-[3-[(1-methyl-5-phenyl-1H-pyrazol-3-yl)oxy]propyl]-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 165742-32-5

CMF C24 H31 N3 O3




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.



RN 165742-38-1 CAPLUS

CN Benzeneethanamine, N-methyl-N-[3-[[5-(4-nitrophenyl)-1H-pyrazol-3-yl]oxy]propyl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 165742-39-2 CAPLUS

CN Benzeneethanamine, N-methyl-N-[3-[[5-(4-nitrophenyl)-1H-pyrazol-3-yl]oxy]propyl]-4-(trifluoromethyl)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 165742-38-1


CMF C22 H23 F3 N4 O3



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 165742-40-5 CAPLUS

CN Benzeneethanamine, N-methyl-N-[3-[(5-phenyl-1H-pyrazol-3-yl)oxy]propyl]-  
(CA INDEX NAME)




RN 165742-41-6 CAPLUS

CN Benzeneethanamine, N-methyl-N-[3-[(5-phenyl-1H-pyrazol-3-yl)oxy]propyl]-,  
ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 165742-40-5


CMF C21 H25 N3 O



CM 2


CRN 144-62-7

CMF C2 H2 O4




RN 165742-42-7 CAPLUS

CN Benzeneethanamine, N-methyl-N-[2-[[5-(4-nitrophenyl)-1H-pyrazol-3-yl]oxy]ethyl]-  
(CA INDEX NAME)



RN 165742-44-9 CAPLUS

CN Benzeneethanamine, 3,4-dimethoxy-N-methyl-N-[3-[(5-phenyl-1H-pyrazol-3-yl)oxy]propyl]- (CA INDEX NAME)




RN 165742-47-2 CAPLUS

CN Benzeneethanamine, 4-chloro-N-[3-[[5-(4-fluorophenyl)-1H-pyrazol-3-yl]oxy]propyl]-N-methyl-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 165742-46-1


CMF C21 H23 Cl F N3 O



CM 2

CRN 144-62-7


CMF C2 H2 O4






RN 165742-48-3 CAPLUS

CN Benzeneethanamine, N-[3-[[5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]oxy]propyl]-3,4-dimethoxy-N-methyl- (CA INDEX NAME)




RN 165742-50-7 CAPLUS

CN Benzeneethanamine, N-[2-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]ethyl]-3,4-dimethoxy-N-methyl- (CA INDEX NAME)



RN 165742-54-1 CAPLUS

CN Benzeneethanamine, N-[3-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]propyl]-N-methyl- (CA INDEX NAME)




RN 165742-57-4 CAPLUS

CN Benzeneethanamine, N-[3-[[5-(4-fluorophenyl)-1H-pyrazol-3-yl]oxy]propyl]-N-methyl-4-(trifluoromethyl)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 165742-56-3


CMF C22 H23 F4 N3 O



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 165742-60-9 CAPLUS

CN Piperidine, 1-[2-(3,4-dimethoxyphenyl)ethyl]-3-[[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]methyl]-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 165741-80-0


CMF C27 H35 N3 O5



CM 2


CRN 144-62-7

CMF C2 H2 O4




RN 181934-98-5 CAPLUS

CN Benzenepentanamine, N-[3-[[5-(2-fluorophenyl)-1-methyl-1H-pyrazol-3-yl]oxy]propyl]-N-methyl- (CA INDEX NAME)




RN 181935-07-9 CAPLUS

CN Benzeneethanamine, N-[8-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]octyl]-3,4-dimethoxy-N-methyl- (CA INDEX NAME)



RN 181935-13-7 CAPLUS


CN Benzeneethanamine, N-[3-[[5-(4-chlorophenyl)-1,4-dimethyl-1H-pyrazol-3-yl]oxy]propyl]-3-methoxy-N-methyl- (CA INDEX NAME)



RN 181935-22-8 CAPLUS

CN Phenol, 4-[2-[[3-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-

yl]oxy]propyl]methylamino]ethyl]-2-methoxy- (CA INDEX NAME)




RN 181935-79-5 CAPLUS

CN Benzeneethanamine, N-[6-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]hexyl]-3,4-dimethoxy-N-methyl-, (2R,3R)-2,3-dihydroxybutanedioate (10:11) (CA INDEX NAME)

CM 1

CRN 165741-85-5

CMF C28 H39 N3 O5




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 181935-83-1 CAPLUS

CN Benzeneethanamine, N-[3-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-


yl]oxy]propyl]-3,4-dimethoxy-, (2R,3R)-2,3-dihydroxybutanedioate (1:1)  
(CA INDEX NAME)

CM 1

CRN 165741-89-9

CMF C24 H31 N3 O5

PAGE 1-A



PAGE 2-A




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.




RN 181935-96-6 CAPLUS

CN Benzeneethanamine, 3,4-dimethoxy-N-methyl-N-[3-[[5-(4-nitrophenyl)-1H-pyrazol-3-yl]oxy]propyl]-, (2E)-2-butenedioate (2:1) (CA INDEX NAME)

CM 1

CRN 165741-97-9

CMF C23 H28 N4 O5




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 181936-26-5 CAPLUS

CN Benzenepentanamine, N-[3-[[5-(2-fluorophenyl)-1-methyl-1H-pyrazol-3-yl]oxy]propyl]-N-methyl-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 181934-98-5


CMF C25 H32 F N3 O



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 181936-30-1 CAPLUS

CN Benzeneethanamine, N-[4-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]butyl]-3,4-dimethoxy-N-methyl-, hydrochloride (5:12) (CA INDEX NAME)



● 12/5 HCl


RN 181936-47-0 CAPLUS

CN Benzeneethanamine, N-[8-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]octyl]-3,4-dimethoxy-N-methyl-, ethanedioate (10:9) (CA INDEX NAME)

CM 1

CRN 181935-07-9


CMF C30 H43 N3 O5



CM 2

CRN 144-62-7


CMF C2 H2 O4



RN 181936-57-2 CAPLUS  
 CN Benzeneethanamine, N-[3-[[5-(4-chlorophenyl)-1,4-dimethyl-1H-pyrazol-3-yl]oxy]propyl]-3-methoxy-N-methyl-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1


CRN 181935-13-7  
 CMF C24 H30 Cl N3 O2



CM 2

CRN 87-69-4  
 CMF C4 H6 O6

Absolute stereochemistry.




RN 181936-70-9 CAPLUS  
 CN Benzeneethanamine, N-methyl-N-[2-[[5-(4-nitrophenyl)-1H-pyrazol-3-yl]oxy]ethyl]-, ethanedioate (10:9) (CA INDEX NAME)

CM 1

CRN 165742-42-7  
 CMF C20 H22 N4 O3






CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 181936-71-0 CAPLUS

CN Benzeneethanamine, 3,4-dimethoxy-N-methyl-N-[3-[(5-phenyl-1H-pyrazol-3-yl)oxy]propyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 165742-44-9

CMF C23 H29 N3 O3




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 181936-74-3 CAPLUS


CN Benzeneethanamine, N-[3-[[5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-

yl]oxy]propyl]-3,4-dimethoxy-N-methyl-, (2R,3R)-2,3-dihydroxybutanedioate  
(5:6) (CA INDEX NAME)

CM 1

CRN 165742-48-3

CMF C24 H30 Cl N3 O3




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.




RN 181936-78-7 CAPLUS

CN Benzeneethanamine, N-[2-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]ethyl]-3,4-dimethoxy-N-methyl-, (2R,3R)-2,3-dihydroxybutanedioate  
(10:11) (CA INDEX NAME)

CM 1

CRN 165742-50-7

CMF C24 H31 N3 O5




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.




RN 181936-83-4 CAPLUS

CN Benzeneethanamine, N-[3-[[5-(4-fluorophenyl)-1H-pyrazol-3-yl]oxy]propyl]-N-methyl-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 165742-52-9

CMF C21 H24 F N3 O




CM 2


CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.




RN 181936-86-7 CAPLUS  
 CN Benzeneethanamine, N-[3-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]propyl]-N-methyl-, (2E)-2-butenedioate (5:6) (CA INDEX NAME)  
 CM 1  
 CRN 165742-54-1  
 CMF C23 H29 N3 O3




CM 2  
 CRN 110-17-8  
 CMF C4 H4 O4

Double bond geometry as shown.



RN 181936-96-9 CAPLUS  
 CN Phenol, 4-[2-[[3-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]propyl]methylamino]ethyl]-2-methoxy-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 181935-22-8  
 CMF C24 H31 N3 O5




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.




RN 181954-86-9 CAPLUS

CN Benzeneethanamine, N-[3-[[5-(2-fluorophenyl)-1-methyl-1H-pyrazol-3-yl]oxy]propyl]-N-methyl-, (2R,3R)-2,3-dihydroxybutanedioate (10:9) (CA INDEX NAME)

CM 1

CRN 165742-11-0

CMF C22 H26 F N3 O




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.




RN 181955-81-7 CAPLUS

CN Hexanamide, N-[2-(3,4-dimethoxyphenyl)ethyl]-6-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]-N-methyl-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 165741-77-5

CMF C28 H37 N3 O6




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.




IT 165741-77-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

((phenylalkylaminoalkyloxy)-heteroaryl compds. having heart-rate-lowering and anti-ischemic effects)

RN 165741-77-5 CAPLUS

CN Hexanamide, N-[2-(3,4-dimethoxyphenyl)ethyl]-6-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]-N-methyl- (CA INDEX NAME)



L3 ANSWER 43 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:716928 CAPLUS Full-text

DOCUMENT NUMBER: 123:112059

ORIGINAL REFERENCE NO.: 123:20021a,20024a

TITLE: Preparation of 3-(phenylalkylaminoalkyloxy)-5-phenylpyrazole antiarrhythmics

INVENTOR(S): Kehrbach, Wolfgang; Mlinaric, Michael; Ziegler, Dieter; Brueckner, Reinhard; Bielenberg, Willi

PATENT ASSIGNEE(S): Kali-Chemie Pharma GmbH, Germany

SOURCE: Ger. Offen., 35 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
DE 4341749	A1	19950614	DE 1993-4341749	19931208
AU 9477694	A	19950615	AU 1994-77694	19941108
ZA 9409537	A	19950811	ZA 1994-9537	19941130
HU 68518	A2	19950628	HU 1994-3458	19941202
EP 663395	A1	19950719	EP 1994-119149	19941205
EP 663395	B1	20010516		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
ES 2156135	T3	20010616	ES 1994-119149	19941205
CA 2137446	A1	19950609	CA 1994-2137446	19941206
JP 07196622	A	19950801	JP 1994-302359	19941206
JP 3492433	B2	20040203		
FI 9405750	A	19950609	FI 1994-5750	19941207
NO 9404722	A	19950609	NO 1994-4722	19941207
CN 1109051	A	19950927	CN 1994-119876	19941207
US 5547967	A	19960820	US 1995-476118	19950607
US 5679699	A	19971021	US 1995-576699	19951221
PRIORITY APPLN. INFO.:			DE 1993-4341749	A 19931208
			US 1994-352353	B2 19941208
			DE 1995-19513503	A 19950410
			US 1995-476118	A3 19950607

OTHER SOURCE(S): MARPAT 123:112059

GI




AB The title compds. [I; A = N-containing (un)substituted bridging group; R2 = H, halogen, alkyl, alkoxy, CF3, NO2; R3 = H, halogen, alkyl, alkoxy, OH; R4 = H, lower alkyl; R5 = H, lower alkyl, phenylalkyl; R6 = H, alkyl, alkoxy, HO, halogen, CF3, NO2; R7 = H, alkyl, alkoxy, HO, halogen; n = 1-5], useful as antiarrhythmics, are prepared and a I-containing tablet formulation presented. Thus, 3-[3-[N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methylamino]propyloxy]-5-(3,4-dimethoxyphenyl)pyrazole hydrochloride (m.p. 189-192°), prepared from 3,4-dimethoxybenzoyl chloride in 6 steps, demonstrated a 75% heart-rate reduction at 1.6  $\mu\text{mol/L}$ .

IT 165741-63-9P 165741-64-0P 165741-80-0P  
 165741-81-1P 165741-82-2P 165741-83-3P  
 165741-85-5P 165741-86-6P 165741-87-7P  
 165741-88-8P 165741-89-9P 165741-90-2P  
 165741-98-0P 165742-00-7P 165742-12-1P  
 165742-15-4P 165742-22-3P 165742-23-4P  
 165742-25-6P 165742-27-8P 165742-31-4P  
 165742-33-6P 165742-39-2P 165742-41-6P  
 165742-43-8P 165742-45-0P 165742-47-2P  
 165742-49-4P 165742-51-8P 165742-53-0P  
 165742-55-2P 165742-57-4P 165742-60-9P  
 165742-61-0P 165742-62-1P 165742-63-2P  
 165742-65-4P 165742-66-5P 165742-67-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of 3-(phenylalkylaminoalkyloxy)-5-phenylpyrazole antiarrhythmics)

RN 165741-63-9 CAPLUS

CN Benzeneethanamine, N-[3-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]propyl]-3,4-dimethoxy-N-methyl- (CA INDEX NAME)




RN 165741-64-0 CAPLUS

CN Benzeneethanamine, N-[3-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]propyl]-3,4-dimethoxy-N-methyl-, hydrochloride (1:1) (CA INDEX




NAME)



● HCl


RN 165741-80-0 CAPLUS

CN Piperidine, 1-[2-(3,4-dimethoxyphenyl)ethyl]-3-[[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]methyl]- (CA INDEX NAME)




RN 165741-81-1 CAPLUS

CN Benzeneethanamine, N-[3-[[[5-(2-fluorophenyl)-1-methyl-1H-pyrazol-3-yl]oxy]propyl]-N,3-dimethyl- (CA INDEX NAME)




RN 165741-82-2 CAPLUS

CN Benzeneethanamine, N-[3-[[[5-(2-fluorophenyl)-1-methyl-1H-pyrazol-3-yl]oxy]propyl]-N-methyl-4-nitro- (CA INDEX NAME)




RN 165741-83-3 CAPLUS

CN 2-Propanol, 1-[[[(3,4-dimethylphenyl)methyl]methylamino]-3-[[5-(2-fluorophenyl)-1-methyl-1H-pyrazol-3-yl]oxy]- (CA INDEX NAME)




RN 165741-85-5 CAPLUS

CN Benzeneethanamine, N-[6-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]hexyl]-3,4-dimethoxy-N-methyl- (CA INDEX NAME)




RN 165741-86-6 CAPLUS

CN Phenol, 4-[3-[2-[[2-(4-chlorophenyl)ethyl]methylamino]ethoxy]-1-methyl-1H-pyrazol-5-yl]- (CA INDEX NAME)



RN 165741-87-7 CAPLUS


CN Ethanone, 1-[4-[3-[2-[[2-(4-chlorophenyl)ethyl]methylamino]ethoxy]-1-methyl-1H-pyrazol-5-yl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 165741-88-8 CAPLUS

CN Benzeneethanamine, N-[3-[[5-(3,4-dimethoxyphenyl)-1-(phenylmethyl)-1H-pyrazol-3-yl]oxy]propyl]-3,4-dimethoxy- (CA INDEX NAME)




RN 165741-89-9 CAPLUS

CN Benzeneethanamine, N-[3-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]propyl]-3,4-dimethoxy- (CA INDEX NAME)



RN 165741-90-2 CAPLUS

CN Benzeneethanamine, N-[3-[[5-(3,4-dimethoxyphenyl)-1-(phenylmethyl)-1H-pyrazol-3-yl]oxy]propyl]-3,4-dimethoxy-N-methyl- (CA INDEX NAME)




RN 165741-98-0 CAPLUS

CN Benzeneethanamine, 3,4-dimethoxy-N-methyl-N-[3-[[5-(4-nitrophenyl)-1H-pyrazol-3-yl]oxy]propyl]-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 165741-97-9

CMF C23 H28 N4 O5




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 165742-00-7 CAPLUS

CN Benzeneethanamine, N-[3-[[5-(3,4-dichlorophenyl)-1H-pyrazol-3-yl]oxy]propyl]-3,4-dimethoxy-N-methyl-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 165741-99-1

CMF C23 H27 Cl2 N3 O3




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 165742-12-1 CAPLUS

CN Butanedioic acid, 2,3-bis(benzoyloxy)-, (2R,3R)-, compd. with  
N-[3-[[5-(2-fluorophenyl)-1-methyl-1H-pyrazol-3-yl]oxy]propyl]-N-  
methylbenzeneethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 165742-11-0

CMF C22 H26 F N3 O




CM 2

CRN 2743-38-6


CMF C18 H14 O8

Absolute stereochemistry. Rotation (-).



RN 165742-15-4 CAPLUS

CN Benzeneethanamine, N-[4-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-  
yl]oxy]butyl]-3,4-dimethoxy-N-methyl-, hydrochloride (1:1) (CA INDEX  
NAME)



● HCl


RN 165742-22-3 CAPLUS

CN Benzenethanamine, 3,4-dimethoxy-N-methyl-N-[3-[(5-phenyl-4-propyl-1H-pyrazol-3-yl)oxy]propyl]-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 165742-21-2


CMF C26 H35 N3 O3



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 165742-23-4 CAPLUS

CN Benzenethanamine, N-[6-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]hexyl]-3,4-dimethoxy-N-methyl-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 165741-85-5


CMF C28 H39 N3 O5



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 165742-25-6 CAPLUS

CN Benzeneethanamine, N-[2-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]ethyl]-N-methyl-4-nitro-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 165742-24-5


CMF C22 H26 N4 O5



CM 2

CRN 144-62-7

CMF C2 H2 O4






RN 165742-27-8 CAPLUS  
 CN Benzeneethanamine, 3,4-dimethoxy-N-methyl-N-[3-[[5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]oxy]propyl]-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1


CRN 165742-26-7  
 CMF C24 H28 F3 N3 O3



CM 2

CRN 110-17-8  
 CMF C4 H4 O4


Double bond geometry as shown.



RN 165742-31-4 CAPLUS  
 CN Butanedioic acid, 2,3-bis(benzoyloxy)-, (2R,3R)-, compd. with N-[3-[[5-(4-chlorophenyl)-4-methoxy-1-methyl-1H-pyrazol-3-yl]oxy]propyl]-3-methoxy-N-methylbenzeneethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 165742-30-3  
 CMF C24 H30 Cl N3 O3




CM 2

CRN 2743-38-6

CMF C18 H14 O8

Absolute stereochemistry. Rotation (-).




RN 165742-33-6 CAPLUS

CN Benzeneethanamine, 3,4-dimethoxy-N-methyl-N-[3-[(1-methyl-5-phenyl-1H-pyrazol-3-yl)oxy]propyl]-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 165742-32-5

CMF C24 H31 N3 O3




CM 2


CRN 110-17-8

CMF C4 H4 O4


Double bond geometry as shown.




RN 165742-39-2 CAPLUS  
 CN Benzeneethanamine, N-methyl-N-[3-[[5-(4-nitrophenyl)-1H-pyrazol-3-yl]oxy]propyl]-4-(trifluoromethyl)-, ethanedioate (1:1) (CA INDEX NAME)  
 CM 1  
 CRN 165742-38-1  
 CMF C22 H23 F3 N4 O3



CM 2  
 CRN 144-62-7  
 CMF C2 H2 O4




RN 165742-41-6 CAPLUS  
 CN Benzeneethanamine, N-methyl-N-[3-[(5-phenyl-1H-pyrazol-3-yl)oxy]propyl]-, ethanedioate (1:1) (CA INDEX NAME)  
 CM 1  
 CRN 165742-40-5  
 CMF C21 H25 N3 O



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 165742-43-8 CAPLUS

CN Benzeneethanamine, N-methyl-N-[2-[[5-(4-nitrophenyl)-1H-pyrazol-3-yl]oxy]ethyl]-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 165742-42-7


CMF C20 H22 N4 O3



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 165742-45-0 CAPLUS

CN Butanedioic acid, 2,3-bis(benzoyloxy)-, (2R,3R)-, compd. with 3,4-dimethoxy-N-methyl-N-[3-[(5-phenyl-1H-pyrazol-3-yl)oxy]propyl]benzeneethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 165742-44-9

CMF C23 H29 N3 O3




CM 2

CRN 2743-38-6

CMF C18 H14 O8

Absolute stereochemistry. Rotation (-).




RN 165742-47-2 CAPLUS

CN Benzeneethanamine, 4-chloro-N-[3-[[5-(4-fluorophenyl)-1H-pyrazol-3-yl]oxy]propyl]-N-methyl-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 165742-46-1


CMF C21 H23 Cl F N3 O



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 165742-49-4 CAPLUS

CN Butanedioic acid, 2,3-bis(benzoyloxy)-, (2R,3R)-, compd. with  
N-[3-[[5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]oxy]propyl]-3,4-  
dimethoxy-N-methylbenzeneethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 165742-48-3

CMF C24 H30 Cl N3 O3




CM 2

CRN 2743-38-6

CMF C18 H14 O8

Absolute stereochemistry. Rotation (-).




RN 165742-51-8 CAPLUS

CN Butanedioic acid, 2,3-bis(benzoyloxy)-, (2R,3R)-, compd. with  
N-[2-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]ethyl]-3,4-dimethoxy-N-  
methylbenzeneethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 165742-50-7


CMF C24 H31 N3 O5



CM 2

CRN 2743-38-6  
CMF C18 H14 O8

Absolute stereochemistry. Rotation (-).




RN 165742-53-0 CAPLUS

CN Benzeneethanamine, N-[3-[[5-(4-fluorophenyl)-1H-pyrazol-3-yl]oxy]propyl]-N-methyl-, ethanedioate (1:1) (CA INDEX NAME)

CM 1


CRN 165742-52-9  
CMF C21 H24 F N3 O



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 165742-55-2 CAPLUS

CN Benzeneethanamine, N-[3-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]propyl]-N-methyl-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 165742-54-1

CMF C23 H29 N3 O3




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 165742-57-4 CAPLUS


CN Benzeneethanamine, N-[3-[[5-(4-fluorophenyl)-1H-pyrazol-3-yl]oxy]propyl]-N-methyl-4-(trifluoromethyl)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 165742-56-3

CMF C22 H23 F4 N3 O






CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 165742-60-9 CAPLUS

CN Piperidine, 1-[2-(3,4-dimethoxyphenyl)ethyl]-3-[[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]methyl]-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 165741-80-0


CMF C27 H35 N3 O5



CM 2

CRN 144-62-7


CMF C2 H2 O4



RN 165742-61-0 CAPLUS  
 CN Butanedioic acid, 2,3-bis(benzoyloxy)-, (2R,3R)-, compd. with  
 N-[3-[[5-(2-fluorophenyl)-1-methyl-1H-pyrazol-3-yl]oxy]propyl]-N,3-  
 dimethylbenzeneethanamine (1:1) (CA INDEX NAME)

CM 1


CRN 165741-81-1  
 CMF C23 H28 F N3 O



CM 2

CRN 2743-38-6  
 CMF C18 H14 O8


Absolute stereochemistry. Rotation (-).



RN 165742-62-1 CAPLUS  
 CN Butanedioic acid, 2,3-bis(benzoyloxy)-, (2R,3R)-, compd. with  
 N-[3-[[5-(2-fluorophenyl)-1-methyl-1H-pyrazol-3-yl]oxy]propyl]-N-methyl-4-  
 nitrobenzeneethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 165741-82-2  
 CMF C22 H25 F N4 O3




CM 2

CRN 2743-38-6

CMF C18 H14 O8

Absolute stereochemistry. Rotation (-).




RN 165742-63-2 CAPLUS

CN 2-Propanol, 1-[[[(3,4-dimethylphenyl)methyl]methylamino]-3-[[5-(2-fluorophenyl)-1-methyl-1H-pyrazol-3-yl]oxy]-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 165741-83-3

CMF C23 H28 F N3 O2




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 165742-65-4 CAPLUS

CN Butanedioic acid, 2,3-bis(benzoyloxy)-, (2R,3R)-, compd. with  
N-[6-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]hexyl]-3,4-dimethoxy-N-  
methylbenzeneethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 165741-85-5

CMF C28 H39 N3 O5




CM 2

CRN 2743-38-6

CMF C18 H14 O8

Absolute stereochemistry. Rotation (-).



RN 165742-66-5 CAPLUS


CN Butanedioic acid, 2,3-bis(benzoyloxy)-, (2R,3R)-, compd. with  
N-[3-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]propyl]-3,4-  
dimethoxybenzeneethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 165741-89-9

CMF C24 H31 N3 O5

PAGE 1-A




PAGE 2-A



CM 2

CRN 2743-38-6  
CMF C18 H14 O8


Absolute stereochemistry. Rotation (-).



RN 165742-67-6 CAPLUS  
CN Benzeneethanamine, N-[3-[[5-(3,4-dimethoxyphenyl)-1-(phenylmethyl)-1H-pyrazol-3-yl]oxy]propyl]-3,4-dimethoxy-N-methyl-, ethanedioate (1:1) (CA INDEX NAME)


CM 1

CRN 165741-90-2  
CMF C32 H39 N3 O5




CM 2


CRN 144-62-7  
CMF C2 H2 O4



IT 165741-63-9P 165741-77-5P 165741-79-7P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of 3-(phenylalkylaminoalkoxy)-5-phenylpyrazole  
antiarrhythmics from)  
RN 165741-63-9 CAPLUS  
CN Benzeneethanamine, N-[3-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]propyl]-3,4-dimethoxy-N-methyl- (CA INDEX NAME)




RN 165741-77-5 CAPLUS  
CN Hexanamide, N-[2-(3,4-dimethoxyphenyl)ethyl]-6-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 165741-79-7 CAPLUS

CN 1H-Pyrazole, 3-(3-chloropropoxy)-5-(3,4-dimethoxyphenyl)-1-(phenylmethyl)-  
(CA INDEX NAME)



L3 ANSWER 44 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:144163 CAPLUS Full-text

DOCUMENT NUMBER: 120:144163

ORIGINAL REFERENCE NO.: 120:25227a,25230a

TITLE: Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents

INVENTOR(S): Desantis, Louis, Jr.

PATENT ASSIGNEE(S): Alcon Laboratories, Inc., USA

SOURCE: PCT Int. Appl., 20 PP.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9323082	A1	19931125	WO 1993-US4505	19930512
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9342467	A	19931213	AU 1993-42467	19930512
EP 639986	A1	19950301	EP 1993-911276	19930512
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 07508030	T	19950907	JP 1993-503718	19930512
PRIORITY APPLN. INFO.:			US 1992-882328	A 19920513
			WO 1993-US4505	A 19930512

AB Calcium antagonists and compds. which lower intraocular pressure are combined in ophthalmic compns. to treat glaucoma. The calcium antagonists prevent or


reduce the loss of visual field, while the intraocular pressure-lowering compds. maintain the intraocular pressure at normal levels.

IT 86384-98-7

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(calcium antagonist, ophthalmic compns. containing intraocular pressure-lowering agents and, for glaucoma treatment)

RN 86384-98-7 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 6-[(5-phenyl-1H-pyrazol-3-yl)oxy]hexyl ester (9CI) (CA INDEX NAME)



L3 ANSWER 45 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1992:448403 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 117:48403

ORIGINAL REFERENCE NO.: 117:8631a,8634a

TITLE: Hydrogenolysis of 1-aminopyrazoles: synthesis of primary and secondary alkylamines

AUTHOR(S): Adembri, G.; Camparini, A.; Ponticelli, F.; Scotton, M.

CORPORATE SOURCE: Ist. Chim. Org., Univ. Siena, Siena, 53100, Italy


SOURCE: Journal of Heterocyclic Chemistry (1992), 29(2), 321-6  
CODEN: JHTCAD; ISSN: 0022-152X

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 117:48403

GI



AB The tautomerizable N-aminopyrazolone I (R = R1 = R2 = H), the O-Me derivative I (R = Me, R1 = R2 = H) and N-Me pyrazolone II (R3 = NH2, R4 = Me) were condensed with R5COR6 [R5 = Me, Ph, Et, Ph, 4-biphenyl, R5R6 = (CH2)5; R5COR6 = (+)-camphor] to give I (R = H, R1R2 = CMePh; R = Me, R1R2 = CR5R6) and II (R3 = N:CPhMe), resp., which, under mild conditions, were hydrogenated to the corresponding alkylamino derivs. The subsequent hydrogenation of the latter ones gave different results according to the structure of the starting material. I (R = Me, R1R2 = CR5R6) yielded 3-phenyl-4-methyl-5-methoxypyrazole and the corresponding primary amines in good




yields. On the contrary, II (R3 = NHCHMePh, R4 = Me) gave II (R3 = H, R4 = CHMePh).

IT 39513-12-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and amination of)

RN 39513-12-7 CAPLUS

CN 1H-Pyrazole, 3-methoxy-4-methyl-5-phenyl- (CA INDEX NAME)



L3 ANSWER 46 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1990:104871 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 112:104871

ORIGINAL REFERENCE NO.: 112:17703a,17706a

TITLE: Enteric antihypertensives containing CV 159

INVENTOR(S): Imai, Takahiro; Taguma, Kazunori; Fukamachi, Takashi

PATENT ASSIGNEE(S): Tokyo Tanabe Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 01131116	A	19890524	JP 1987-179070	19870720
PRIORITY APPLN. INFO.:			JP 1987-179070	19870720

GI



AB An antihypertensive CV 159 (I) with a polymeric base, optionally a surfactant, is coated with hydroxypropyl Me cellulose phthalate or its derivative to give a formulation with enhanced bioavailability. Thus, I 10, Et acrylate-methacrylic acid copolymer 10, and poly(oxyethylene) hydrogenated castor oil 5 g were dissolved in 50 mL EtOH, and then lauryl sulfate 5 and lactose 30 g were dispersed, dried, and pulverized. The powder (12 g) was mixed with Mg metasilicate aluminate 15.7, CM-cellulose Na 4 and Mg stearate 0.3 g, and made

into tablets. The tablets were then spray-coated with a mixture consisting of hydroxypropyl Me cellulose phthalate 10, talc 3, polyethylene glycol 1 g and EtOH-CH<sub>2</sub>Cl<sub>2</sub> (1:1) 280 mL. The enhancement of bioavailability of I was demonstrated in dogs.


IT 86384-98-7, CV 159

RL: BIOL (Biological study)

(antihypertensive containing, enteric coating of)

RN 86384-98-7 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 6-[(5-phenyl-1H-pyrazol-3-yl)oxy]hexyl ester (9CI) (CA INDEX NAME)



L3 ANSWER 47 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1988:604888 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 109:204888

ORIGINAL REFERENCE NO.: 109:33715a,33718a

TITLE: Inhibition of calmodulin function by CV-159, a novel dihydropyridine compound

AUTHOR(S): Umekawa, Hayato; Yamakawa, Kaoru; Nunoki, Kazuo; Taira, Norio; Tanaka, Toshio; Hidaka, Hiroyoshi

CORPORATE SOURCE: Fac. Bioresour., Mie Univ., Tsu, 514, Japan


SOURCE: Biochemical Pharmacology (1988), 37(18), 3377-81

CODEN: BCPA6; ISSN: 0006-2952

DOCUMENT TYPE: Journal

LANGUAGE: English

GI




AB CV-159 (I), a new compound synthesized from dihydropyridine, was examined for its effect on calmodulin (CaM) function. The concentration of CV-159 producing 50% inhibition of Ca<sup>2+</sup>/CaM-activated myosin light-chain kinase (MLC kinase) was 6.2  $\mu$ M. The apparent K<sub>i</sub> value of CV-159 was 0.8  $\mu$ M for MLC kinase. On the other hand, the concentration of CV-159 producing 50% inhibition of Ca<sup>2+</sup>/CaM-activated cyclic nucleotide phosphodiesterase (Ca<sup>2+</sup>-

IT 86384-98-7, CV-159  
RL: BIOL (Biological study)  
(calmodulin antagonism by)


RN 86384-98-7 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-  
methyl 6-[(5-phenyl-1H-pyrazol-3-yl)oxy]hexyl ester (9CI) (CA INDEX  
NAME)



L3 ANSWER 48 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 1988:226840 CAPLUS Full-text  
DOCUMENT NUMBER: 108:226840  
ORIGINAL REFERENCE NO.: 108:37145a,37148a  
TITLE: Sustained-release antihypertensives containing CV-159  
and soluble polymers  
INVENTOR(S): Imai, Takahiro; Rinka, Kazumi; Matsushita, Tomohisa;  
Fukamachi, Takashi  
PATENT ASSIGNEE(S): Tokyo Tanabe Co., Ltd., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 62221626	A	19870929	JP 1986-60625	19860320
PRIORITY APPLN. INFO.:			JP 1986-60625	19860320
GI				



AB An antihypertensive contains CV-159 (I), at least one soluble polymer base, and optionally a surfactant; the formulation provides a long-lasting activity and a greater bioavailability than conventional formulations. Crystalline I 140, polyvinylpyrrolidone 420, and polyoxyethylene sorbitan monooleate 42 g were dissolved in 1 L of Me<sub>2</sub>CO, and this solution was sprayed over 420 g of crystalline lactose at 60° and dried to give granules. The granules 219, lactose 75, corn starch 35, CMC Ca salt 17.5, and Mg stearate 3.5 g were mixed and made into tablets (350 mg/tablet).


IT 86384-98-7, CV-159

RL: BIOL (Biological study)

(antihypertensive containing soluble polymers and surfactants and, sustained-release)

RN 86384-98-7 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 6-[(5-phenyl-1H-pyrazol-3-yl)oxy]hexyl ester (9CI) (CA INDEX NAME)



L3 ANSWER 49 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1988:75226 CAPLUS Full-text

DOCUMENT NUMBER: 108:75226

ORIGINAL REFERENCE NO.: 108:12439a,12442a

TITLE: Preparation of 4-phenyldihydropyridine-3,5-dicarboxylates as calcium channel blockers

INVENTOR(S): Baxter, Andrew John Gilby; Dixon, John; Mcinally, Thomas; Tinker, Alan Charles

PATENT ASSIGNEE(S): Fisons PLC, UK

SOURCE: Eur. Pat. Appl., 77 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

EP 225175	A2	19870610	EP 1986-309244	19861127
EP 225175	A3	19881228		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 62187453	A	19870815	JP 1986-280953	19861127
PRIORITY APPLN. INFO.:			GB 1985-29301	A 19851128
			GB 1985-29786	A 19851203
			GB 1985-29787	A 19851203
			GB 1986-4421	A 19860221
			GB 1986-4422	A 19860221
			GB 1986-4423	A 19860221
			GB 1986-4424	A 19860221
			GB 1986-5000	A 19860228
			GB 1986-21514	A 19860906

OTHER SOURCE(S):            MARPAT 108:75226

GI




AB The title compds. I [R1 = H, alkyl; R2 = (fluoro)alkyl; R3 = alkyl; R4 = (un)substituted Ph, naphthyl, S-containing heterocyclyl; R5 = (un)substituted alkyl, thietanyl; R6 = H, CH2CH2NH2, N-containing heterocyclyl, etc.; X = O, NR, SOn, bond; Z = H; ZR = bond; n = 0-2] were prepared as calcium channel blockers (no data). Title compound II (A = H) was stirred with pyridinium bromide perbromide in CH2Cl2 containing pyridine to give II (A = Br) which was stirred with NaOMe and pyridin-3-ol in MeCN to give II (A = 3-pyridyloxy).

IT 112641-16-4P 112641-17-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and reaction of, in preparation of calcium channel blockers)


RN 112641-16-4 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[3-[(5-phenyl-1H-pyrazol-3-yl)oxy]propyl]-  
 (CA INDEX NAME)



RN 112641-17-5 CAPLUS

CN 1-Propanamine, 3-[(5-phenyl-1H-pyrazol-3-yl)oxy]- (CA INDEX NAME)




IT 112639-78-8P 112662-12-1P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as calcium channel blocker)


RN 112639-78-8 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-[3-chloro-6-fluoro-2-(trifluoromethyl)phenyl]-2-(fluoromethyl)-1,4-dihydro-6-methyl-, 3-methyl 5-[6-[(1-methyl-5-phenyl-1H-pyrazol-3-yl)oxy]hexyl] ester (CA INDEX NAME)



RN 112662-12-1 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-[3-chloro-6-fluoro-2-(trifluoromethyl)phenyl]-2-(fluoromethyl)-1,4-dihydro-6-methyl-, 3-methyl 5-[2-oxo-2-[[3-[(5-phenyl-1H-pyrazol-3-yl)oxy]propyl]amino]ethyl] ester (CA INDEX NAME)



L3 ANSWER 50 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1988:68599 CAPLUS [Full-text](#)


DOCUMENT NUMBER: 108:68599

ORIGINAL REFERENCE NO.: 108:11207a,11210a

TITLE: Effects of the new dihydropyridine derivative  
1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-  
pyridinedicarboxylic acid methyl 6-(5-phenyl-3-  
pyrazolyloxy)hexyl ester on the cardiohemodynamics and  
the energy metabolism of the ischemic myocardium

AUTHOR(S): Imai, H.; Matsui, K.; Ochi, S.; Nakazawa, M.;

CORPORATE SOURCE: Nakagawa, Y.; Imai, S.  
 SOURCE: Sch. Med., Niigata Univ., Niigata, 951, Japan  
 Arzneimittel-Forschung (1987), 37(12), 1348-52  
 CODEN: ARZNAD; ISSN: 0004-4172  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI




AB To characterize the effects of a new Ca antagonist CV-159 (I) on the cardiovascular system, expts. were performed in the anesthetized open-chest dogs and in the heart-lung preparation with a support dog in comparison with those of nicardipine. In the anesthetized dog CV-159 (1-30 µg/kg) produced a dose-related decrease in mean blood pressure with a decrease in total peripheral resistance and an increase in coronary flow. There was a reflex increase in heart rate, aortic flow and left ventricular dP/dtmax.. Nicardipine (1-30 µg/kg) produced qual. similar changes in these parameters, although the onset of action was quicker and the duration shorter. Hypotensive effects of CV-159 were .apprx.3 times less potent than those of nicardipine. In doses >3 µg CV-159 produced a long-lasting increase in coronary flow and slight neg. inotropic and chronotropic effects in the heart-lung preparation. In doses >1 µg nicardipine produced an increase in coronary flow without producing any change in the cardiac functions. The increase in coronary flow produced by these 2 compds. was not associated with an increase in myocardial O consumption. Studies conducted with <sup>31</sup>P-NMR in the isolated perfused heart preparation of the rat demonstrated no improvement of the ischemic derangement of the myocardial energy metabolism with doses of CV-159 and nicardipine producing an increase in coronary flow rate, but no change in myocardial O demand as assessed by heart rate + left ventricular pressure.

IT 86384-98-7

RL: BIOL (Biological study)  
 (cardiohemodynamic effects of and heart ischemia response to)

RN 86384-98-7 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 6-[(5-phenyl-1H-pyrazol-3-yl)oxy]hexyl ester (9CI) (CA INDEX NAME)



L3 ANSWER 51 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1986:514914 CAPLUS Full-text

DOCUMENT NUMBER: 105:114914

ORIGINAL REFERENCE NO.: 105:18599a,18602a

TITLE: Dihydropyridines, intermediates for their production,  
and pharmaceutical formulations containing them

INVENTOR(S): Baxter, Andrew John Gilby; Dixon, John; Gould, Kenneth  
John; Tinker, Alan Charles

PATENT ASSIGNEE(S): Fisons PLC, UK

SOURCE: Eur. Pat. Appl., 115 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
EP 174131	A2	19860312	EP 1985-305930	19850821
EP 174131	A3	19890607		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AU 8546827	A	19860306	AU 1985-46827	19850828
DK 8503926	A	19860302	DK 1985-3926	19850829
FI 8503304	A	19860302	FI 1985-3304	19850829
ZA 8506626	A	19860528	ZA 1985-6626	19850829
NO 8503430	A	19860303	NO 1985-3430	19850830
JP 61065867	A	19860404	JP 1985-189998	19850830
DD 238383	A5	19860820	DD 1985-280182	19850830
HU 40079	A2	19861128	HU 1985-3307	19850830
ES 546596	A1	19871101	ES 1985-546596	19850830
CN 85106878	A	19860723	CN 1985-106878	19850912
ES 554033	A1	19880216	ES 1986-554033	19860416
PRIORITY APPLN. INFO.:				
			GB 1984-22139	A 19840901
			GB 1984-26559	A 19841019
			GB 1984-26560	A 19841019
			GB 1984-26562	A 19841019
			GB 1984-26563	A 19841019
			GB 1984-26569	A 19841019
			GB 1984-26570	A 19841019
			GB 1984-26571	A 19841019
			GB 1984-30296	A 19841130
			GB 1985-7163	A 19850320

OTHER SOURCE(S): MARPAT 105:114914

GI






AB The title compds. I [R<sub>1</sub> = H, alkyl; R<sub>2</sub>, R<sub>6</sub> = cyano, CHO, pyrimidinylalkyl, (un)substituted (oxa)alkyl; R<sub>3</sub>, R<sub>5</sub> = (un)substituted alkyl, heterocyclylalkyl; R<sub>4</sub> = (un)substituted Ph, heterocyclyl] were prepared as cardiovascular agents (no data). Thus, 3-thietanol and 5-acetyl-2,2-dimethyl-1,3-dioxane-4,6-dione were refluxed in C<sub>6</sub>H<sub>6</sub> to give 3-thietanyl 3-oxobutanoate. This was condensed with AcONH<sub>4</sub> to give enamine II. The latter was cyclocondensed with 4,3,2-F(HCO)(F<sub>3</sub>C)C<sub>6</sub>H<sub>2</sub>CN and FCH<sub>2</sub>COCH<sub>2</sub>CO<sub>2</sub>Me to give dihydropyridine III.

IT 104044-40-8  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (esterification by, of butanoate derivative)

RN 104044-40-8 CAPLUS


CN 1-Hexanol, 6-[(5-phenyl-1H-pyrazol-3-yl)oxy]- (CA INDEX NAME)



IT 104044-22-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and cyclocondensation of, with ammonium acetate and aromatic aldehydes)

RN 104044-22-6 CAPLUS

CN Butanoic acid, 3-oxo-, 6-[(5-phenyl-1H-pyrazol-3-yl)oxy]hexyl ester (CA INDEX NAME)




IT 104026-76-8P 104043-33-6P 104043-37-0P  
 104043-46-1P 104043-47-2P 104043-68-7P  
 104053-09-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of, as cardiovascular agent)


RN 104026-76-8 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-[3-cyano-6-fluoro-2-(trifluoromethyl)phenyl]-2-(fluoromethyl)-1,4-dihydro-6-methyl-, 3-methyl 5-[6-[(5-phenyl-1H-pyrazol-3-yl)oxy]hexyl] ester (CA INDEX NAME)




RN 104043-33-6 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-[3-cyano-6-fluoro-2-(trifluoromethyl)phenyl]-1,4-dihydro-2,6-dimethyl-, methyl 6-[(5-phenyl-1H-pyrazol-3-yl)oxy]hexyl ester (9CI) (CA INDEX NAME)




RN 104043-37-0 CAPLUS


CN 3,5-Pyridinedicarboxylic acid, 4-[3,6-difluoro-2-(trifluoromethyl)phenyl]-1,4-dihydro-2,6-dimethyl-, methyl 6-[(5-phenyl-1H-pyrazol-3-yl)oxy]hexyl ester (9CI) (CA INDEX NAME)




CN 3,5-Pyridinedicarboxylic acid, 4-[3-chloro-6-fluoro-2-(trifluoromethyl)phenyl]-2-(fluoromethyl)-1,4-dihydro-6-methyl-, 3-methyl 5-[6-[(5-phenyl-1H-pyrazol-3-yl)oxy]hexyl] ester (CA INDEX NAME)



CN 3,5-Pyridinedicarboxylic acid, 4-[3,6-difluoro-2-(trifluoromethyl)phenyl]-  
2-(fluoromethyl)-1,4-dihydro-6-methyl-, 3-methyl 5-[6-[(5-phenyl-1H-  
pyrazol-3-yl)oxy]hexyl] ester (CA INDEX NAME)




CN 3,5-Pyridinedicarboxylic acid, 4-[3-chloro-6-fluoro-2-(trifluoromethyl)phenyl]-2-(fluoromethyl)-1,4-dihydro-6-methyl-, 5-methyl 3-[6-[(5-phenyl-1H-pyrazol-3-yl)oxy]hexyl] ester (CA INDEX NAME)





RN 104053-09-0 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-[3-chloro-6-fluoro-2-(trifluoromethyl)phenyl]-1,4-dihydro-2,6-dimethyl-, methyl 6-[(5-phenyl-1H-pyrazol-3-yl)oxy]hexyl ester (9CI) (CA INDEX NAME)




L3 ANSWER 52 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1986:442788 CAPLUS Full-text  
 DOCUMENT NUMBER: 105:42788  
 ORIGINAL REFERENCE NO.: 105:7093a,7096a  
 TITLE: 3-(Carbamoylmethoxy)-5-phenylpyrazoles  
 INVENTOR(S): Heinemann, Henning; Kehrbach, Wolfgang; Schoen, Uwe;  
 Buschmann, Gerd; Kuehl, Ulrich  
 PATENT ASSIGNEE(S): Kali-Chemie Pharma G.m.b.H., Fed. Rep. Ger.  
 SOURCE: Ger. Offen., 45 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3424586	A1	19860109	DE 1984-3424586	19840704
ZA 8504422	A	19860129	ZA 1985-4422	19850612
EP 170861	A1	19860212	EP 1985-107960	19850627
EP 170861	B1	19880309		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 32890	T	19880315	AT 1985-107960	19850627
CA 1254561	A1	19890523	CA 1985-485571	19850627
HU 38318	A2	19860528	HU 1985-2560	19850701
HU 194183	B	19880128		
DD 238790	A5	19860903	DD 1985-278167	19850702
US 4695566	A	19870922	US 1985-751045	19850702
DK 8503024	A	19860105	DK 1985-3024	19850703
NO 8502663	A	19860106	NO 1985-2663	19850703
AU 8544553	A	19860109	AU 1985-44553	19850703
AU 575972	B2	19880811		
IL 75712	A	19890731	IL 1985-75712	19850703
FI 8502647	A	19860105	FI 1985-2647	19850704
JP 61040267	A	19860226	JP 1985-145950	19850704
JP 06002744	B	19940112		
PRIORITY APPLN. INFO.:			DE 1984-3424586	A 19840704
			EP 1985-107960	A 19850627
OTHER SOURCE(S):	CASREACT 105:42788; MARPAT 105:42788			
GI				




AB The title compds. [I; R1, R2, R5, R7, R8, R9 = H, alkyl; R3 = H, halo, alkyl, alkoxy; R4 = F3C, NO2, OH, R3; R3R4 = alkylenedioxy; R6 = H, Me; R5R6 = alkylene; Z = alkylene, CH2CH(OH)CH2; R8R9 = alkylene, (CH2CH2)2O] were prepared as antiarrhythmics. Thus, PhCOCH2CO2Et was cyclocondensed with N2H4 to give 5-phenylpyrazolin-3-one. This was alkylated with Me2CBrCO2Et, then saponified to give 3-(carboxymethoxy)pyrazole II (R10 = OH). The latter was treated with MeSO2Cl followed by H2N(CH2)3NEt2 to give II [R10 = Et2N(CH2)3NH] (III). In mice 25 mg III/kg gave 100% protection against CHCl3-induced heart fibrillations.

IT 103015-35-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and amidation of)  
 RN 103015-35-6 CAPLUS  
 CN Acetic acid, [(5-phenyl-1H-pyrazol-3-yl)oxy]- (9CI) (CA INDEX NAME)



IT 103015-34-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and hydrolysis of)  
 RN 103015-34-5 CAPLUS  
 CN Acetonitrile, [(5-phenyl-1H-pyrazol-3-yl)oxy]- (9CI) (CA INDEX NAME)




IT 103014-65-9P 103014-66-0P 103014-69-3P  
 103014-75-1P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of, as antiarrhythmic)


RN 103014-65-9 CAPLUS

CN Acetamide, N-[2-(diethylamino)ethyl]-2-[(5-phenyl-1H-pyrazol-3-yl)oxy]-  
(CA INDEX NAME)




RN 103014-66-0 CAPLUS

CN Acetamide, N-[2-(4-morpholinyl)ethyl]-2-[(5-phenyl-1H-pyrazol-3-yl)oxy]-  
(CA INDEX NAME)




RN 103014-69-3 CAPLUS

CN Acetamide, N-[2-(dimethylamino)ethyl]-2-[(5-phenyl-1H-pyrazol-3-yl)oxy]-  
(CA INDEX NAME)



RN 103014-75-1 CAPLUS

CN Acetamide, N-[3-(diethylamino)propyl]-2-[(5-phenyl-1H-pyrazol-3-yl)oxy]-  
(CA INDEX NAME)



L3 ANSWER 53 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1986:10589 CAPLUS Full-text

DOCUMENT NUMBER: 104:10589

ORIGINAL REFERENCE NO.: 104:1783a,1786a

TITLE: Powdery preparation of an amorphous dihydropyridine compound

INVENTOR(S): Masato, Kamibayashi; Shinji, Tsuchiya; Tsutomu, Araki; Susumu, Tsuchiya

PATENT ASSIGNEE(S): Tokyo Tanabe Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 10 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
EP 147171	A2	19850703	EP 1984-308908	19841219
EP 147171	A3	19870128		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 60139688	A	19850724	JP 1983-245213	19831228
AU 8436537	A	19850704	AU 1984-36537	19841212
PRIORITY APPLN. INFO.:			JP 1983-245213	A 19831228

GI



AB The title compound 6-[(5-phenyl-3-pyrazolyl)oxy]hexyl 1,4-dihydro-2,6-dimethyl-3-(methoxycarbonyl)-4-(3-nitrophenyl)pyridine-5-carboxylate (I) [99473-06-0] having a mean particle size  $\leq 30 \mu\text{m}$  has improved long-lasting hypotensive effect and bioavailability by oral administration compared to the crystalline form. In spontaneous hypotensive rats, I (mean particle size of 3.7 and 30  $\mu\text{m}$ ) given orally at 30 mg/kg exerted a long-lasting hypotensive effect 23 times higher than the powdery crystalline I of approx. same particle size. The I powder preparation can be obtained by melting I crystals at 155-

IT 86384-98-7

(amorphous powder, with improved oral bioavailability and long-lasting hypertensive effect)

RN 86384-98-7 CAPLUS

Cc1c(C(=O)OC)c2c(c1)c(c[nH]2)C(=O)OCCCOc3cc[nH]3C4=CC=CC=C4

ACCESSION NUMBER: 1984:551841 CAPLUS Full-text

DOCUMENT NUMBER: 101:151841

ORIGINAL REFERENCE NO.: 101:22987a,22990a

TITLE: 1,4-Dihydropyridine derivatives

PATENT ASSIGNEE(S) : Tokyo Tanabe Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 16 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 59078184	A	19840504	JP 1982-187516	19821027
JP 03041469	B	19910624		

PRIORITY APPLN. INFO.: JP 1982-187516 19821027

OTHER SOURCE(S): CASREACT 101:151841

GI






AB Thirty-three 1,4-dihydropyridine derivs. I (R = alkyl; R1 = H, halo; R2 = halo, CF3, NO2; R3, R4 = H, alkyl, CF3, PhO, etc.; n = 7, 8) were prepared Thus, refluxing 4.98 g 3-O2NC6H4CH:C(COMe)CO2Me with 7.15 g 7-(5-phenyl-3-pyrazolyloxy)heptyl 3-aminocrotonate in EtOH 5 h gave 43.3% I (R = Me, R1 = R3 = H, R2 = 3-O2N, R4 = Ph, n = 7) (II). Hypotensive and vasodilator activity of II is superior to that of nicardipine.

IT 92338-10-8  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (cyclocondensation of, with benzylideneacetoacetate, pyridine from)

RN 92338-10-8 CAPLUS


CN 2-Butenoic acid, 3-amino-, 7-[(5-phenyl-1H-pyrazol-3-yl)oxy]heptyl ester  
 (CA INDEX NAME)



IT 92310-44-6P 92310-45-7P 92310-46-8P  
 92310-48-0P 92310-49-1P 92310-50-4P  
 92310-52-6P 92310-54-8P 92310-55-9P  
 92310-56-0P 92310-59-3P 92310-60-6P  
 92310-61-7P 92310-62-8P 92310-63-9P  
 92338-08-4P 92338-09-5P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)


RN 92310-44-6 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-[2-(trifluoromethyl)phenyl]-, methyl 7-[(5-phenyl-1H-pyrazol-3-yl)oxy]heptyl ester (9CI) (CA INDEX NAME)




RN 92310-45-7 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, ethyl 7-[(5-phenyl-1H-pyrazol-3-yl)oxy]heptyl ester (9CI) (CA INDEX NAME)




RN 92310-46-8 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, 7-[[5-(2-chlorophenyl)-1H-pyrazol-3-yl]oxy]heptyl methyl ester (9CI)  
(CA INDEX NAME)




RN 92310-48-0 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 7-[[5-(2-chlorophenyl)-1H-pyrazol-3-yl]oxy]heptyl 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 92310-49-1 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 7-[[5-(2-fluorophenyl)-1H-pyrazol-3-yl]oxy]heptyl methyl ester (9CI)  
(CA INDEX NAME)




RN 92310-50-4 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-  
, 7-[[5-(3-fluorophenyl)-1H-pyrazol-3-yl]oxy]heptyl methyl ester (9CI)  
(CA INDEX NAME)




RN 92310-52-6 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-  
, 7-[[5-(2-methoxyphenyl)-1H-pyrazol-3-yl]oxy]heptyl methyl ester (9CI)  
(CA INDEX NAME)




RN 92310-54-8 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-  
, 7-[[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]heptyl methyl ester (9CI)  
(CA INDEX NAME)




RN 92310-55-9 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 7-[[5-(2,3-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]heptyl methyl ester (9CI) (CA INDEX NAME)




RN 92310-56-0 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 7-[[5-(3,4,5-trimethoxyphenyl)-1H-pyrazol-3-yl]oxy]heptyl ester (9CI) (CA INDEX NAME)




RN 92310-59-3 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 7-[[5-(2-methylphenyl)-1H-pyrazol-3-yl]oxy]heptyl ester (9CI) (CA INDEX NAME)




RN 92310-60-6 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 7-[[5-(3,4-dimethylphenyl)-1H-pyrazol-3-yl]oxy]heptyl methyl ester (9CI) (CA INDEX NAME)




RN 92310-61-7 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 7-[[5-(3-cyanophenyl)-1H-pyrazol-3-yl]oxy]heptyl methyl ester (9CI) (CA INDEX NAME)




RN 92310-62-8 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 7-[[5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]oxy]heptyl ester (9CI) (CA INDEX NAME)




RN 92310-63-9 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 7-[[5-(4-nitrophenyl)-1H-pyrazol-3-yl]oxy]heptyl ester (9CI) (CA INDEX NAME)




RN 92338-08-4 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 7-[(5-phenyl-1H-pyrazol-3-yl)oxy]heptyl ester (9CI) (CA INDEX NAME)



RN 92338-09-5 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 8-[[5-(4-fluorophenyl)-1H-pyrazol-3-yl]oxy]octyl 2-methylpropyl ester (9CI) (CA INDEX NAME)




IT 92310-37-7F 92310-42-4P 92310-43-5P  
92310-47-9P 92310-51-5P 92310-53-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation, antihypertensive, and vasodilator activity of)


RN 92310-37-7 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-  
, methyl 7-[(5-phenyl-1H-pyrazol-3-yl)oxy]heptyl ester (9CI) (CA INDEX  
NAME)




RN 92310-42-4 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-  
, methyl 8-[(5-phenyl-1H-pyrazol-3-yl)oxy]octyl ester (9CI) (CA INDEX  
NAME)




RN 92310-43-5 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-  
dimethyl-, methyl 7-[(5-phenyl-1H-pyrazol-3-yl)oxy]heptyl ester (9CI) (CA  
INDEX NAME)




RN 92310-47-9 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 7-[[5-(2-chlorophenyl)-1H-pyrazol-3-yl]oxy]heptyl methyl ester (9CI)  
(CA INDEX NAME)



RN 92310-51-5 CAPLUS


CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 7-[[5-(4-fluorophenyl)-1H-pyrazol-3-yl]oxy]heptyl methyl ester (9CI)  
(CA INDEX NAME)



RN 92310-53-7 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 7-[[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]heptyl methyl ester (9CI)  
(CA INDEX NAME)






L3 ANSWER 55 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1983:539935 CAPLUS Full-text  
 DOCUMENT NUMBER: 99:139935  
 ORIGINAL REFERENCE NO.: 99:21501a,21504a  
 TITLE: Pyrazole derivatives and their therapeutical application  
 INVENTOR(S): Jarreau, Francois Xavier; Koenig, Jean Jacques  
 PATENT ASSIGNEE(S): Etablissements Nativelle S. A., Fr.  
 SOURCE: Eur. Pat. Appl., 24 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 76756	A1	19830413	EP 1982-401794	19821001
EP 76756	B1	19870304		
R: BE, CH, DE, FR, GB, IT, LI, LU, NL				
FR 2513996	A1	19830408	FR 1981-18596	19811002
FR 2513996	B1	19840330		
JP 58067674	A	19830422	JP 1982-167759	19820928
JP 04028699	B	19920515		
US 4410525	A	19831018	US 1982-427344	19820929
PRIORITY APPLN. INFO.:			FR 1981-18596	A 19811002
OTHER SOURCE(S):	CASREACT 99:139935; MARPAT 99:139935			

GI



I


AB 5-(Aminoalkoxy)pyrazoles I [R = (un)substituted aryl; R1 = H, alkyl, Ph, PhCH2; n = 1, 2, 3, 4; R2 and R3 (same or different) are H, alkyl, or NR2R3 form a heterocycle], which were prepared, exhibited antiarrhythmic activity. A mixture of 3-(4-chlorophenyl)-5-pyrazolone, K2CO3, and Cl(CH2)3NMe3 in dioxane was refluxed to give I (R = 4-ClC6H4, R1 = H, n = 3, R2 = R3 = Me).

IT 86871-46-7P 86871-47-8P 86871-52-5P  
 86871-53-6P 86871-58-1P 86871-59-2P  
 86871-62-7P 86871-63-8P 86871-78-5P  
 86871-79-6P 86888-53-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation and antiarrhythmic activity of)


RN 86871-46-7 CAPLUS

CN Piperidine, 1-[3-[[5-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]propyl]- (CA INDEX NAME)




RN 86871-47-8 CAPLUS

CN Morpholine, 4-[2-[(4-methyl-5-phenyl-1H-pyrazol-3-yl)oxy]ethyl]- (CA INDEX NAME)



RN 86871-52-5 CAPLUS


CN Piperidine, 1-[2-[[5-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]ethyl]- (CA INDEX NAME)



RN 86871-53-6 CAPLUS  
 CN Piperidine, 1-[2-[[5-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]ethyl]-,  
 (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1


CRN 86871-52-5  
 CMF C16 H20 Cl N3 O




CM 2

CRN 87-69-4  
 CMF C4 H6 O6

Absolute stereochemistry.




RN 86871-58-1 CAPLUS  
 CN Piperidine, 1-[2-[(5-phenyl-1H-pyrazol-3-yl)oxy]ethyl]- (CA INDEX NAME)



RN 86871-59-2 CAPLUS  
 CN Piperidine, 1-[2-[(5-phenyl-1H-pyrazol-3-yl)oxy]ethyl]-,  
 (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1


CRN 86871-58-1  
 CMF C16 H21 N3 O




CM 2

CRN 110-16-7  
 CMF C4 H4 O4

Double bond geometry as shown.




RN 86871-62-7 CAPLUS  
 CN Piperidine, 1-[2-[(4-methyl-5-phenyl-1H-pyrazol-3-yl)oxy]ethyl]- (CA  
 INDEX NAME)



RN 86871-63-8 CAPLUS  
 CN Piperidine, 1-[2-[(4-methyl-5-phenyl-1H-pyrazol-3-yl)oxy]ethyl]-,  
 (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1


CRN 86871-62-7  
 CMF C17 H23 N3 O




CM 2

CRN 110-16-7  
 CMF C4 H4 O4

Double bond geometry as shown.



RN 86871-78-5 CAPLUS  
 CN Piperidine, 1-[3-[[5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]oxy]propyl]-  
 (CA INDEX NAME)




RN 86871-79-6 CAPLUS  
 CN Piperidine, 1-[3-[[5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]oxy]propyl]-,  
 (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 86871-78-5


CMF C18 H24 Cl N3 O



CM 2

CRN 87-69-4  
CMF C4 H6 O6


Absolute stereochemistry.



RN 86888-53-1 CAPLUS  
CN Morpholine, 4-[2-[(4-methyl-5-phenyl-1H-pyrazol-3-yl)oxy]ethyl]-,  
(2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 86871-47-8  
CMF C16 H21 N3 O2




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




IT 86871-48-9P 86871-68-3P 86871-69-4P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and cardiovascular activity of)


RN 86871-48-9 CAPLUS

CN Morpholine, 4-[2-[(5-phenyl-1H-pyrazol-3-yl)oxy]ethyl]- (CA INDEX NAME)



RN 86871-68-3 CAPLUS

CN Piperidine, 1-[3-[(4-methyl-5-phenyl-1H-pyrazol-3-yl)oxy]propyl]- (CA INDEX NAME)




RN 86871-69-4 CAPLUS

CN Piperidine, 1-[3-[(4-methyl-5-phenyl-1H-pyrazol-3-yl)oxy]propyl]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 86871-68-3

CMF C18 H25 N3 O




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




IT 86871-42-3P 86871-43-4P 86871-56-9P  
86871-57-0P 86871-60-5P 86871-61-6P  
86871-66-1P 86871-67-2P 86871-70-7P  
86871-71-8P 86871-72-9P 86871-73-0P  
86871-74-1P 86871-75-2P 86871-82-1P  
86871-83-2P 86871-84-3P 86871-85-4P  
86871-86-5P 86871-87-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 86871-42-3 CAPLUS

CN 1-Propanamine, 3-[[5-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]-N,N-dimethyl-  
(CA INDEX NAME)



RN 86871-43-4 CAPLUS


CN 1-Propanamine, 3-[[5-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]-N,N-dimethyl-,  
(2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 86871-42-3

CMF C14 H18 Cl N3 O






CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 86871-56-9 CAPLUS

CN 1-Propanamine, N,N-dimethyl-3-[(5-phenyl-1H-pyrazol-3-yl)oxy]- (CA INDEX NAME)




RN 86871-57-0 CAPLUS

CN 1-Propanamine, N,N-dimethyl-3-[(5-phenyl-1H-pyrazol-3-yl)oxy]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 86871-56-9


CMF C14 H19 N3 O




CM 2

CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.




RN 86871-60-5 CAPLUS  
CN Morpholine, 4-[2-[[5-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]ethyl]- (CA  
INDEX NAME)



RN 86871-61-6 CAPLUS  
CN Morpholine, 4-[2-[[5-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]ethyl]-,  
(2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 86871-60-5  
CMF C15 H18 Cl N3 O2




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 86871-66-1 CAPLUS

CN Piperidine, 1-[3-[(5-phenyl-1H-pyrazol-3-yl)oxy]propyl]- (CA INDEX NAME)




RN 86871-67-2 CAPLUS

CN Piperidine, 1-[3-[(5-phenyl-1H-pyrazol-3-yl)oxy]propyl]-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 86871-66-1


CMF C17 H23 N3 O




CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 86871-70-7 CAPLUS  
 CN 1-Propanamine, N,N-dimethyl-3-[(4-methyl-5-phenyl-1H-pyrazol-3-yl)oxy]-  
 (CA INDEX NAME)



RN 86871-71-8 CAPLUS  
 CN 1-Propanamine, N,N-dimethyl-3-[(4-methyl-5-phenyl-1H-pyrazol-3-yl)oxy]-,  
 (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1


CRN 86871-70-7  
 CMF C15 H21 N3 O




CM 2

CRN 110-16-7  
 CMF C4 H4 O4

Double bond geometry as shown.




RN 86871-72-9 CAPLUS  
 CN Morpholine, 4-[2-[[5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]oxy]ethyl]-  
 (CA INDEX NAME)



RN 86871-73-0 CAPLUS


CN Morpholine, 4-[2-[[5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]oxy]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 86871-74-1 CAPLUS

CN 1-Propanamine, 3-[[5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 86871-75-2 CAPLUS

CN 1-Propanamine, 3-[[5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]oxy]-N,N-dimethyl-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1


CRN 86871-74-1  
 CMF C15 H20 Cl N3 O




CM 2

CRN 87-69-4  
 CMF C4 H6 O6

Absolute stereochemistry.




RN 86871-82-1 CAPLUS  
 CN Piperidine, 1-[2-[[5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]oxy]ethyl]-  
 (CA INDEX NAME)



RN 86871-83-2 CAPLUS  
 CN Piperidine, 1-[2-[[5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]oxy]ethyl]-  
 , (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 86871-82-1  
 CMF C17 H22 Cl N3 O




CM 2

CRN 87-69-4


CMF C4 H6 O6

Absolute stereochemistry.



RN 86871-84-3 CAPLUS

CN Morpholine, 4-[2-[[5-phenyl-4-(phenylmethyl)-1H-pyrazol-3-yl]oxy]ethyl]-  
(CA INDEX NAME)




RN 86871-85-4 CAPLUS

CN Morpholine, 4-[2-[[5-phenyl-4-(phenylmethyl)-1H-pyrazol-3-yl]oxy]ethyl]-,  
(2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1


CRN 86871-84-3  
 CMF C22 H25 N3 O2




CM 2

CRN 87-69-4  
 CMF C4 H6 O6

Absolute stereochemistry.



RN 86871-86-5 CAPLUS  
 CN Piperidine, 1-[3-[[5-(3,4-dichlorophenyl)-1H-pyrazol-3-yl]oxy]propyl]-  
 (CA INDEX NAME)




RN 86871-87-6 CAPLUS  
 CN Piperidine, 1-[3-[[5-(3,4-dichlorophenyl)-1H-pyrazol-3-yl]oxy]propyl]-,  
 (2Z)-2-butenedioate (1:1) (CA INDEX NAME)



CM 1

CRN 86871-86-5

CMF C17 H21 Cl2 N3 O




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



L3 ANSWER 56 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1983:438457 CAPLUS Full-text

DOCUMENT NUMBER: 99:38457

ORIGINAL REFERENCE NO.: 99:6045a,6048a

TITLE: 1,4-Dihydropyridine derivatives with vasodilating and hypotensive activity

PATENT ASSIGNEE(S): Tokyo Tanabe Co. Ltd., Japan

SOURCE: Fr. Demande, 81 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent


LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
FR 2511370	A1	19830218	FR 1982-14008	19820811
FR 2511370	B1	19861024		
JP 58026882	A	19830217	JP 1981-125216	19810812
JP 63021674	B	19880509		
JP 58131982	A	19830806	JP 1982-13398	19820201
JP 63023193	B	19880516		
GB 2108108	A	19830511	GB 1982-23168	19820811
GB 2108108	B	19850807		

DE 3230400	A1	19830324	DE 1982-3230400	19820812
DE 3230400	C2	19930225		
US 4418197	A	19831129	US 1983-457867	19830113
PRIORITY APPLN. INFO.:			JP 1981-125216	A 19810812
			JP 1982-13398	A 19820201
OTHER SOURCE(S):	CASREACT 99:38457; MARPAT 99:38457			
GI				



AB Pyrazoles I [X = (un)substituted (CH<sub>2</sub>)<sub>6</sub>; R = O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>, dihalophenyl; R<sub>1</sub> = alkyl, alkoxyalkyl; R<sub>2</sub> = (un)substituted alkyl, pyridyl, Ph] (119 compds.) were prepared. Thus, I [X = (CH<sub>2</sub>)<sub>6</sub>, R = 3-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>, R<sub>1</sub> = Me, R<sub>2</sub> = 5-Me, II] was obtained in 62.4% yield by treating the tosyloxyhexyl dihydropyridinecarboxylate with 3-methyl-5-pyrazolone. At 3 µg/kg i.v. in dogs II gave a decrease in blood pressure of 14.5 ± 1.3 mmHg for 46.5 ± 2.8 min. and a change in heart rate of 0.8 beats/min.


IT 86384-98-7P 86384-99-8P 86385-00-4P  
 86385-02-6P 86385-03-7P 86385-04-8P  
 86385-05-9P 86385-06-0P 86385-07-1P  
 86418-95-3P 86418-96-4P 86418-97-5P  
 86418-98-6P 86418-99-7P 86419-02-5P  
 86419-04-7P 86419-05-8P 86419-06-9P  
 86419-07-0P 86419-08-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and antihypertensive activity of)


RN 86384-98-7 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 6-[(5-phenyl-1H-pyrazol-3-yl)oxy]hexyl ester (9CI) (CA INDEX NAME)




RN 86384-99-8 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 6-[[5-(3-fluorophenyl)-1H-pyrazol-3-yl]oxy]hexyl methyl ester (9CI) (CA INDEX NAME)




RN 86385-00-4 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 6-[(5-phenyl-1H-pyrazol-3-yl)oxy]hexyl ester (9CI) (CA INDEX NAME)




RN 86385-02-6 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 6-[[5-(2-chlorophenyl)-1H-pyrazol-3-yl]oxy]hexyl methyl ester (9CI) (CA INDEX NAME)




RN 86385-03-7 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, 6-[[5-(2-chlorophenyl)-1H-pyrazol-3-yl]oxy]hexyl methyl ester (9CI) (CA INDEX NAME)




RN 86385-04-8 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 6-[[5-(2,4-dichlorophenyl)-1H-pyrazol-3-yl]oxy]hexyl propyl ester (9CI)  
(CA INDEX NAME)




RN 86385-05-9 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 6-[[5-(2-methoxyphenyl)-1H-pyrazol-3-yl]oxy]hexyl methyl ester (9CI)  
(CA INDEX NAME)




RN 86385-06-0 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3,4-dimethyl-6-[[5-(2-nitrophenyl)-1H-pyrazol-3-yl]oxy]hexyl methyl ester (9CI) (CA INDEX NAME)




RN 86385-07-1 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 6-[[5-(3-fluorophenyl)-1H-pyrazol-3-yl]oxy]hexyl 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 86418-95-3 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 6-[[5-(3-fluorophenyl)-1H-pyrazol-3-yl]oxy]hexyl 2-(2-methylpropoxy)ethyl ester (9CI) (CA INDEX NAME)




RN 86418-96-4 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 6-[[5-(2-methylphenyl)-1H-pyrazol-3-yl]oxy]hexyl ester (9CI) (CA INDEX NAME)




RN 86418-97-5 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(1-methylethoxy)ethyl 6-[[5-(2-methylphenyl)-1H-pyrazol-3-yl]oxy]hexyl ester (9CI) (CA INDEX NAME)




RN 86418-98-6 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 6-[[5-(3-cyanophenyl)-1H-pyrazol-3-yl]oxy]hexyl methyl ester (9CI) (CA INDEX NAME)




RN 86418-99-7 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 6-[[5-[2-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]oxy]hexyl ester (9CI) (CA INDEX NAME)




RN 86419-02-5 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 6-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]hexyl methyl ester (9CI) (CA INDEX NAME)




RN 86419-04-7 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, methyl 6-[5-(phenyl)-1H-pyrazol-3-yl]oxy]hexyl ester (9CI) (CA INDEX NAME)




RN 86419-05-8 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 6-[5-(2-chlorophenyl)-1H-pyrazol-3-yl]oxy]hexyl ethyl ester (9CI) (CA INDEX NAME)




RN 86419-06-9 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 6-[[5-[4-(acetylamino)phenyl]-1H-pyrazol-3-yl]oxy]hexyl methyl ester (9CI) (CA INDEX NAME)



RN 86419-07-0 CAPLUS


CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, ethyl 6-[[5-(4-(acetylamino)phenyl)-1H-pyrazol-3-yl]oxy]hexyl ester (9CI) (CA INDEX NAME)



RN 86419-08-1 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, 6-[[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]hexyl methyl ester (9CI) (CA INDEX NAME)






IT 86385-08-2P 86385-09-3P 86385-10-6P  
 86385-11-7P 86385-12-8P 86385-13-9P  
 86385-14-0P 86385-15-1P 86385-17-3P  
 86385-18-4P 86385-19-5P 86385-20-8P  
 86385-21-9P 86385-22-0P 86385-23-1P  
 86385-24-2P 86385-25-3P 86385-29-7P  
 86385-30-0P 86385-32-2P 86385-33-3P  
 86385-34-4P 86385-35-5P 86385-36-6P  
 86385-37-7P 86385-38-8P 86385-39-9P  
 86385-40-2P 86385-41-3P 86385-42-4P  
 86419-37-6P 86419-38-7P 86419-39-8P  
 86419-40-1P 86419-41-2P 86419-42-3P  
 86419-43-4P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)


RN 86385-08-2 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-  
 , 6-[[5-(2-chlorophenyl)-1H-pyrazol-3-yl]oxy]hexyl 1-methylethyl ester  
 (9CI) (CA INDEX NAME)




RN 86385-09-3 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-  
 , 6-[[5-(3,4-dichlorophenyl)-1H-pyrazol-3-yl]oxy]hexyl methyl ester (9CI)  
 (CA INDEX NAME)




RN 86385-10-6 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, 6-[[5-(2-methoxyphenyl)-1H-pyrazol-3-yl]oxy]hexyl methyl ester (9CI) (CA INDEX NAME)




RN 86385-11-7 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 6-[[5-(2-methoxyphenyl)-1H-pyrazol-3-yl]oxy]hexyl 2-propoxyethyl ester (9CI) (CA INDEX NAME)




RN 86385-12-8 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, 6-[[5-(3-methoxyphenyl)-1H-pyrazol-3-yl]oxy]hexyl methyl ester (9CI) (CA INDEX NAME)




RN 86385-13-9 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 6-[[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]hexyl 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 86385-14-0 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 6-[[5-(2,3-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]hexyl methyl ester (9CI) (CA INDEX NAME)




RN 86385-15-1 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 6-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]hexyl methyl ester (9CI) (CA INDEX NAME)




RN 86385-17-3 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 6-[[5-(3,4,5-trimethoxyphenyl)-1H-pyrazol-3-yl]oxy]hexyl ester (9CI) (CA INDEX NAME)




RN 86385-18-4 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 6-[[5-(3-nitrophenyl)-1H-pyrazol-3-yl]oxy]hexyl ester (9CI) (CA INDEX NAME)




RN 86385-19-5 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 1-methylethyl 6-[[5-(3-nitrophenyl)-1H-pyrazol-3-yl]oxy]hexyl ester (9CI) (CA INDEX NAME)




RN 86385-20-8 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 6-[[5-(2-fluorophenyl)-1H-pyrazol-3-yl]oxy]hexyl methyl ester (9CI) (CA INDEX NAME)




RN 86385-21-9 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 6-[[5-(4-fluorophenyl)-1H-pyrazol-3-yl]oxy]hexyl methyl ester (9CI) (CA INDEX NAME)




RN 86385-22-0 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 6-[[5-(2-methylphenyl)-1H-pyrazol-3-yl]oxy]hexyl ester (9CI) (CA INDEX NAME)




RN 86385-23-1 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, 6-[[5-(2-cyanophenyl)-1H-pyrazol-3-yl]oxy]hexyl methyl ester (9CI) (CA INDEX NAME)




RN 86385-24-2 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 6-[[5-(4-cyanophenyl)-1H-pyrazol-3-yl]oxy]hexyl methyl ester (9CI) (CA INDEX NAME)




RN 86385-25-3 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 6-[[5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]oxy]hexyl ester (9CI) (CA INDEX NAME)




RN 86385-29-7 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 6-[[5-(4-nitrophenyl)-1H-pyrazol-3-yl]oxy]hexyl ester (9CI) (CA INDEX NAME)




RN 86385-30-0 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 6-[[5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]oxy]hexyl ester (9CI) (CA INDEX NAME)




RN 86385-32-2 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, ethyl 6-[[5-(2-methylphenyl)-1H-pyrazol-3-yl]oxy]hexyl ester (9CI) (CA INDEX NAME)




RN 86385-33-3 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, ethyl 6-[[5-(2-methylphenyl)-1H-pyrazol-3-yl]oxy]hexyl ester (9CI) (CA INDEX NAME)



RN 86385-34-4 CAPLUS


CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, 6-[[5-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]hexyl ethyl ester (9CI) (CA INDEX NAME)



RN 86385-35-5 CAPLUS


CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 5-[[[5-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]heptyl ethyl ester (9CI) (CA INDEX NAME)






RN 86385-36-6 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, methyl 6-[[5-(4-nitrophenyl)-1H-pyrazol-3-yl]oxy]hexyl ester (9CI) (CA INDEX NAME)




RN 86385-37-7 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, 6-[[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]hexyl methyl ester (9CI) (CA INDEX NAME)




RN 86385-38-8 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 6-[[5-(3-methylphenyl)-1H-pyrazol-3-yl]oxy]hexyl ester (9CI) (CA INDEX NAME)




RN 86385-39-9 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 6-[[5-(4-methylphenyl)-1H-pyrazol-3-yl]oxy]hexyl ester (9CI) (CA INDEX NAME)




RN 86385-40-2 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 6-[[5-[4-(dimethylamino)phenyl]-1H-pyrazol-3-yl]oxy]hexyl methyl ester (9CI) (CA INDEX NAME)




RN 86385-41-3 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 6-[[5-[3-(ethylamino)phenyl]-1H-pyrazol-3-yl]oxy]hexyl methyl ester (9CI) (CA INDEX NAME)




RN 86385-42-4 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, 6-[[5-(4-aminophenyl)-1H-pyrazol-3-yl]oxy]hexyl methyl ester (9CI) (CA INDEX NAME)




RN 86419-37-6 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, ethyl 6-[(5-phenyl-1H-pyrazol-3-yl)oxy]hexyl ester (9CI) (CA INDEX NAME)




RN 86419-38-7 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 1-methylethyl 6-[(5-phenyl-1H-pyrazol-3-yl)oxy]hexyl ester (9CI) (CA INDEX NAME)




RN 86419-39-8 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 6-[(5-phenyl-1H-pyrazol-3-yl)oxy]hexyl ester (9CI) (CA INDEX NAME)




RN 86419-40-1 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 6-[[5-(3-chlorophenyl)-1H-pyrazol-3-yl]oxy]hexyl methyl ester (9CI) (CA INDEX NAME)




RN 86419-41-2 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 6-[[5-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]-1-methylhexyl ethyl ester (9CI) (CA INDEX NAME)




RN 86419-42-3 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, 6-[[5-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]hexyl methyl ester (9CI) (CA INDEX NAME)



RN 86419-43-4 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 6-[[5-(2,6-dichlorophenyl)-1H-pyrazol-3-yl]oxy]hexyl methyl ester (9CI) (CA INDEX NAME)




IT 86385-51-5

RL: RCT (Reactant); RACT (Reactant or reagent)  
(reaction of, with nitrobenzaldehyde and aminocrotonate)

RN 86385-51-5 CAPLUS

CN Butanoic acid, 3-oxo-, 6-[[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]hexyl ester (CA INDEX NAME)




IT ~~86385-48-0~~ ~~86385-49-1~~ ~~86385-50-4~~

RL: RCT (Reactant); RACT (Reactant or reagent)  
(reaction of, with nitrobenzylideneacetoacetate)


RN 86385-48-0 CAPLUS

CN 2-Butenoic acid, 3-amino-, 6-[(5-phenyl-1H-pyrazol-3-yl)oxy]hexyl ester  
(CA INDEX NAME)




RN 86385-49-1 CAPLUS

CN 2-Butenoic acid, 3-amino-, 6-[[5-(3-fluorophenyl)-1H-pyrazol-3-yl]oxy]hexyl ester (CA INDEX NAME)



RN 86385-50-4 CAPLUS

CN 2-Butenoic acid, 3-amino-, 6-[[5-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]hexyl ester (CA INDEX NAME)




ORIGINAL REFERENCE NO.: 98:30135a,30138a  
 TITLE: 1,5-Diphenylpyrazolin-3-one compounds, intermediate products for their production and a drug containing these compounds  
 INVENTOR(S): Heinemann, Henning; Jasserand, Daniel; Milkowski, Wolfgang; Yavordios, Dimitri; Zeugner, Horst  
 PATENT ASSIGNEE(S): Kali-Chemie Pharma G.m.b.H., Fed. Rep. Ger.  
 SOURCE: Ger. Offen., 39 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3132915	A1	19830303	DE 1981-3132915	19810820
ZA 8205381	A	19830525	ZA 1982-5381	19820727
EP 72960	A2	19830302	EP 1982-107193	19820809
EP 72960	A3	19840307		
EP 72960	B1	19890607		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 43841	T	19890615	AT 1982-107193	19820809
CA 1208643	A1	19860729	CA 1982-409072	19820810
DD 202563	A5	19830921	DD 1982-242578	19820817
HU 30281	A2	19840328	HU 1982-2675	19820818
HU 187572	B	19860128		
DK 8203723	A	19830221	DK 1982-3723	19820819
DK 149947	B	19861103		
DK 149947	C	19870615		
FI 8202883	A	19830221	FI 1982-2883	19820819
FI 73673	B	19870731		
FI 73673	C	19871109		
NO 8202827	A	19830221	NO 1982-2827	19820819
NO 158185	B	19880418		
NO 158185	C	19880727		
AU 8287424	A	19830224	AU 1982-87424	19820819
AU 555215	B2	19860918		
US 4442102	A	19840410	US 1982-409631	19820819
IL 66580	A	19851031	IL 1982-66580	19820819
JP 58039668	A	19830308	JP 1982-143479	19820820
JP 03075542	B	19911202		
US 4515944	A	19850507	US 1983-564399	19831222
CA 1210763	A2	19860902	CA 1985-488742	19850814
DK 8601810	A	19860421	DK 1986-1810	19860421
DK 154834	B	19881227		
DK 154834	C	19890529		

PRIORITY APPLN. INFO.:  
 DE 1981-3132915 A 19810820  
 EP 1982-107193 A 19820809  
 CA 1982-409072 A3 19820810  
 DK 1982-3723 A 19820819  
 US 1982-409631 A3 19820819

OTHER SOURCE(S): CASREACT 98:198214; MARPAT 98:198214  
 GI




AB I [R, R2 = H, lower alkyl, alkoxy, or acyloxy, OH, halo, CF3; R1 = H, lower alkyl or alkoxy, halo, or (RR1) and/or (R2R3) = OCH2O or OCH2CH2O; R4 = (un)substituted pyridyl, thienyl, phenyl; Z = C2-6 alkylene] were prepared as antiallergy agents (no data). Thus, 1,5-diphenyl-3-pyrazolinone was alkylated with ClCH2CH2CH2Br, then treated with 1-(2-pyridyl)piperazine to give II.

IT 85673-82-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and rearrangement of)

RN 85673-82-1 CAPLUS

CN 1H-Pyrazole, 3-(3-chloropropoxy)-1,5-diphenyl- (CA INDEX NAME)



L3 ANSWER 58 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1981:515384 CAPLUS Full-text

DOCUMENT NUMBER: 95:115384

ORIGINAL REFERENCE NO.: 95:19361a,19364a

TITLE: Photochemical benzyl migration in 3-pyrazolin-5-ones

AUTHOR(S): Singh, Gurbakhsh; Singh, Devender; Ram, Ram Nath

CORPORATE SOURCE: Univ. Delhi, Delhi, India

SOURCE: Tetrahedron Letters (1981), 22(23), 2213-16  
 CODEN: TELEAY; ISSN: 0040-4039


DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 95:115384

GI






AB The pyrazolinones I (R = R1 = Me, R2 = H, Me, PhCH2; R = Me, R1 = Ph, R2 = H; R = CH2Ph, R1 = Me, R2 = H) on irradiation underwent N→O and N→C-4 benzyl migrations to give 18-25% benzyloxypyrazoles II and the betaines III (R = Me, CH2Ph) (56 and 27%, resp.) or, owing to a subsequent prototropic shift, 18-25% hydroxypyrazoles IV (R = Me, R1 = Me, Ph; R = CH2Ph, R1 = Me; R2 = PhCH2), resp. IV (R = R1 = Me, R2 = H, Me, CH2Ph; R = Me, R1 = Ph, R2 = H; R = CH2Ph, R1 = Me, R2 = H) were also formed (16-32%) by fragmentation followed by H abstraction. I (R = CH2Ph, R1 = Me, R2 = H) also gave V (R = CH2Ph, H) (14 and 10%, resp.). A free-radical mechanism is proposed.

IT 79000-05-8P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 79000-05-8 CAPLUS

CN 1H-Pyrazole, 1-methyl-5-phenyl-3-(phenylmethoxy)- (CA INDEX NAME)



L3 ANSWER 59 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1980:181176 CAPLUS Full-text

DOCUMENT NUMBER: 92:181176

ORIGINAL REFERENCE NO.: 92:29357a,29360a

TITLE: 5-Phenylpyrazole derivatives

INVENTOR(S): Heinemann, Henning; Milkowski, Wolfgang; Zeugner, Horst; Hempel, Reinhard; Weiser, Dieter

PATENT ASSIGNEE(S): Kali-Chemie Pharma G.m.b.H., Fed. Rep. Ger.

SOURCE: Ger. Offen., 37 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2828529	A1	19800117	DE 1978-2828529	19780629
EP 7019	A1	19800123	EP 1979-102022	19790619

R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE

DK 7902734	A	19800204	DK 1979-2734	19790628
JP 55009078	A	19800122	JP 1979-81558	19790629
PRIORITY APPLN. INFO.:			DE 1978-2828529	19780629
OTHER SOURCE(S):	MARPAT 92:181176			
GI				




AB The phenylpyrazole derivs. I [R, R1 = H, Cl, CF3; R2 = H, alkyl, Ph, PhCH2; R3 = H, Me; R4 = (cyclo)alkyl; R5 = CO2H, alkoxycarbonyl, CN, (substituted) CONH2] and their salts were prepared for use as hypolipemics (test data tabulated). Thus, 1,2-dihydro-1,5-diphenyl-3H-pyrazol-3-one reacted with NaH and BrCHMeCO2Et in DMF to give 64.7% I (R = R1 = R3 = H, R2 = Ph, R4 = Me, R5 = CO2Et).

IT 73457-62-2  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (amination of)

RN 73457-62-2 CAPLUS


CN Acetic acid, [(1,5-diphenyl-1H-pyrazol-3-yl)oxy]- (9CI) (CA INDEX NAME)



IT 73457-84-8P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and hydrolysis of)

RN 73457-84-8 CAPLUS


CN Acetonitrile, [(1,5-diphenyl-1H-pyrazol-3-yl)oxy]- (9CI) (CA INDEX NAME)



IT 73457-75-7P 73457-92-8P 73457-94-0P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)


RN 73457-75-7 CAPLUS

CN Acetamide, 2-[(1,5-diphenyl-1H-pyrazol-3-yl)oxy]- (CA INDEX NAME)



RN 73457-92-8 CAPLUS


CN Acetic acid, [(5-phenyl-1H-pyrazol-3-yl)oxy]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 73457-94-0 CAPLUS

CN Acetic acid, [(1,5-diphenyl-1H-pyrazol-3-yl)oxy]-, sodium salt (9CI) (CA INDEX NAME)



● Na

L3 ANSWER 60 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1980:76420 CAPLUS Full-text

DOCUMENT NUMBER: 92:76420

ORIGINAL REFERENCE NO.: 92:12590h,12591a

TITLE: Polar cycloadditions of electron-rich multiple bond systems to 1,3,4-oxadiazolium salts: synthesis of 3aH-[1,3,4]oxadiazolo[3,2- $\alpha$ ]quinolines

AUTHOR(S): Franke, Hermann; Grasshoff, Helga; Scherowsky, Guenther

CORPORATE SOURCE: Inst. Org. Chem., Tech. Univ. Berlin, Berlin, D-1000/12, Fed. Rep. Ger.

SOURCE: Chemische Berichte (1979), 112(11), 3623-36  
CODEN: CHBEAM; ISSN: 0009-2940

DOCUMENT TYPE: Journal

LANGUAGE: German

OTHER SOURCE(S): CASREACT 92:76420  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB Oxadiazolium salts I (R1-R3 = H, R4 = Ph, X = ClO4; R1, R2 = H, R3 = NO2, R4 = H, Me, Ph, X = BF4; R1, R2 = H, R3 = NO2, R4 = 4-O2NC6H4, X = ClO4) underwent [4+ + 2] cycloaddn. with MeC.tplbond.CNEt2 to give oxadiazoloquinolines II. A [2+ + 2] cycloaddn. of EtO2CC.tplbond.CCO2Et with II (R3 = H, R4 = Ph, X = ClO4) (III) gave tetracyclic IV. Alkaline hydrolysis of III or II (R3 = NO2, R4 = Ph, X = BF4) gave the corresponding quinolones V. I (R1, R2 = NO2, R3, R4 = H, X = SbCl6; R1, R2 = H, R3 = NO2, R4 = 4-MeOC6H4, X = ClO4) or VI, on [3+ + 2] cycloaddn. cycloreversion with MeC.tplbond.CNEt2 gave VII (R5 = NEt2, R6 = Me; R5 = 4-O2NC6H4, R6 = NEt2) or VIII (R7 = Ph, R8 = NEt2) and VIII (R7 = NEt2, R8 = 3-MeOC6H4), resp. Similarly, H2C:C(OEt)2 with I (R1-R3 = H, R4 = 4-MeOC6H4, X = ClO4) gave IX (R7 = EtO, R8 = 4-MeOC6H4).

IT 72606-92-9P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and ether cleavage of)

RN 72606-92-9 CAPLUS

CN 1H-Pyrazole, 3-ethoxy-5-(4-methoxyphenyl)-1-phenyl- (CA INDEX NAME)



L3 ANSWER 61 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1978:170027 CAPLUS Full-text

DOCUMENT NUMBER: 88:170027

ORIGINAL REFERENCE NO.: 88:26799a,26802a

TITLE: Enehydrazines, 20. Pyrazolinium betaines from  
1,1-dimethylhydrazine and 3-phenylglycidic esters

AUTHOR(S): Sucrow, Wolfgang; Slopianka, Marion; Vetter, Hans  
Juergen

CORPORATE SOURCE: Fachber. Naturwiss. II, Gesamthochsch. Paderborn,  
Paderborn, Fed. Rep. Ger.


SOURCE: Chemische Berichte (1978), 111(2), 791-6  
CODEN: CHBEAM; ISSN: 0009-2940

DOCUMENT TYPE: Journal

LANGUAGE: German

OTHER SOURCE(S): CASREACT 88:170027

GI




AB The reaction of trans-Et 3-phenylglycidate and 1,1-dimethylhydrazine gave trans-betaine I. Hydrogenation of I gave erythro-3-dimethylamino-2-hydroxy-2,3-dihydrocinnamide (II). Similarly prepared was the cis-betaine which was hydrogenated to the threo-isomer of II.

IT 27349-34-4P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 27349-34-4 CAPLUS

CN 1H-Pyrazole, 3-methoxy-1-methyl-5-phenyl- (CA INDEX NAME)



L3 ANSWER 62 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1978:136510 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 88:136510

ORIGINAL REFERENCE NO.: 88:21459a, 21462a

TITLE: Reactions of 5-pyrazolone derivatives

AUTHOR(S): Al-Hajjar, Farouk H.

CORPORATE SOURCE: Dep. Chem., Univ. Kuwait, Kuwait, Kuwait


SOURCE: Journal of the University of Kuwait, Science (1976),  
3, 39-56

CODEN: JUKSD8; ISSN: 0376-4818

DOCUMENT TYPE: Journal

LANGUAGE: English


GI




AB Methylation of hydroxypyrazoles I (R = Ph, 4-MeC<sub>6</sub>H<sub>4</sub>, 4-MeOC<sub>6</sub>H<sub>4</sub>; R<sub>1</sub>-R<sub>3</sub> = H) with CH<sub>2</sub>N<sub>2</sub> or Me<sub>2</sub>SO<sub>4</sub> in neutral or alkaline media gave I (R = Ph, 4-MeC<sub>6</sub>H<sub>4</sub>, 4-MeOC<sub>6</sub>H<sub>4</sub>; R<sub>1</sub> = R<sub>3</sub> = H, R<sub>2</sub> = Me). The bromination of I (R = Ph, R<sub>1</sub>-R<sub>3</sub> = H) gave

I (R3 = Br), which was methylated to give I (R = Ph, R1 = H, R2 = Me, R3 = Br) and acetylated to give I (R = Ph, R1 = R2 = Ac, R3 = Br). When the phenylazopyrazole II (R4 = R5 = H) was treated with Me2SO4, Ac2O, and Br the corresponding II (R4 = Me, R5 = H), II (R4 = Ac, R5 = H), and II (R4 = H, R5 = Br) were obtained. The reaction of III (R6 = R7 = H) with CH2N2 gave III (R6 = H, R7 = Me) which was brominated to give III (R6 = Br, R7 = Me).


IT 39513-07-0P 66076-79-7P 66076-80-0P  
 66076-89-9P 66076-97-9P 66076-98-0P  
 66076-99-1P 66077-02-9P 66077-03-0P  
 66077-04-1P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 39513-07-0 CAPLUS  
 CN 1H-Pyrazole, 3-methoxy-5-phenyl- (CA INDEX NAME)




RN 66076-79-7 CAPLUS  
 CN 1H-Pyrazole, 3-methoxy-5-(4-methylphenyl)- (CA INDEX NAME)




RN 66076-80-0 CAPLUS  
 CN 1H-Pyrazole, 3-methoxy-5-(4-methoxyphenyl)- (CA INDEX NAME)




RN 66076-89-9 CAPLUS  
 CN 1H-Pyrazole, 4-bromo-3-methoxy-5-phenyl- (CA INDEX NAME)



RN 66076-97-9 CAPLUS  
CN 1H-Pyrazole, 4-bromo-3-methoxy-1,5-diphenyl- (CA INDEX NAME)




RN 66076-98-0 CAPLUS  
CN 1H-Pyrazole, 3-methoxy-1,5-diphenyl- (CA INDEX NAME)



RN 66076-99-1 CAPLUS  
CN 1H-Pyrazole, 3-methoxy-1,5-diphenyl-, compd. with 2,4,6-trinitrophenol  
(1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 66076-98-0  
CMF C16 H14 N2 O



CM 2

CRN 88-89-1  
CMF C6 H3 N3 O7




RN 66077-02-9 CAPLUS

CN 1H-Pyrazole, 3-methoxy-5-phenyl-, compd. with 2,4,6-trinitrophenol (1:1)  
(9CI) (CA INDEX NAME)

CM 1

CRN 39513-07-0


CMF C10 H10 N2 O



CM 2

CRN 88-89-1

CMF C6 H3 N3 O7




RN 66077-03-0 CAPLUS

CN 1H-Pyrazole, 3-methoxy-5-(4-methylphenyl)-, compd. with  
2,4,6-trinitrophenol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 66076-79-7

CMF C11 H12 N2 O




CM 2


CRN 88-89-1

CMF C6 H3 N3 O7







RN 66077-04-1 CAPLUS  
 CN 1H-Pyrazole, 3-methoxy-5-(4-methoxyphenyl)-, compd. with  
 2,4,6-trinitrophenol (1:1) (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 66076-80-0  
 CMF C11 H12 N2 O2



CM 2  
 CRN 88-89-1  
 CMF C6 H3 N3 O7



L3 ANSWER 63 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1977:120492 CAPLUS Full-text  
 DOCUMENT NUMBER: 86:120492  
 ORIGINAL REFERENCE NO.: 86:19023a,19026a  
 TITLE: 3-Diazopyrazoles: sources of unusual carbenes and  
 dipolar reagents  
 AUTHOR(S): Magee, Walter L.; Shechter, Harold  
 CORPORATE SOURCE: Dep. Chem., Ohio State Univ., Columbus, OH, USA  
 SOURCE: Journal of the American Chemical Society (1977),  
 99(2), 633-4  
 CODEN: JACSAT; ISSN: 0002-7863  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI




AB 3H-Pyrazolylidenes (I; R = H, R1 = Me3C, Ph; R = Me, R1 = Ph) (a) isomerize to 2H-azirines, (b) are capturable prior to carbenic rearrangement by insertion into CH bonds, (c) react with C6H6 by substitution and by ring expansion/sigmatropic rearrangement processes and (d) cleave ethers by nucleophilic attack on O to give 1,2- and 1,3-adducts.

IT 62072-17-7P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 62072-17-7 CAPLUS

CN 1H-Pyrazole, 3-ethoxy-1-ethyl-5-phenyl- (CA INDEX NAME)



L3 ANSWER 64 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1976:150561 CAPLUS Full-text

DOCUMENT NUMBER: 84:150561

ORIGINAL REFERENCE NO.: 84:24467a,24470a

TITLE: A novel one step synthesis of 5(3)-methylthio-, alkoxy-, amino- and hydroxypyrazoles using  $\alpha$ -ketoketene-S,S-diacetals

AUTHOR(S): Chauhan, S. M. S.; Junjappa, H.

CORPORATE SOURCE: Div. Med. Chem., Cent. Drug Res. Inst., Lucknow, India


SOURCE: Synthesis (1975), (12), 798-801  
CODEN: SYNTBF; ISSN: 0039-7881

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 84:150561

GI




AB Pyrazoles (I, R = Ph, p-MeOC6H4) were obtained in 88-90% yields by refluxing RCOCH:C(SMe)2 with N2H4.H2O 6 hr. II (R = Ph, p-MeOC6H4, R1 = EtO, PrO, morpholino, III) were obtained in 60-72% yields by refluxing RCOCH:C(SMe)2 with RONa or the corresponding amine in alc. followed by treatment with N2H4.H2O. Addnl. obtained were 75 and 84% IV (R = Ph, p-MeOC6H4).

IT 16105-56-9F 58876-83-8P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)


RN 16105-56-9 CAPLUS

CN 1H-Pyrazole, 3-ethoxy-5-phenyl- (CA INDEX NAME)



RN 58876-83-8 CAPLUS

CN 1H-Pyrazole, 3-ethoxy-5-(4-methoxyphenyl)- (CA INDEX NAME)



L3 ANSWER 65 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1973:71965 CAPLUS Full-text

DOCUMENT NUMBER: 78:71965

ORIGINAL REFERENCE NO.: 78:11437a,11440a

TITLE: Rearrangements of 5-isoxazolyldiazines. 1-Amino- and 4-aminopyrazolin-5-ones

AUTHOR(S): Adembri, G.; Ponticelli, F.; Tedeschi, P.

CORPORATE SOURCE: Ist. Chim. Org., Univ. Siena, Siena, Italy

SOURCE: Journal of Heterocyclic Chemistry (1972), 95(6), 1219-25

CODEN: JHTCAD; ISSN: 0022-152X

DOCUMENT TYPE: Journal


LANGUAGE: English

AB 5-Isioxazolyldiazines rearranged to 1-aminopyrazolin-5-ones on heating. Under the same conditions, 5-(3-methyl-4-phenylisoxazolyldiazine also gave 3-methyl-4-amino-4-phenylpyrazolin-5-one. The structures of aminopyrazolones were assigned on the basis of spectroscopic properties and chemical behavior.


IT 39513-07-0P 39513-12-7P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)

RN 39513-07-0 CAPLUS


CN 1H-Pyrazole, 3-methoxy-5-phenyl- (CA INDEX NAME)



RN 39513-12-7 CAPLUS  
CN 1H-Pyrazole, 3-methoxy-4-methyl-5-phenyl- (CA INDEX NAME)




L3 ANSWER 66 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 1967:421866 CAPLUS Full-text  
DOCUMENT NUMBER: 67:21866  
ORIGINAL REFERENCE NO.: 67:4175a, 4178a  
TITLE: Thionocarboxylic acid esters. II. Reactions of monothionomalononic acid esters with amino compounds  
AUTHOR(S): Barnikow, Guenter; Strickmann, Guenter  
CORPORATE SOURCE: Humboldt-Univ., Berlin, Fed. Rep. Ger.  
SOURCE: Chemische Berichte (1967), 100(5), 1661-6  
CODEN: CHBEAM; ISSN: 0009-2940  
DOCUMENT TYPE: Journal  
LANGUAGE: German  
OTHER SOURCE(S): CASREACT 67:21866  
GI For diagram(s), see printed CA Issue.  
AB cf. CA 67: 11152k. Monothionomalononic acid esters reacted with 1,2-diamines or with 1-amino-2-hydroxy compds. to give 2-imidazolinyl- and 2-oxazolinylacetic acid esters, resp., and with hydrazine compds. to give 3-alkoxy-5-pyrazolones. Thus, EtOCSCH<sub>2</sub>CO<sub>2</sub>Et reacted with (H<sub>2</sub>NCH<sub>2</sub>)<sub>2</sub>, H<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>OH or N<sub>2</sub>H<sub>4</sub>.H<sub>2</sub>O to give Et 2-imidazolin-2-ylacetate (II), Et 2-oxazolin-2-ylacetate, or 3-ethoxy-Δ<sup>2</sup>-pyrazol-5-one, resp. Other CH-acid thionocarboxylic acid esters, such as iso-Pr coumarin-3- thionocarboxylate, behaved similarly.  
IT 16105-56-9P  
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)  
RN 16105-56-9 CAPLUS  
CN 1H-Pyrazole, 3-ethoxy-5-phenyl- (CA INDEX NAME)



L3 ANSWER 67 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1963:3270 CAPLUS Full-text  
 DOCUMENT NUMBER: 58:3270  
 ORIGINAL REFERENCE NO.: 58:516c-f  
 TITLE: Syntheses of heterocycles with ethoxyacetylene. II.  
 Ethoxyacetylene and diphenyldiazomethane  
 AUTHOR(S): Gruenanger, Paolo; Finzi, Paola Vita  
 CORPORATE SOURCE: Politecnico, Milan  
 SOURCE: Atti Accad. Nazl. Lincei, Rend., Classe Sci. Fis.,  
 Mat. e Nat. (1961), 31, 128-33  
 DOCUMENT TYPE: Journal  
 LANGUAGE: Unavailable  
 AB cf. CA 55, 11397a. Diphenyldiazomethane (12.4 g.) and 13.5 g. ethoxyacetylene  
 in 10 cc. dry Et<sub>2</sub>O were left in the dark at room temperature 14 days, and the  
 crude precipitate was filtered off and washed with cold hexane. Chromatography  
 on alumina, by eluting resp. with hexane, C<sub>6</sub>H<sub>6</sub>, and Et<sub>2</sub>O gave 0.58 g.  
 (Ph<sub>2</sub>C:N)<sub>2</sub>, m. 165°, 6.61 g. 3,3-diphenyl-5-ethoxypyrazole (I), m. 114-15°  
 (MeOH or hexane),  $\nu$  1634, 1227, 1189, 1030, 762, 701 cm.<sup>-1</sup>,  $\lambda$  (EtOH) 242.5,  
 297i  $\mu$ (log  $\epsilon$  3.52, 3.17);  $\lambda$  (N HCl in EtOH) 229i, 263  $\mu$ (log  $\epsilon$  4.22, 4.02);  $\lambda$   
 (N NaOH in EtOH) 247, 297i  $\mu$  (log  $\epsilon$  3.64, 3.43) (i = inflexion; ultraviolet  
 data are in this same order throughout), and 4.91 g. of a compound m. 123-4°  
 (MeOH or hexane)  $\nu$  1600, 1580, 1493, 1311, 1050, 1034, 865, 787, 772, 755, 702  
 cm.<sup>-1</sup>, probably 3,3-diphenyl-4-ethoxypyrazole. By boiling 20 min. with  
 concentrated HCl, or by heating 3 hrs. at 100° in AcOH, diluting, and  
 filtering off, I rearranged quant. to 3,4-diphenyl-5-ethoxypyrazole (II), m.  
 157-8° (hexane),  $\nu$  3289, 1504, 1294, 1050, 769, 699 cm.<sup>-1</sup>,  $\lambda$  238, 264.5 (4.21,  
 4.09); 231, 265 (4.26, 4.12); 237.5i, 258  $\mu$ (3.67, 3.50). By heating 1 hr. at  
 175-80° in Carius tube 0.5 g. II with 10 cc. concentrated HCl and 4 cc. EtOH,  
 diluting, filtering, dissolving in 2% NaOH, extracting with Et<sub>2</sub>O, acidifying  
 aqueous layer, was obtained 3,4-diphenyl-5-pyrazolone (III) (0.42 g.), m. 234-  
 5° (dilute EtOH),  $\nu$  3597, 3236, 1610, 1513, 1019, 760, 694 cm.<sup>-1</sup>,  $\lambda$  238, 263.5  
 (4.11, 4.00); 226, 255i (4.31, 4.08); 253.5, 295i  $\mu$ (4.11, 3.85). III was  
 synthesized from 1 g. PhCOCHPhCO<sub>2</sub>Et and 0.4 g. N<sub>2</sub>H<sub>4</sub>.H<sub>2</sub>O in AcOH for 2 days.  
 Methylation of II by heating 0.63 g. II in 60 cc. Me<sub>2</sub>CO with 30 cc. 0.1N NaOH  
 at 40°, adding 1 cc. Me<sub>2</sub>SO<sub>4</sub> in Me<sub>2</sub>CO, adding dropwise 160 cc. 0.1N NaOH,  
 stirring 1 hr. at 40°, leaving overnight, filtering off, gave 0.41 g. 1-  
 methyl-3,4-diphenyl-5-ethoxypyrazole (IV) m. 89-90°,  $\lambda$  244.5, 266i (4.14,  
 4.04); 243, 266i (4.19, 4.07); 243, 265i m $\lambda$ (4.16, 4.05). By heating 0.4 g. IV  
 with HCl at 160-70°, and crystallizing from BuOH or by sublimation in vacuo  
 were obtained 0.35 g. 1-methyl-3,4-diphenyl-5-pyrazolone m. 272.4°,  $\lambda$  244.5,  
 262.5i (4.14, 4.06); 234i, 263i (4.21, 4.07); 265.5, 298i  $\mu$ (4.27, 4.11).  
 IT 97978-59-1P, Pyrazole, 3(or 5)-ethoxy-4,5(or 3,4)-diphenyl-  
 RL: PREP (Preparation)  
 (preparation of)  
 RN 97978-59-1 CAPLUS  
 CN Pyrazole, 3(or 5)-ethoxy-4,5(or 3,4)-diphenyl- (7CI) (CA INDEX NAME)



DOCUMENT NUMBER: 56:60604  
ORIGINAL REFERENCE NO.: 56:11593f-i,11594a-e  
TITLE: The formation of pyrazoles from thiohydrazides and  $\alpha$ -halo carbonyl compounds. II.  
5,6-Diphenylthiadiazines and 4,5-diphenylpyrazoles

AUTHOR(S): Sandstrom, Jan  
SOURCE: Arkiv foer Kemi (1960), 15, 195-210  
CODEN: ARKEAD; ISSN: 0365-6128


DOCUMENT TYPE: Journal  
LANGUAGE: Unavailable

GI For diagram(s), see printed CA Issue.

AB cf. CA 50, 12029f.-PhCSNHNH<sub>2</sub> (I) (1.5 g.) and 2.3 g. PhCHClBz (II) in 30 cc. absolute EtOH and 10 cc. N NaOEt kept overnight, diluted with 40 cc. H<sub>2</sub>O, and filtered yielded 3.1 g. 2,5,6-triphenyl-5-hydroxy- $\Delta^2$ -dihydro-1,3,4-thiadiazine (III), decomposing at 130°, resolidified and m. 205-7° (on rapid heating) (petr. ether). I (1.5 g.) and 2.3 g. II in 30 cc. absolute EtOH and 10 cc. N NaOEt kept overnight, treated with 1 cc. 4N HCl, filtered immediately (within 2 min.), and the residue washed with absolute EtOH yielded 1.0 g. 2,5,6-triphenyl-6(or 4)H-1,3,4-thiadiazine (IV), m. 192-3° (precipitated from petr. ether with CHCl<sub>3</sub>), resolidified and m. 268-70°, Rf 0.52-0.54 (iso-Pr<sub>2</sub>O on Me<sub>2</sub>SO-treated paper). III (0.35 g.) in 3 cc. CHCl<sub>3</sub> refluxed 10 min. with 5 cc. EtOH and evaporated gave 0.32 g. IV. III (8.3 mg.) in 1 cc. CHCl<sub>3</sub> kept 16 hrs. at room temperature with 1 drop Ac<sub>2</sub>O and diluted with absolute EtOH gave a solution exhibiting the spectrum of IV. IV (1.64 g.) in 25 cc. xylene refluxed 12 hrs. and cooled gave 1.40 g. 3,4,5-triphenylpyrazole (V), m. 269-70°; the mother liquor chromatographed on Al<sub>2</sub>O<sub>3</sub> yielded 0.15 g. S. Me dithiocarbazate (21 g.) and 2.3 g. II in 20 cc. absolute EtOH and 10 cc. N NaOEt-EtOH kept overnight gave 2.4 g. 2-MeS analog (VI) of III, rods, m. 122-4° (rapid heating), 147-9° (slow heating). VI (1.6 g.) in 10 cc. EtOH refluxed 0.5 hr. and cooled yielded 1.2 g. 2-MeS analog (VII) of IV, yellow plates, m. 156-7°. VI could be converted quant. to VII by treatment with Ac<sub>2</sub>O at room temperature VII (1.5 g.) in 20 cc. xylene refluxed 12 hrs. and chromatographed on Al<sub>2</sub>O<sub>3</sub> gave 153 mg. S and 1.32 g. 3-MeS analog (VIII) of V, needles, m. 157-8° (PhMe). VII (0.30 g.) in 2 cc. CHCl<sub>3</sub> and 10 cc. 0.5N HCl-EtOH kept 1 hr. and evaporated, and the residue chromatographed on Al<sub>2</sub>O<sub>3</sub> yielded 30 mg. S and 260 mg. VIII. Benzyl dithiocarbazate (2.0 g.) in 10 cc. N NaOEt-EtOH and 2.3 g. II in 30 cc. EtOH mixed, filtered after 4 hrs., diluted with 200 cc. H<sub>2</sub>O, and extracted with 20 cc. CHCl<sub>3</sub>, and the extract concentrated to half-volume, diluted with 50 cc. petr. ether, cooled 24 hrs. to -30°, and kept 24 hrs. at room temperature deposited 2.0 g. 2-benzyl analog (IX) of III, pale yellow plates, m. 119-20°. IX was converted quant. in boiling xylene and in acid at room temperature to S and the 3-PhCH<sub>2</sub>S analog of V, needles, m. 182-3° (PhMe), Rf 0.33-0.36 (iso-Pr<sub>2</sub>O). PhCSNHNHPh (2.2 g.) and 2.3 g. II in 30 cc. absolute EtOH and 10 cc. N NaOEt-EtOH kept overnight, treated with 10 cc. alc. 4N HCl, and filtered gave 3.2 g. 1,3,4,5-tetraphenylpyrazole (X), plates, m. 220-1° (PhMe), Rf 0.80-0.85 (1:1 heptane-Bu<sub>2</sub>O). PhC(:CHPh)Bz (2.8 g.) and 1.5 g. PhNHNH<sub>2</sub> refluxed 5 min. with 20 cc. EtOH and 1 cc. AcOH, kept overnight, and filtered, and the residue chromatographed on Al<sub>2</sub>O<sub>3</sub> gave 1.8 g. oily material and 1.1 g. partly crystalline material which dissolved in 5 cc. hot PhMe and cooled gave 0.7 g. X, plates, m. 220-1°. Et 3-phenyldithiocarbazate (2.1 g.) and 2.3 g. II in 25 cc. absolute EtOH and 10 cc. N alc. NaOEt kept overnight, filtered, and treated with 5 cc. 4N alc. HCl gave 1.9 g. (crude) 3-EtS analog of X, needles, m. 177-8° (ligroine, b. 80-100°), Rf about 0.9. PhCSNHNHCH<sub>2</sub>Ph and II (equimolar amts.) gave similarly 70% S and 70% 1-PhCH<sub>2</sub> analog (XI) of X, prisms, m. 116-17°, Rf about 0.8 (1:1 heptane-BU<sub>2</sub>O). Me 3-benzyl dithiocarbazate (2.1 g.) and 2.3 g. II in 20 cc. absolute EtOH and 10 cc. N alc. NaOEt filtered after 3 hrs. and kept overnight deposited 2.3 g. 2-methylthio-4 benzyl-5-hydroxy-5,6-diphenyl- $\Delta^2$ -dihydro-1,3,4-thiadiazine

(XII), rods, m. 116-17° (CHCl<sub>3</sub>-petr. ether). XII (0.41 g.) in 2 cc. CHCl<sub>3</sub> and 10 cc. absolute EtOH treated with 1 cc. 4N alc. HCl gave 0.2 g. 3-MeS analog (XIII) of XI, rods, m. 136-7°; the residue from the mother liquor chromatographed on Al<sub>2</sub>O<sub>3</sub> gave 30 mg. S and 0.15 g. XIII, R<sub>f</sub> about 0.8 (1:1 heptane-BU<sub>2</sub>O). XII (8.0 mg.) in 1 cc. CHCl<sub>3</sub> and 1 drop Ac<sub>2</sub>O kept overnight and diluted with absolute EtOH gave a solution showing the spectrum of XIII. Me 3-benzylthiocarbazate (20 g.) and 2.3 g. II in 20 cc. absolute EtOH and 10 cc. N NaOEt in absolute EtOH kept overnight, filtered, and diluted with H<sub>2</sub>O, and the pale yellow oily precipitate dissolved in 5 cc. C<sub>6</sub>H<sub>6</sub> and chromatographed on Al<sub>2</sub>O<sub>3</sub> yielded 0.10 g. S and 1.55 g. 3-MeO analog of XIII, m. 83-4° (EtOH). The infrared absorption spectra of III, IV, V, VI, VII, VIII, XII, and XIII and the ultraviolet spectra of VI, VII, VIII, and XII are recorded.

IT 95434-86-9P, Pyrazole, 1-benzyl-3-methoxy-4,5-diphenyl-  
 RL: PREP (Preparation)  
 (preparation of)  
 RN 95434-86-9 CAPLUS  
 CN Pyrazole, 1-benzyl-3-methoxy-4,5-diphenyl- (7CI) (CA INDEX NAME)



L3 ANSWER 69 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1945:8902 CAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 39:8902  
 ORIGINAL REFERENCE NO.: 39:1402a-i,1403a-d  
 TITLE: 4-Hydroxycoumarin. VIII. Phenylhydrazine degradation of 3,3'-methylenebis(4-hydroxycoumarin)  
 AUTHOR(S): Huebner, Charles F.; Link, Karl P.  
 SOURCE: Journal of the American Chemical Society (1945), 67, 102-7  
 CODEN: JACSAT; ISSN: 0002-7863  
 DOCUMENT TYPE: Journal  
 LANGUAGE: Unavailable

GI For diagram(s), see printed CA Issue.

AB The red compound C<sub>21</sub>H<sub>16</sub>N<sub>4</sub>O<sub>2</sub> (I), m. 189-9.5° prepared from 3,3'-methylenebis(4-hydroxycoumarin) by heating with PhNHNH<sub>2</sub> at 135° (Stahmann, Huebner and Link, C.A. 35, 4397.9), is 2-phenyl-5-(o-hydroxyphenyl)-4-phenylazo-3-pyrazolone; I is identical with the compound obtained by Anschütz (C.A. 3, 2976) from 4-hydroxycoumarin and PhNHNH<sub>2</sub>. That one of the phenylhydrazine residues occupies the 3-position of the 4-hydroxycoumarin residue is shown by the following reactions. 3-Phenyl-4-hydroxycoumarin (2 g.) and 5 ml. PhNHNH<sub>2</sub>, heated 1 hr. at 135°, give 2 g. of 3-phenyl-4-phenylhydrazinocoumarin, m. 184-5°. 2,3,4-Trioxochroman 3-phenylhydrazone (II) (1 g.) and 3 ml. PhNHNH<sub>2</sub>, heated 2 hrs. at 135°, give 0.85 g. of I. II (16 g.) and 20 ml. PhNHNH<sub>2</sub> in 20 ml. AcOH and 500 ml. EtOH, refluxed 12 hrs., give 10 g. of I and, from the EtOH mother liquor, 11 g. of 1-phenyl-4-phenylazo- 5-(o-hydroxyphenyl)-3-pyrazolone (III), deep red, m. 189-90° (from ether-Skellysolve B); recrystn. from EtOH gives an orange polymorphic form, m. 184-5°; the reverse transformation could not be effected by irradiation with ultraviolet light, prolonged heating of a melt or treatment with iodine. 2,3,4-Trioxochroman-3-(p-methylphenylhydrazone) (27 g.), 35 ml. PhNHNH<sub>2</sub> and 35 ml. AcOH in 250 ml. EtOH, refluxed 2 hrs., give 12 g. of 2-phenyl-5-(o-hydroxyphenyl)-4-(p-methylphenylazo)-3-pyrazolone (IIIA), red, m. 215-16°; the mother liquors

yield 10 g. of a mixture of products, purification of which through Al<sub>2</sub>O<sub>3</sub>, yields 7 g. of 1-phenyl-4-(p-methylphenylazo)-5-(o-hydroxyphenyl)-3-pyrazolone (IIIB), m. 205-6°. The 4-(p-nitrophenylazo) analog of I, red, m. 284-5°. I (3.8 g.) and CH<sub>2</sub>N<sub>2</sub> in AcOEt at 0° (4 hrs.) give 3 g. of the enol O-Me ether (IV) (R = Me), orange-red, m. 121-3°; with Me<sub>2</sub>SO<sub>4</sub> I yields the 1-Me derivative (V), m. 135-7°, of I. IV and MeI in C<sub>6</sub>H<sub>6</sub>, refluxed with Ag<sub>2</sub>O for 6 hrs., give the Me ether (VI) (R = Me) of IV, orange-yellow, m. 122-3°; this also results from the 5-(o-methoxyphenyl) analog of I and CH<sub>2</sub>N<sub>2</sub> in AcOEt. III (5 g.) and CH<sub>2</sub>N<sub>2</sub> in EtOH give 3 g. of the enol di-Me ether, 3-methoxy-5-(o-methoxyphenyl)-1-phenyl-4-phenylazopyrazole (Va), m. 170-3°. I (1 g.) and 5 ml. Ac<sub>2</sub>O with 5 ml. C<sub>5</sub>H<sub>5</sub>N give 1 g. of the 5-acetoxy analog (VII) of IV (R = OAc), red-orange, m. 154-5°; III yields the diacetoxy analog (VIII) of Va (AcO instead of MeO), m. 134-6°; VII cannot be methylated by CH<sub>2</sub>N<sub>2</sub>. The possibility that the Me and Ac compds. are derivs. of the hydrazone tautomers of I and III is eliminated by the fact that IV, VI, VII and VIII on hydrogenation yield PhNH<sub>2</sub> rather than PhNHMe or PhNHAc. I (9 g.) and 25 ml. 58% HI in 100 ml. AcOH, refluxed 1 hr., give 5 g. of the HCl salt of 2-phenyl-5-(o-hydroxyphenyl)-4-amino-3-pyrazolone (IX); monoacetate, which forms a (probably N-) Ac compound, m. 172-5° tetra-Ac compound, m. 131-2°; tri-Bz compound, m. 150-2°. The HCl salt of IX (5 g.) and 3 g. AcONa in 200 ml. H<sub>2</sub>O, stirred for 3 days, give 1.4 g. of the rubazonic acid (X), iridescent purple-bronze leaflets, m. 222-5°; the alkaline solution is intense purple and can be reduced to the leuco form by NaHSO<sub>3</sub>. Catalytic reduction (Pd) of 20 g. of III in 300 ml. EtOH and 12 ml. concentrated HCl for 2 hrs. gives 15 g. of the HCl salt, m. 170-5°, of 1-phenyl-4-amino-5-(o-hydroxyphenyl)-3-pyrazolone (XI), m. 255-60°; tetra-Ac compound, m. 134.5-5.5°. XI with HCl and NaNO<sub>2</sub> gives the diazo oxide (XII), yellow, m. 245-50° (decomposition). Reduction of IIIA with HI gives IX, whereas IIIB yields XI. 1-Phenyl-3-(o-methoxyphenyl)-5-pyrazolone (4.3 g.), 4 g. Na<sub>2</sub>CO<sub>3</sub> and 1 g. NaOH in 50 ml. H<sub>2</sub>O at 5°, treated with 20 millimoles of PhN<sub>2</sub>Cl, give 4 g. of 2-phenyl-5-(o-methoxyphenyl)-4-phenylazo-3-pyrazolone (XIII), m. 149-51°; this also results in 10-g. yield from 12 g. of o-MeOC<sub>6</sub>H<sub>4</sub>COCH<sub>2</sub>CO<sub>2</sub>Et in aqueous Na<sub>2</sub>CO<sub>3</sub> and PhN<sub>2</sub>Cl. Reduction of XIII with HI for 30 min. and acetylation yield a tri-Ac mono-Me derivative of IX, m. 128-30°; with AcONa (stirring for 24 hrs.) this yields the di-Me ether of X, bright scarlet, m. 235-8°. Reduction of XIII with HI for 12 hrs. and acetylation give the tetra-Ac derivative of IX. o-MeOC<sub>6</sub>H<sub>4</sub>COCH<sub>2</sub>CO<sub>2</sub>Et (12 g.), 8.1 g. PhNHNHAc and 4.9 ml. PCl<sub>3</sub>, heated on the water bath for 30 min., give 4.4 g. of 1-phenyl-5-(o-methoxyphenyl)-3-pyrazolone (XIV), m. 222-5°; 1 g. XIV and 7 ml. concentrated HNO<sub>3</sub> at 0° give 0.7 g. of the 4-NO<sub>2</sub> derivative, greenish yellow, m. 164-5°; catalytic reduction, followed by demethylation with HI, gives XI, characterized as the tetra-Ac compound 3,3'-Benzylidenebis (4-hydroxycoumarin) (10 g.) and 50 ml. PhNH<sub>2</sub>, refluxed 4 hrs., give 10.1 g. of 4-anilinocoumarin and 5 g. of (4-H<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>)<sub>2</sub>CHPh; on the basis of this reaction, an explanation is given of the formation of I.


IT 854698-14-9P, Pyrazole, 3-methoxy-5-(o-methoxyphenyl)-1-phenyl-4-phenylazo-

RL: PREP (Preparation)  
(preparation of)

RN 854698-14-9 CAPLUS

CN 1H-Pyrazole, 3-methoxy-5-(2-methoxyphenyl)-1-phenyl-4-(2-phenyldiazenyl)-  
(CA INDEX NAME)





L3 ANSWER 70 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1925:22633 CAPLUS Full-text

DOCUMENT NUMBER: 19:22633

ORIGINAL REFERENCE NO.: 19:2952i,2953a-d

TITLE: Isomerism relationships in the pyrazole series. IV. Alkyl derivatives of 3-phenyl-5-pyrazolone and 3(5)-phenyl-5(3)-chloropyrazole and acyl derivatives of 3(5)-phenyl- and 3(5)-methyl-5(3)-chloropyrazole

AUTHOR(S): v. Auwsrs, K.; Mauss, H.

SOURCE: Journal fuer Praktische Chemie (Leipzig) (1925), 110, 204-34

CODEN: JPCEAO; ISSN: 0021-8383

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

AB 3-Phenyl-5-pyrazolone (X) and MeI or Me<sub>2</sub>SO<sub>4</sub> without alkali gave poor yields of the 1-Me derivative (XI), m. 207°. p-MeC<sub>6</sub>H<sub>4</sub>SO<sub>3</sub>Me and the Na salt of X in MeOH gave some XI, a little 1-methyl-5-phenyl-3-pyrazolone (XII), in. 161°, and 3-phenyl-5-methoxypyrazole, m. 106-6.5°. 3-Phenyl-4-methyl-5-pyrazolone, m. 213-4.5°, from N<sub>2</sub>H<sub>4</sub> and BzCHMeCO<sub>2</sub>Et. XII and POCl<sub>3</sub> give 1-methyl-5-phenyl-3-chloropyrazole (XIII), m. 76°. The behavior of 3-phenyl-5-chloropyrazolone (XIV) towards various methylating agents is discussed. XIII (or the isomeric 3-Ph derivative), and MeI at 100° give 1,2-dimethyl-3-phenyl-5-chloropyrazolium iodide, m. 165°; in attempting to increase the yield by heating at 140°, the Cl is replaced by I, giving the 5-iodo derivative, yellowish, m. 189-90°. Dry distillation splits off MeI, giving XIII. 3-Phenyl-4-methyl-5-chloropyrazole, m. 115-6°; HCl salt, m. 140-50°. XIV and EtI at 100° give 1-ethyl-3-phenyl-5-chloropyrazole (XV), m. 160-1°; the HCl salt softens 88-90°, m. 92°. In alkaline solution there results also the isomeric 5-Ph derivative (XVI), b<sub>14</sub> 152-3°, which does not form a HCl or HBr salt. XV is unchanged after heating with MeI at 100°, while XVI gives a small amount of a compound, decomp. 194-5°. 1-Benzyl-3-phenyl-5-chloropyrazole, m. 53-4° (HCl salt, m. 107-8°). In alkaline solution there also results the isomeric 5-Ph derivative, m. 67-8°. XIV and AcCl gave a mixture of 1-acetyl-3-phenyl-5-chloropyrazole, m. 69-70° and the 5-Ph derivative, m. 75-6°. XIV and BzCl gave N-benzoyl-3(6)-phenyl-5(3)-chloropyrazole, m. 89-90°. o-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>COCl gave a mixture of the 1-[o-nitrobenzoyl]-3-phenyl-5-chloropyrazole, m. 111-3°, and the 5-Ph derivative, m. 188-9°; the Ag salt of XIV gave only the lower melting isomer, while the Na salt in PhMe gave about 2 parts of the lower and 1 part of the higher melting isomer. Neither isomer is changed by heating 15 min. at 200°. I and AcCl, under all conditions, gave only the N-Ac derivative, b. 200°, m. 20-1°. BzCl also gave only the N-Bz derivative, b. 300-2°, m. 36-7°. N-[m-Nitrobenzoyl] derivative, m. 125-5.5°. o-Nitro isomer, m. 139-40°, The Na salt does not give an isomeric derivative


IT 39513-07-0P, Pyrazole, 5-methoxy-3-phenyl-

RL: PREP (Preparation)

(preparation of)

RN 39513-07-0 CAPLUS

CN 1H-Pyrazole, 3-methoxy-5-phenyl- (CA INDEX NAME)



=> log off

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

STN INTERNATIONAL LOGOFF AT 09:41:13 ON 16 SEP 2008